The pharmacogenetic and immunomodulatory response to Vitamin D in tuberculosis by Hawthorne, Gemma Mary
   1 
 
The Pharmacogenetic and 
Immunomodulatory Response to Vitamin 









A thesis submitted to the University of Birmingham for the 
degree of Doctor of Medicine (MD) 
 
 
School of Clinical and Experimental Medicine 
University of Birmingham 
















This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 










Tuberculosis is a global problem, with little change in antibiotic therapy over the last fifty years, but 
with the emergence of both multi-drug resistant disease and extensive drug resistant disease further 
treatments are needed to ensure successful management of the disease. 
Severe vitamin D deficiency is prevalent in patients with tuberculosis and the immunomodulatory 
mechanisms of elements of the vitamin D axis, including vitamin D binding protein (DBP) and 
vitamin D receptor (VDR) have been explored in part. 
 
Aims  
This thesis will ascertain the role of polymorphisms in vitamin D axis genes in determining response 
to vitamin D in tuberculosis patients.  Additionally it will aim to determine whether the interaction 
between underlying genotype, baseline vitamin D level and other elements of the vitamin D axis has 
the potential to influence clinical outcome and further investigate in vitro effects of vitamin D and 
elements of the vitamin D axis in influencing the frequency and functionality of monocytes and T 
cells, both of which are key elements in the immune response to tuberculosis infection. 
 
Results 
Associations between vitamin D baseline and response to supplementation appear to have a genetic 
association with DBP, VDR and DHCR7 genotypes and varying DBP haplotypes appear to 
determine the level of DBP at baseline measurement.  The effect of vitamin D has an 
immunomodulatory role in both monocyte response and T regulatory activity, with a clear effect of 
vitamin D on cytokine response. 
 
Conclusion 
There appears to be a role for vitamin D in the treatment of tuberculosis but further questions are 
raised regarding the benefits and risks of immune response modulation in an inflammatory/ 
cytopathogenic condition such as tuberculosis. 
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Tuberculosis (TB) is a worldwide problem with 9 million new cases globally and 1.5 million deaths 
due to the disease in 2013.  The Millennium Development Goals (MDG) for 2015 are that incidence 
should be decreasing, with prevalence and mortality halved and although globally there is a 1.5% 
reduction in new cases, 11 of the high burden countries (HBCs) account for 80% of the global 
burden of TB cases) and are failing to meet the MDG requirements.  This is in part due to financial 
constraints, conflict and HIV epidemics in the regions. [1].  There has been little change in the drugs 
used to treat TB and the occurrence of both multidrug resistant TB (MDR-TB) and extensive drug 
resistant TB (XDR-TB) has prompted consideration of additional therapeutic agents.  Vitamin D 
may be one such agent, of broad relevance to infectious disease because of its immunomodulatory 
properties.  Indeed, in the pre- antibiotic era Vitamin D was used with some success as a sole agent 
[2] and early treatment of TB included light therapy for the skin manifestation lupus vulgaris [3].  
More recently roles for variation in its carrier protein (vitamin D binding protein; DBP) [4] and its 
receptor (vitamin D receptor; VDR) [5] due to genetic polymorphism have been reported to 
determine risk of disease and response to treatment respectively. 
 




1.1.1 Transmission and causative organism 
 
Tuberculosis is the result of infection with Mycobacterium tuberculosis (M.tb) which is spread 
through droplet infection.  The bacteria, carried in a suspension can remain airborne if the particle 
size is less than 4 micrometres allowing the bacteria to circulate for some time, increasing the 
likelihood of transfer from person to person, particularly in crowded conditions.   
Mycobacteria have a complex lipid rich cell wall (Figure 1.1) consisting of peptidoglycan, 
arabinogalactan and mycolic acids, which are covalently linked. The structure of the cell wall is 
thought to aid pathogen survival in the host cell, both structurally and immunologically.  The 
hydrophobic nature of the wall prevents entry of hydrophilic drugs into the cell, whilst mycolic 
acids are known to influence the differentiation of macrophages to foamy macrophages [6], 
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Figure 1.1  Schematic diagram of Mycobacterium tuberculosis cell wall.   
Components of the mycobacterial cell wall include a peptidoglycan layer, the arabinogalactan layer and 
mycolic acid covalently bonded together forming the mycolic acid-arabinogalactan-peptidoglycan complex 
(MAP-c).  The peptidoglycan layer contains N-acetyl glucosamine–N-acetyl muramic acid (NAG–NAM) 
which is heavily cross linked and surrounds the cell membrane.  The arabinogalactan layer, surrounding the 
peptidoglycans, consists of repeating disaccharide units (galactan) modified with arabinan polymers.   This 
can undergo further modifications to increase pathogenicity of the mycobacteria.  The arabinan is bound to 
long carbon chain mycolic acids, which form the waxy layer around the mycobacteria and contribute to its 
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1.1.2 Infection with mycobacterium tuberculosis 
 
Infection with M.tb results in an increase in alveolar macrophages, dendritic cells, monocytes, small 
macrophages and granulocytes within the lung [7].  The risk of infection with M.tb is influenced by 
several factors including the immune status of the individual, ethnicity, excessive alcohol 
consumption, drug use, residing in an urban area and homelessness [8].  
The normal immune response to infection involves both the innate and cell mediated immune 
system.  The innate immune response is non-specific and involves the general recruitment of 
immune cells to sites of infection.  The cell-mediated (adaptive) immune response involves antigen 
presentation and subsequent T cell activation secondary to this specific stimulus.  On entering the 
lung, the M.tb bacilli are initially taken up by local alveolar macrophages and dendritic cells and 
thus move to an intracellular environment.  Phagocytosis of a pathogen by the macrophage may 
occur when the pathogen is recognised by a particular pathogen associated molecular pattern 
(PAMP) or secondary to opsonisation of the pathogen by complement.  Internalisation of the 
pathogen then occurs via receptors including mannose receptors and complement receptors [9].  A 
phagosome is formed, which in turn matures and fuses with a lysosome to form a phagolysosome. 
In addition to the innate immune response, cellular immunity is essential in the formation of a 
granuloma (consisting of naïve T cells encasing the infected macrophages), which is thought to 
control dissemination of the bacillus.   It is believed that although the cell mediated response is 
important in the formation of the granuloma, this can also occur in the presence of innate immune 
activity alone [10].  The action of cytokines such as tumour necrosis factor alpha (TNFα), produced 
by both macrophages and T cells, is essential in maintaining granuloma structure [11] and studies in 
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mice have shown that TNFα knockout animals succumb to overwhelming infection due to 
uncontrolled replication and dissemination of mycobacteria.  The inability to form granulomas 
results in the formation of necrotic lesions [12]. 
M.tb uses a number of strategies to evade the host response and these contribute to its potential 
survival and persistence in the host.  For instance, M.tb is capable of causing an arrest in phagosome 
maturation  [13] and resisting acidification in the phagolysosome [14]. 
   
1.1.3 Clinical features 
 
Tuberculosis has a variety of clinical presentations.  In individuals who have not been previously 
exposed to M.tb, primary tuberculosis occurs which may be subclinical in an immune competent 
individual. The initial infection results in multiplication of the bacillus in the lung, known as the 
Ghon focus.  Local involvement of peri-bronchial lymph nodes results in the primary complex.  The 
infected person may eradicate the disease or through persistence of the bacillus in the macrophage, 
develop latent tuberculosis with the risk of reactivation at a later time.  Primary infection may result 
in clinically evident (active) infection in the form of pulmonary / pleural manifestations, 
hypersensitivity reactions or disseminated extra-pulmonary manifestations such as tuberculous 
adenopathy, meningitis, pericarditis or miliary TB [15].  
The risk of reactivation of latent infection is around 0.084 per 100,000 person years [16] and results 
in post-primary tuberculosis.  Post primary infection typically results in pulmonary disease with 
cavitation and lung tissue destruction.  The patient is likely to have positive smear microscopy for 
acid fast bacilli in the sputum [17].  Extra-pulmonary manifestations may occur in reactivation such 
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as cervical lymphadenopathy, pleural, pericardial, meningeal, bone or abdominal / gastrointestinal 
disease.  Other tissues and organs may more rarely be infected. 
In addition to reactivation, a person may develop post–primary tuberculosis through reinfection as a 
result of a second exposure to tubercle bacillus. 
 
1.1.4 HIV associated tuberculosis 
 
13% of new cases of tuberculosis worldwide in 2013 were co-infected with HIV with 25% of all TB 
deaths related to HIV co-infection [1].  It is recommended by the Stop TB Partnership (a 
collaboration of nearly 1000 groups working together to improve diagnosis and treatment of TB), 
that all patients with tuberculosis should be tested for HIV [18].  TB in HIV infected persons can be 
difficult to diagnose due to lower rates of sputum smear positivity and the lack of classical 
pulmonary features typically associated with post-primary infection.  In addition, higher treatment 
failure rates are seen due to an increased risk of adverse drug reaction and lack of health care 
support in developing regions [19]. 
 
1.1.5 Diagnosis of Tuberculosis 
 
Latent tuberculosis occurs when an individual is infected with M.tb but the immune response is 
adequate to control replication and the disease remains ‘dormant’.  When the immune response is no 
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longer able to provide effective control the disease may become active and systemic / localising 
features of disease are usually present.  These methods concern the diagnosis of active disease.  
History 
 
A suggestive history may include symptoms of cough, haemoptysis, weight loss, sweats, lethargy or 
manifestations such as palpable lymphadenopathy.   
Microscopic detection 
 
Detection of tubercle bacilli can be done using auramine-rhodamine or Ziehl-Neelson stain, 
resulting in the common term for TB appearances on microscopy of ‘acid fast bacilli’.   Microscopy 
is an inexpensive method of identification and can be done easily with relatively simple equipment 
and a microscope.  Microscopy also diagnoses the most infectious patients (i.e. those with bacilli in 
the sputum).  Although microscopy is highly specific, it has had variable reported sensitivities [20] 
and cannot differentiate viable from non-viable organisms or give information on drug 
susceptibility, which requires culture of the organism. 
At least three sputum samples for microscopy are recommended.  A systematic review evaluating 
the yield of serial microscopy found that regardless of the method of data stratification, the mean 
incremental yield in smear positivity and mean sensitivity of the third specimen were between 2% 
and 5%, suggesting that when considered in light of the additional manpower required to process the 
third specimen, in low-resource areas with heavy workloads, two specimens may be a more feasible 
option [21]. 




Culture of M.tb is preferred for diagnosis as it is the most sensitive of the diagnostic techniques and 
gives information on antibiotic sensitivity. It has traditionally been done on solid media 
(Lowenstein–Jensen) but is associated with prolonged culture times (6-8 weeks) due to the slow 
growth of M.tb.  Liquid culture (manual, automated or semi-automated), more recently introduced, 
has the advantage of higher turnaround time in the laboratory and increased recovery rate of 
mycobacteria [22, 23].   
 
Tuberculin skin testing (TST) 
 
Intradermal injection of Purified Protein Derivative (PPD) results in delayed hypersensitivity 
reaction in those who have been exposed to mycobacterial infection previously.  The BCG (Bacille 
Calmette Guerin) vaccination, administered to selected individuals is derived from Mycobacteria 
bovis (M.bovis) and due to cross reactivity previous vaccination may result in a positive response to 
PPD.  An induration of the skin is positive at 5mm or larger, regardless of BCG vaccination history.  
It is easy to perform and inexpensive but lacks the specificity of interferon gamma release assays 
(IGRA) described below. 
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Interferon gamma release assay (IGRA) 
 
IGRA tests are blood assays based on the release of interferon gamma from T-cells when activated 
by specific M.tb antigens ESAT-6 and CFP-10, complexes of which add structural stability to the 
mycobacterial cell wall.  There are two commonly used IGRA tests in the UK – the T-spot®.TB 
(Oxford Immunotec, UK) and the Quanti-FERON®-TB Gold (Cellestis).  A high level of agreement 
has been found between the T-SPOT.TB and the QuantiFERON-TB Gold assays [24].  The benefits 
of IGRA testing are that it has better sensitivity that TST [25],  appears to maintain its sensitivity 
even in immune compromised individuals [26] and has high specificity in the BCG vaccinated [27].  
These tests are not currently recommended as the sole test for diagnosis except in certain sub-groups 
where latent, rather than active TB is suspected [22].   
 
Nucleic acid amplification test (NAAT) (Xpert-MTB/RIF) 
 
This is a fully automated diagnostic molecular test which was strongly endorsed by the WHO 
(World Health Organisation) in 2010 for use in patients with suspected MDR-TB or HIV/TB.  It is a 
rapid test carried out on untreated sputum which provides information on the presence of M.tb and 
rifampicin resistance in less than two hours [28].   
 
 




Chest radiographs are often suggestive of active disease.  They classically show upper zone 
consolidation but may also provide information on mediastinal and para-tracheal lymphadenopathy. 
Computed tomography (CT) is used for further evaluation of possible mediastinal lymphadenopathy 
for example, in order to determine preferable sites for biopsy.  It also provides further information 
on the presence of disease within other organs.  Magnetic resonance imaging (MRI) is commonly 
used for imaging the spine if spinal TB is suspected and for evaluating skeletal disease.  It can also 








   21 
 
 
Figure 1.2 (A) Upper zone cavity on chest radiograph (B) change in MRI signal / oedema in vertebrae 
secondary to tuberculosis. 
Radiological changes such as upper zone cavitation or consolidation may be suggestive of tuberculosis but 
microbiological sampling is essential.  Although supportive, radiology cannot give a conclusive diagnosis and 
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1.1.6 Management of Tuberculosis 
 
Active fully sensitive tuberculosis is treated with standard quadruple therapy (rifampicin, isoniazid, 
pyrazinamide and ethambutol).  Standard treatment is 2 months initiation phase with four drugs 
followed by 4 months continuation with rifampicin and isoniazid alone [29].  This schedule is 
extended to 12 months treatment in TB meningitis.  Treatment schedules will also vary depending 
on the presence of drug resistance, which inevitably prolongs the regime and requires the use of 
second line drugs. 
Latent infection can be treated with isoniazid as a sole agent for six months or with a combination of 
rifampicin and isoniazid for three months.  A variety of preparations are available which combine 
the antibiotics and these can be administered as a daily regime or more recently as a weekly regime 
[30]. 
Multidrug resistant tuberculosis (MDR-TB), resistant to both of the first line drugs rifampicin and 
isoniazid, requires the use of an injectable agent for around 6 months along with the use of the 
remaining first line along with second line drugs, resulting in an extended treatment regime of at 
least 18 months.  This presents difficulties in adherence and treatment completion rates [31].  Newer 
drugs are being marketed for MDR-TB and XDR-TB such as bedaquiline which inhibits 
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1.2 Vitamin D 
 
The majority of Vitamin D is obtained from sunlight with just 10% obtained from the diet, 
predominantly from fish, meat and fortified foods.  During exposure to sunlight, UVB is absorbed 
by 7-dehydrocholesterol which forms pre-vitamin D3.  This is then converted to vitamin D3 and 
moves from the skin to the extracellular space [34].  This, bound to DBP, moves into the vascular 
system and is converted by hydroxylation to 25-hydroxyvitamin D3 (25(OH)D3) in the liver and 
further hydroxylated in the kidneys to form active 1,25-dihydroxyvitamin D3 (1,25(OH)2D3).  This 
has the effect of increasing calcium absorption and osteoclastic activity.  Vitamin D receptors 
(VDRs) are present in tissues of the central nervous system, endocrine system, epithelium, muscle 
and adipose [35] as well as all cells of the immune system including activated T and B cells [36, 37] 
where VDR levels increase in the presence of 1,25(OH)2D3[38].  Targeted gene expression, through 
binding to vitamin D response elements (VDREs),  triggered by the presence of vitamin D generates 
key antimicrobial products in the immune response including cathelicidin, and defensin B4 
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Figure 1.3  The vitamin D axis and the effect of DBP and VDR on immune mechanisms. 
Sunlight converts 7- dehydrocholesterol in the skin to a pre-vitamin D3, which forms Vitamin D3.  This is 
then hydroxylated in the liver to form 25(OH)D3 and further hydroxylated by CYP27b1, in the kidney to form 
1,25(OH)2D3 (other cells e.g. macrophages also have this capability).  25(OH)D3 can enter the cell by binding 
with DBP and transporter proteins cubulin or megalin or it can enter the cell by diffusion.  It can also be 
converted within the mitochondria to 1,25(OH)D3.  On entering the nucleus 1,25(OH)2D3 binds to VDR, 
causes a heterodimer to form with retinoid X receptor and binding to the VDREs of gene promotors.  The 
result of this is the alteration of gene expression (up to 9000 genes), upregulation of antimicrobial products 
such as cathelicidin, alterations in TH1-TH2 balance, activity of T regulatory cells and reduced cellular 
proliferation. 
VDR: Vitamin D receptor; DBP: Vitamin D Binding Protein; RXR: Retinoid X Receptor; VDRE: Vitamin D 
Response Element 
¶ DBP actions include sterol binding, G actin binding, chemotaxis and as macrophage activating factor 
(MAF) precursor. 
†VDR functions include control of transcription of target genes in innate immunity (cathelicidin production) 
and epidermal / hair differentiation. 
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1.2.1 Definition of Vitamin D Deficiency 
 
Serum 25(OH)D is the indicator used for assessing vitamin D levels because it best represents whole 
body vitamin D levels [40]. In contrast 1,25(OH)2D3  is tightly regulated by the parathyroid 
hormone system, and as such varies little.  25(OH)D is generally measured by one of two 
techniques: competitive immunoassay or chromatographic separation followed by non-
immunological direct detection (tandem mass spectrometry).  It is best measured by tandem mass 
spectrometry because it can be automated and is highly accurate when validated [41].   
Deficiency can result in the development of diseases such as osteomalacia and rickets, and in the 
past the critical blood level to cause these diseases has defined deficiency.  Levels of <10ng/ml 
(<25nmol/l) are known to result in rickets but are often lower in practice [42].  However a single cut 
off value for deficiency is difficult to produce, given the multifunctional effects of vitamin D; 
indeed the levels required to affect risk of extra-articular manifestations may be higher than those 
required to prevent bone loss [43].  A recent expert panel review recommended 25(OH)D level 
>30ng/ml (>75nmol/l) in those with or at risk of musculoskeletal, autoimmune, cardiovascular 
disease and cancer [44].  For this purpose during this thesis adequate circulating levels will be taken 
as ≥ 20ng/ml (≥ 50nmol/l) as recommended recently by the Institute of Medicine to meet the needs 
of 97.5% of the population [45] (see table 1.1).  More recently in 2014 NICE produced a set of 
guidelines, highlighting the importance of identifying and supplementing vitamin D in at risk groups 
[46], reiterating the statement by the Scientific Committee on Nutrition in 2007 [47]. 
 
 




Table 1.1  Vitamin D status according to 25(OH)D levels 
For the purpose of this study, sufficiency is determined as ≥50nmol/l as suggested by the Institute of 



















25(OH)D levels Vitamin D Status 
<10ng/ml (<25nmo/l) Deficient 
<20ng/ml (<50nmol/l) Insufficient 
≥20ng/ml (≥50nmol/l) Sufficient 
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1.2.2 Vitamin D Levels and Tuberculosis 
 
Numerous studies have assessed vitamin D status in TB in different populations and ethnicities.  In 
most studies the level of 25(OH)D3 was measured to assess the vitamin D status of the patient.   
1,25(OH)2D3 and 24,25(OH)D3 were also measured in other studies [48].  The definitions of severe, 
moderate and mild vitamin D deficiency varied but there are a number which noted significantly 
lower vitamin D levels in patients with tuberculosis.   
 
1.2.3 Vitamin D levels prior to and during anti-tuberculous therapy 
 
A systematic review and meta-analysis of this topic in 2008 concluded that vitamin D levels were 
highly likely to be lower in tuberculosis compared to health, although few studies met their 
inclusion criteria [49].  A further small systematic review in 2014 resulted in similar conclusions 
[50].  Some of the key original studies contributing to these, together with subsequent work are 






















(P) 6.4  
(C) 10.9  
 
Difference between patients and control 
25(OH)D levels highly significant : P<0.005  
 








(C) 26.2  
 
Significant difference in 25(OH)D levels 
between patients and controls P<0.05  
 











Significant difference in 25(OH)D levels 
between patients and controls p<0.001 
Chan et al.  
[54] 
 
Chinese (P) 23 




(C) 20.9  
 
No significant difference in 25(OH)D levels 
between groups. 
Sasidaran et 
al.  [55] 
 
Indian (P) 35 




(C) 19.5  
 
Statistically significant difference in mean 
25(OH)D levels p<0.005  
 
Wilkinson et 
al.  [56] 
Gujurati, London  
 
(P)103  




(C) 12  
 
OR for 25(OH)D level < 10 nmol/l 
(25ng/ml) in patients to controls = 2·9 ([95% 
CI 1·3–6·5], p=0·008)  
 





(P) 40  




(C) 27.8  
 
No significant difference between groups 
Ho-Pham et 
al.  [58] 






Statistically significant difference in 
25(OH)D levels only in the male group. 
P=0.001 
Sita-Lumsden 
et al.  [59] 
UK, predominantly 





25(OH)D levels were significantly lower in  
patients than control group.  P<0.001 
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Table 1.2  Summary of studies of vitamin D levels in tuberculosis patients prior to anti-tuberculous therapy.   
The table summarises the findings of key studies comparing vitamin D levels in patient (smear or culture 
positive tuberculosis) and control groups.  (P: patient; C: control; M: male; F: female).  The first seven 
studies were included in 2008 meta-analysis, two of which show no statistical significance between patient 
and control groups.  The remaining studies were carried out subsequently.  Overall the findings suggest lower 























Significant when further 8 patients included 
in patient group who were on treatment for 
TB or had a past history of TB treatment. 
Hong et al. 
[61] 
Korean (P) 94 




Median baseline 25(OH)D in the TB group 
(9.86 ng/ml, IQR 
7.19–14.15) was lower than in controls 
(16.03 ng/ml, 
IQR 12.38–20.30, P < 0.001) 
Mastala et al. 
[62] 




(C) 33.7  
Statistically significant difference in mean 
levels comparing medical patients with a 
2008 cohort of TB patients.  
Kim et al. 
[63] 




(C) 18.7  
Statistically significant difference in baseline 
25(OH)D levels between cases and controls. 
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Whether the serum 25(OH)D3 levels should be measured prior to or during treatment is a 
contentious issue.  Yamshchikov et al retrospectively measured 25(OH)D3 levels from stored serum 
before and during treatment with standard anti-tuberculous therapy in a non-controlled trial.  It was 
noted that the mean baseline serum 25(OH)D3 levels were insufficient (20.4ng/ml; range 6.9-
53.1ng/ml) and that 86% of patients had serum levels <30ng/ml.  However no significant change in 
these levels was noted during treatment [64], suggesting that assessment at either time point may be 
valid for comparisons to control groups.  This finding was also noted in a study by Banda et al 
where no significant difference was found between duration of treatment and vitamin D levels [65] 
and by Kim et al who noted no significant change in 25(OH)D levels one year after TB treatment, 
despite an improvement in nutritional status [63] .   
Despite this, other studies of 25(OH)D levels during TB treatment have been inconsistent in their 
results, unlike those performed prior to treatment. There are numerous factors which may explain 
these inconsistencies, such as socioeconomic status, sun exposure, diet, gender and ethnicity – 
illustrated by the following studies: Wejse’s study of a West African population of TB patients in 
Guinea Bissau noted hypovitaminosis (25(OH)D3<50nmol/l) in 46% of TB patients and 39% of 
controls.  However there were no significant group differences when adjusted for socioeconomic 
and demographic factors [66].  The sampling mean lag time of seven days after commencing 
therapy may have affected serum 25(OH)D levels.  Another factor to consider is that high levels of 
UVB exposure in both patients and controls may influence serum 25(OH)D levels; differences may 
be more difficult to detect in this population compared to those in sun-deprived regions [66] and the 
research is lacking regarding ultraviolet radiation exposure and anti-mycobacterial effect. Dietary 
intake of vitamin D in certain populations (e.g. Inuits who consume relatively large quantities of oily 
fish, which is high in vitamin D)  may influence pre-treatment serum 25(OH)D levels and this may 
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be the reason that in a large case control study in Greenland there were no patients with severe 
deficiency and only one with levels <20ng/ml (<50nmol/L) despite the potential lack of sun 
exposure [67].  
Gender may also influence results, as noted by Ho-Pham et al, where a statistically significant 
difference in serum 25(OH)D levels between the case and control group was only noted in the male 
group studied [58] and in the study by Talat et al, which noted significantly higher baseline 
25(OH)D values in males compared to females [60, 68]. This may perhaps be attributed to higher 
sun exposure in males at work etc. and traditional dress which may be worn and reduce sun 
exposure in females. 
Vitamin D levels were noted to be low in a case-note analysis by Ustianowski [69], where 56% of 
unselected patient with tuberculosis had undetectable levels of 25(OH)D3 (<13nmol/L) and 76% had 
levels below normal (<22nmol/L).    Somalian, East African Asian and Indian patients demonstrated 
significantly lower levels when compared to White Europeans, Chinese or SE Asians, suggesting a 
plausible role of ethnicity / skin colour on vitamin D levels. 
 
1.2.4 Vitamin D Supplementation in Tuberculosis 
 
Three major trials of vitamin D supplementation have been carried out in TB, as well as a number of 
smaller trials, observational work, and some studies looking at its role at a cellular level. The latter 
studies suggested that increasing vitamin D levels may be beneficial in TB treatment, and preceded 
the trials by some years. In vitro, vitamin D enhances the immunity to mycobacteria [70] and inhibit 
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the growth of mycobacteria [71].   Data such as this was the starting point to determine whether 
supplementation could influence levels in TB patients, although the 2011 (and 2015) Cochrane 
review on the use of nutritional supplements suggest that although blood levels of some vitamins 
may be low in patients starting treatment for active tuberculosis, there was a lack of evidence to 
promote supplementation above the recommended daily amount [72]. 
The first study was small, involving just eleven patients tested within seven days of starting anti-
tuberculous treatment, in whom there was a significant increase in 25 hydroxyvitamin D levels post 
supplementation with a single dose of 2.5mg (100000 units) of Vitamin D2 / ergocalciferol at one 
week, when compared with placebo [73].  This effect declined by 8 weeks post dose but levels still 
remained above baseline, consequently an 8 week supplementation regime was used in the later 
randomised controlled trial.  
The largest trial to date studied the effect of administering four doses of 2.5 mg (100000 units) 
vitamin D3 (Vigantol oil) versus placebo on sputum conversion in smear positive patients.  The 
supplementation resulted in improvement in the 25-hydroxyvitamin D concentrations.  However, 
supplementation did not significantly affect time to sputum conversion in the group, although a 
subgroup with rs731236 (tt Taq1) VDR polymorphism were noted to have a significantly shorter 
sputum conversion time [74].  Despite the fact that the dose of vitamin D should have resulted in 
levels >75nmol/L (30ng/ml), this was not attained in all patients receiving supplementation, raising 
questions about compliance or variation in dose-response in the patients.   Salahuddin et al. in the 
SUCCINCT study did not identify any difference in sputum conversion time or TB score between 
vitamin D supplemented (2 doses of 15mg/ 600000 IU vitamin D3) and placebo groups, but did 
however note a comparative improvement in radiological changes and BMI/ weight in the 
   33 
 
supplemented group [68]. Another study by Wejse found no significant difference in TB score or 
mortality but this may have been related to the vitamin D dosing regimen / compliance as there were 
no significant differences in change in 25(OH)D levels between the control and intervention groups 
[75].  
Further randomised controlled clinical trials include those by Morcos et al [76],  Nursyam et al [77] 
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Study Population Sample 
Size 
Intervention Results Problems 








Vitamin D3 at 0, 
5 and 8 months. 
No significant 
difference in TB 
score, mortality. 
No significant difference in 
change of 25(OH)D levels 
between groups. Mean baseline 
serum patients 25(OH)D 
77.5nmol/l (31ng/ml).  Possible 










for 6 weeks 
Significant  
difference in sputum 
conversion time at 6 
weeks 
Small group numbers.  Follow 
up serum 25(OH)D not known 







1,000 units / day Non-significant 
improvement in 
weight gain and 
clinical improvement 
in intervention group. 
Small group numbers. 
? sufficient supplementation. 
Martineau 









difference in sputum 
conversion time 
between groups. 
Expected levels of 25(OH)D 
not obtained with 
supplementation.  ? compliance 








Four doses of 







South Asian (I) 132 
(C) 127 
600000IU 
vitamin D3 at 
initiation and 1 
month. 
Mean weight gain 
4.02 kg in vitamin D 
arm versus 2.61 kg in 
placebo arm (p < 
0.05) 
 
Mean number of lung 
zones involved by 
CXR 1.35 in vitamin 
D arm versus 1.82 in 
placebo arm (p < 
0.05) 
Short follow up of 12 weeks, 
therefore unable to determine if 
response / benefit was sustained 
throughout full treatment phase. 
 
Table 1.3 Clinical trials of supplementation of vitamin D in patients with tuberculosis.  
I: intervention group; C: control group.  This table summarises key clinical trials of vitamin D 
supplementation in tuberculosis.  The intervention (vitamin D dosing regimen) and outcomes are listed for 
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Although the above data suggests a beneficial effect of vitamin D, clinicians must exercise caution 
as adverse effects could occur. In murine models cellular inflammation is lower in VDR knockout 
(KO) mice due to toll-receptor hypo-responsiveness [80], suggesting the importance of vitamin D / 
VDR in the innate immune response. In addition the chemotactic effects of increased local LL-37 
production in response to vitamin D therapy could theoretically increase cell recruitment to the lung 
resulting in exaggerated inflammation [81].   
 
 
1.3 Genetic Association 
 
1.3.1 Basic concepts in genetic association studies 
 
Identifying a genetic link with disease susceptibility can be done by linkage analysis (sharing of 
genome regions in affected relatives) or gene–disease association studies (looking at the coexistence 
of genetic markers with the disease).  
Variation in the gene product may arise through a number of mechanisms.   
Insertions or deletions (Indels) within the DNA is common and most occur in the non-coding region 
of the genome, having no effect on the individual phenotype.  However it may result in variation of 
the protein product through a frameshift mutation with loss or gain of function.  
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Polymorphisms at the DNA level can occur.  The most common form is the single nucleotide 
polymorphism (SNPs), when a difference in a single DNA base occurs at a frequency of >1% at a 
given location within the genome [82].  SNPs which lie within the coding region of the gene may be 
synonymous or non-synonymous.  Synonymous SNPs do not result in any change in the amino acid 
sequence of the protein whereas non-synonymous SNPs do alter the sequence and thereby the 
protein product e.g. CHRNA5 non-synonymous polymorphism and lung cancer risk.   However there 
is increasing evidence that synonymous SNPs are associated with disease risk and treatment 
outcomes. 
Microsatellites, which are di, tri or tetra repeats of variable length are also common and may also be 
useful as markers in genetic studies to identify allelic variants within a population.  Variation in 
these regions can be evaluated with gene localisation studies, which, by screening groups of SNPs 
can identify specific SNPs in the presence of certain disease states.  
Another concept is Copy Number Variation (CNV) which is the duplication or deletion of a DNA 
segment of 1 kilobase or larger, present at a variable copy number compared to a reference genome 
[84].  CNVs may or may not result in early onset, high penetrant genomic disorders such as Prader-
Willi Syndrome.  Instead they may be counted as ‘neutral’ in function but may be related to the 
onset or susceptibility to disease later in life.  An example of this is CNV in the gene encoding 
CCL3L1, which is a HIV-1 suppressive chemokine and ligand for CCR5, a HIV-1 ligand.  Those 
with lower levels of CCL3L had lower CCL3L1-CCR5 binding and therefore more open CCR5 
receptors remained to potentially bind with HIV-1, thereby increasing the risk of infection [83].   
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Identifying a genetic link with disease susceptibility can be done by linkage studies or gene-disease 
association studies. 
1) Linkage studies aim to identify a genetic marker inherited by all those with the disease.  If a 
genetic marker lies in close proximity to the disease gene, then although recombination does 
not occur between the two regions, they have a tendency to be inherited together and are said 
to be linked due to it.  Linkage analysis aims to determine if this link is present. 
2) Gene-disease association studies aim to identify variations within a gene which may 
predispose to the disease in question.  Such studies may be done for single genetic variations, 
a gene, or the whole genome (genome-wide association study; GWAS). 
 
Linkage disequilibrium (LD) is the non- random association of alleles at two or more loci, resulting 
in certain combinations of alleles being more likely to occur on a chromosome than other 
combinations.  By detecting this indirect association between the alleles, disease associations can be 
screened for using a reduced number of markers, with the knowledge that through LD, the whole 
spectrum of variants will be detected [84].  The pattern of SNPs located in close proximity and 
which may be inherited in blocks (due to high linkage disequilibrium), are known as haplotypes.  
These haplotypes can be identified by one of the SNPs, the tagSNP which then allows the resultant 
block to be identified on the Haplotype Map (HapMap) described below.  In practice this means that 
relatively few polymorphisms need to be genotyped in order to identify genetic variance in that 
region. 
The rapid pace at which genotyping technology has developed means that in many common diseases 
huge numbers of genetic association studies have been published.  However in many cases little is 
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known about the role of the polymorphisms, such that functional studies of the gene and/or SNP are 
required.  Functional studies aim to determine (a) the role of a gene and its protein product in 
disease and (b) how a SNP may alter this.  An example of such a study by Ben-Selma et al which 
notes the IL23R functional polymorphism association with the severity of active pulmonary 
tuberculosis [85]. 
 
1.3.2 Genetic resources 
 
The Human Genome Project was an international effort to sequence the whole human genome and 
this has meant that publicly available resources for genetic studies have grown rapidly in the last 10 
years.  Despite being able to identify every human gene, the relevance of this work will not be 
immediately seen and further projects / databases enable the link between the human genome and 
the link between health and disease states to be made. 
An example of an international collaboration in this way is HapMap.  The aim of this project is to 
produce a catalogue of common genetic variants in the form of haplotype identification using 
tagSNPs.  This enables researchers to choose haplotype tagging SNPs for small scale work and, at 
the other end of the spectrum, interpret GWAS results, where large numbers of genes may be 
associated with disease. 
 In addition there are numerous databases such as those in the National Library of Medicine, 
including dbSNP (documenting short variations in nucleotide sequences), OMIM (concentrating on 
genotypic variation and phenotypic expression), Gene (database for known and predicted genes) etc. 
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1.3.3 Genetic association studies in TB 
 
The number of genetic association studies which have researched host susceptibility to tuberculosis 
are limited and often underpowered.  Twin studies have found that  the concordance for tuberculosis 
was significantly higher among monozygotic than dizygotic twin pairs[86].  However despite later 
analysis of specific genetic associations including HLA, NRAMP1, IFNG, NOS2A, SP110, CCL2, 
MBL, CD209, VDR and TLR none have given the degree of association seen in the original twin 
studies.  More recently review of these earlier studies suggest that intensity and duration of exposure 
to the bacilli has a greater influence than zygosity of the twin  and the degree of exposure may in 
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Table 1.4  Association studies between innate immune genes and tuberculosis. 
This table summarises some of the studies of genetic association in tuberculosis susceptibility and protection.  
The polymorphisms studied are listed with the studies in the order that they appear in the references listed.  
Genes studied include SLC11A1 (solute carrier 11A1), TLR (toll like receptor), MBL (mannose binding 
lectin), CISH (ytokine inducible SH2 containing protein), DC-SIGN (dendritic cell-specific intercellular 
adhesion molecule-3-grabbing non-integrin), CCL2 (chemokine (C-C motif) ligand 2), TIRAP (adaptor 
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Two genome wide association studies (GWAS) [117, 118] differ in their conclusions, suggesting 
that there is variation in the susceptibility according to continent of origin [118].  Thye et al 
combined two populations from Ghana and the Gambia, finding in over eleven thousand individuals 
rs4331426 (chromosome 18q11.2) was associated with disease.   Chimusa et al failed to identify this 
association in a GWAS of the admixed South African Coloured (SAC) population, but found SNP 
rs2057178 and rs11031728 had an association result with genome-wide significance (WT1, Wilms 
tumour 1 gene on chromosome 11).  This association was also suggested after imputation of data 
from the 1000 Genomes Project into populations from West Africa, Indonesia and Russia in another 
study by Thye et al [119].  Interestingly WT1 has a role in upregulation of VDR. 
The genetic association studies looking specifically at the association of the vitamin D axis on host 
susceptibility to tuberculosis are discussed in more detail in the thesis and the information on these 
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1.4 Vitamin D Receptor (VDR) and Tuberculosis 
 
 
The presence of a genetic relationship to the protectiveness of 1,25(OH)2D3 was identified in early 
studies reporting inhibition of tubercle bacilli in macrophages with supplementation [120].  Since 
then, allelic variants in VDR have been linked to regulatory pathways in bone and calcium 
homeostasis [121].  VDR polymorphisms have been extensively described in association with bone 
mineral density but there have been numerous studies more recently looking at its relationship with 
resistance or susceptibility to Mycobacterium tuberculosis [56, 122-126].  
 
VDR (a nuclear hormone receptor) is activated by binding of the ligand 1,25(OH)2 D3.  The VDR 
then binds with another intracellular receptor (retinoid X receptor).  A heterodimer is formed which 
enables DNA binding and the effect is usually to activate transcription for target genes, the net result 
being the regulation of expression of proteins involved in calcium homeostasis [127] and 
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Figure 1.4  Vitamin D receptor  (VDR) gene structure 
VDR belongs to the transacting transcriptional regulatory factors.  The non-coding 5’ end of the gene 
contains non coding exons (1a-e), whilst exons 2-9 encode the translated product.  Exons 2 and 3 are 
involved in DNA binding and exons 7, 8 and 9 are involved in binding to vitamin D.  Restriction fragment 
length polymorphisms (RFLP) for Bsm1, Apa1 (exon 8) and Taq1 (exon 9) lie at the 3’UTR (untranslated 
region).  Fok1 polymorphism at exon 2 and CDX2  is found in the promotor area 1e.  Tru91 is a 
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VDR is amongst the best studied genes in tuberculosis. It lies on chromosome 12 (12q13.11) and 
contains 11 exons spanning 75kBa.  The most commonly studied VDR polymorphisms to date are 
FokI, ApaI, TaqI and BsmI (Table 1.5).  These lie at the 3’ un-translated region of the gene (FokI in 
exon 2, BsmI and ApaI in intron 8 and TaqI in exon 9).  They have been shown to be associated with 
stability of the VDR mRNA [128] such that carriers of a variant may potentially have decreased 
ability to respond to vitamin D.  In addition, Cdx-2 and A1012G exist at the 5’regulatory region and 
are known to affect the transcriptional activity of VDR. 
 
The function of VDR in the regulation of antimicrobial products such as cathelicidin closely links it 
to the immune response to tuberculosis.  A recent systematic review noted an association for Fok1 
and Bsm1with tuberculosis in Asians [125], with a more recent study also noting an association of 
Bsm1 variants with TB in a Turkish population [123].  However it is difficult to be sure there is  a 
definite association of VDR polymorphisms with risk of TB, partly due to the small numbers of 
participants in the studies and partly because of confounding factors that may have not been 
addressed such as HIV status [96] and ethnic diversity [129].  Two subsequent studies found no 
significant difference in association with VDR polymorphisms between TB patients and healthy 
controls [130, 131]. 
Regarding the effect of VDR polymorphisms on TB outcome, a study by Martineau noted that when 
supplemented with Vitamin D, the sputum conversion time was faster in those with the tt genotype 
of the Taq1 polymorphism [5]. 
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1.5 Vitamin D Binding Protein (DBP) and Tuberculosis 
 
 
Vitamin D Binding Protein (DBP) is also known as group specific component of serum (Gc-
globulin).  The usual nomenclature for the gene is therefore GC. 
The structure of DBP is similar to albumin.  The structure of albumin and α fetoprotein is made up 
of three domains, each consisting of three sub-domains whereas DBP, although similar, lacks two of 
the sub-domains at the C-terminal.  The conservation of the pattern of disulphide bonds which are 
responsible for the structure of each looped domain supports the evidence for their relationship 
[132].  The finding that α-fetoprotein bound oestrogen with high affinity [133] prompted 
consideration of DBP as a steroid binder. 
DBP has two primary binding functions: sterol binding and G-actin binding.  The ability of DBP to 
bind vitamin D was noted in studies of radiolabelled vitamin D3 [29].  It is this function that allows 
binding and transport of both 25(OH)D3 and 1,25(OH)2D3.  DBP internalises vitamin D using 
receptors megalin and cubulin.  However these only occur in some cells (e.g. renal proximal 
tubules) and studies have indicated that in cells with no evidence of these receptors (e.g. 
monocytes), the uptake of vitamin D is lower.  Paradoxically the genotypes with highest affinity 
(GC1F-1F allele combination) appear to have a reduced response in production of cathelicidin 
(antimicrobial) when compared to the lower affinity genotype (GC 2-1S).  This maybe an 
evolutionary alteration conferring increased cathelicidin production in response to vitamin D 
stimulus in those individuals with lowest affinity for vitamin D ligands at low serum levels [134] .  
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The second binding function of DBP is with G-actin.  Following tissue injury, elevated levels of 
actin appear in the plasma and DBP clears this by forming DBP-actin complexes [135]. This 
prevents the formation of F-actin polymers. The function of these actin arrays in intracellular 
motility  M. marinarum has been noted, although this is not known in M. tb [136].  The function of 
DBP in G-actin binding, related to prevention of direct pulmonary endothelial injury in a study of 
ARDS patients [137] could conceivably be applied to the mechanisms of lung injury in tuberculosis. 
DBP also plays a role in chemotaxis by enhancing C5a activity [138-141]. It appears to have no 
effect on its own but in the presence of even non-chemotactic doses of C5 derived peptides, its 
effect on chemotaxis is noted [139].  Zhang et al identified a 20 amino acid sequence in the N 
terminal domain I of DBP which possessed C5a chemotactic cofactor activity, known to act as a 
chemotactic factor for all leucocytes [142].  DBP may therefore be relevant in recruitment of cells to 
sites infected with M. Tb. 
DBP is also a precursor for macrophage activating factor (MAF) [96].  DBP is converted by 
glycosidases of B and T cells to MAF [143].  The ingestion activity function of macrophages 
(important in determining response to tuberculous infection), is enhanced by MAF. 
GC is located on chromosome 4 (4q11-q13) and study of GC show that it is highly polymorphic 
with three main electrophoretic variants [29] as illustrated in table 1.6.   Single nucleotide 
polymorphisms (SNPs) at exon 11 (rs7041 and rs4588) result in GC1 and GC2 variants [144] with 
GC1 subdivided into GC1S and GC1F, reflecting the presence of aspartic acid or glutamic acid 
respectively at position 416 [145].  Alongside these there are more than one hundred and twenty 
other less common variants [136].   
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Variant Alleles at rs7041 and rs4588 Protein composition at positions 416 and 420 
GC1F T/C Asp/Thr 
GC1S G/C Glu/Thr 
GC2 T/A Asp/Lys 
 
Table 1.6  Haplotypes of rs7041 and rs4588 result in structurally different proteins. 
The table shows the alleles present at rs7041 and rs4588 respectively (forward strand) and the resulting 
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In a study of Caucasian women by Lauridson et al the median plasma levels of 25(OH)D3 differed 
significantly between GC phenotypes (combinations of GC1F, GC1S and GC2), with the highest 
levels being noted in GC1-1 group (also known to have the highest affinity for vitamin D ligands), 
intermediate levels in GC1-2 group and lowest levels in GC2-2 group [146]. However despite this, 
the individuals in the GC2-2 groups showed no signs of vitamin D deficiency clinically, indicating a 
possible reduction in required circulating vitamin D requirements in order to remain ‘sufficient’.   
Martineau et al noted that the association between GC genotype and susceptibility to active 
tuberculosis in Gujurati Asians was dependent on the vitamin D status [147].  It was noted in this 
multi-centre study that there was a significant association between GC genotype (Gc2-2) and 
tuberculosis in those with vitamin D deficiency.  This was lost however in those with serum 
25(OH)D3 levels >20nmol/L [148], suggesting an interaction between genotype and vitamin level in 
disease risk.  
Consistent with these small studies in TB a much larger GWAS in the general population has shown 
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1.6 Other relevant polymorphisms in the vitamin D axis. 
 
 
In addition to GC and VDR there are several other key genes which may be relevant in the cellular 
response to vitamin D (Figure 1.5). 
 
DHCR7/NADSYN1 (dehydrocholesterolreductase, NAD synthetase 1) 
This gene, located at 11q13.4 encodes for 7-dehydrocholesterol reductase which catalyses the 
conversion of 7-dehydrocholesterol to cholesterol by removing the C (7-8) bond in the B ring of 
sterols.  Mutations in this gene could result in reduced conversion of 7-dehydrocholesterol, thereby 
increasing the availability of it for conversion in the skin to pre-vitamin D3. 
Although some smaller studies have found have reached differing conclusions, recently two genome 
wide association studies (GWAS) have found that there is an association between 
DHCR7/NADSYN1 and 25(OH)D levels [150, 151].  
 
CYP27B1 
CYP27B1 is located on chromosome 12 (12q14.1) and the protein it encodes known as 1-α-
hydroxylase is a member of the cytochrome p450 family.  It is responsible for the hydroxylation of 
25(OH)D3 at the 1-alpha position to the active metabolite 1,25(OH)2D3 [152] which in turn binds to 
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the vitamin D receptor and regulates calcium metabolism. Vitamin D-dependent rickets type 1A 
(VDDR1A) is due to a mutation in CYP27B1.   
 
CYP24A1 
This gene encodes the enzyme responsible for degradation of 25(OH)D.  It has not been found to be 
directly linked to vitamin D levels in GWAS but a 5-point frequent haplotype 
(rs2296241:rs17219315:rs2762942:rs2248137:rs2248359) was found to be associated with both 
25(OH)D3 and 1,25(OH)2D3 levels [153]. 
 
CYP2R1 
This is just one of the enzymes responsible for the hydroxylation step to 25(OH)D at the microsomal 
level. Variants in the CYP2R1 locus have been associated with vitamin D levels in GWAS [150, 




CYP27A1, found in the mitochondria, and has vitamin D 25-hydroxylase activity.  The relevance of 
polymorphisms of this gene in relation to vitamin D has not been determined. 
 
 




Figure 1.5  Genetic polymorphisms of key enzymes in the vitamin D axis. 
The key enzymes involved in the conversion and activation of precursors to vitamin D.  7-dehydrocholesterol 
is hydroxylated in the liver to 25(OH)D3 and further hydroxylated in the kidney to produce 1,25(OH)2D3, 
which is then transported into the cell by mechanisms including GC (group specific component) also known 
as vitamin D binding protein.  Ligand bound VDR (vitamin D receptor) forms a heterodimer with RXRA 
(retinoid X receptor alpha) which signals to upregulate the transcription of target genes involved in 
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1.7 Immunomodulatory effects of vitamin D on circulatory blood cells 
 
 
Vitamin D is known to have numerous functions in the response to infection, involving the innate 
and acquired immune systems and the maintenance of epithelial barrier function [155].  All of these 
functions can be applied specifically in the antimicrobial response to infection with M Tb. The 
formation of a granuloma in response to mycobacterial infection, results in a structure rich in 
polymorphonuclear leucocytes, mononuclear leucocytes and lymphocytes.  The most important 
components of anti-mycobacterial activity are macrophages (innate immunity) and lymphocyte 
subsets (adaptive immunity), as illustrated in figure 1.6, with vitamin D exerting both inhibitory and 
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Figure 1.6 Innate and Adaptive Immune Response to Mycobacterium Tuberculosis Infection.   
Mycobacterium tuberculosis uptake occurs by binding to a variety of receptors on macrophages and dendritic 
cells.  Signalling pathways (after binding to toll like receptors) result in cell activation, cytokine and 
chemokine production.  Binding of mycobacterial structures with toll like receptors results in activation and 
nuclear translocation of transcription factors such as NF-kB, leading to gene transcription and activation of 
the innate defence mainly by cytokine production such as TNFα, IL1β, IL12 and nitric oxide. 
Neutrophils play a key role in innate defence.  The production of specific cytokine such as TNFα stimulates 
dendritic cells and macrophage activation and differentiation.   
The adaptive immune response (cell mediated response) is activated by antigen presentation of mycobacterial 
peptides as dendritic cells move to the draining lymph nodes.  This activates naïve T cells to differentiate into 
various phenotypes according the cytokine profile.  The naïve T cell differentiates into effector Th1, Th2, 
Th17 and T regulatory cells which can then migrate to the lung.  A protective Th1 response results in the 
activation of macrophages and the production of antimicrobial products driven by IFNγ.  Granuloma 
formation occurs, encasing the mycobacterium and is rich in polymorphs and lymphocytes.  Dysregulation in 
this cytokine response results in breakdown of the granuloma and dissemination of infection. 
The immune response is regulated by other effector responses to avoid damage from a vigorous host immune 
response.  This is driven by IL10 production from regulatory T cells and may lead to persistence of infection. 
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Figure 1.7  Effect of vitamin D on lymphocyte and immune regulatory cells. 
An illustration of the multicomponent effect of vitamin D within the immune system, including its effect on 
B and T lymphocytes, macrophages and antigen presentation. 
TLR, toll like receptor; MHC, major histocompatibility complex; IL, interleukin; NFkB, nuclear factor kappa 
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Innate Immune Response 
 
Toll Like Receptors and Cathelicidin Production 
 
Infection with microbial pathogens such as M Tb results in activation of toll like receptors (TLRs) 
which are triggered by PAMPs, which in turn results in cytokine production.  Data suggests that the 
TLR activation results in the up-regulation of VDR and CYP27B1 (1α hydroxylase, which converts 
25(OH)D3 to the active 1,25(OH)2D3) expression [156].  Under the correct conditions, this then 
results in cathelicidin production (h-CAP, cleaved to produce LL37 in humans) which has direct 
anti-mycobacterial effect [157], since the human cathelicidin gene promoter contains three vitamin 
D response elements [158].  In addition LL37 has chemotactic activity for polymorphonuclear 
leucocytes and CD4+ T lymphocytes [159].  This appears to be a clinically relevant response since 
higher levels of LL37 correlate with increased disease burden from M.tb infection [160]. 
Another antibacterial protein DEFβ4 requires occupancy of not only VDRE but also nuclear factor 




Recent studies have reported an association between vitamin D, cathelicidin and autophagy.  
Autophagy is an essential anti-mycobacterial strategy [162] augmenting the bactericidal degradation 
of the mycobacterium by fusion of the autophagosome with the lysosome, thus disturbing the 
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evasion strategies of M. tuberculosis.  Vitamin D (1,25(OH)2D3) enhances the recruitment of 
cathelicidin to autophagosomes, thereby inducing autophagy [163]. It has also been shown to inhibit 
M.tb and HIV replication in co-infected macrophages via the cathelicidin dependent autophagy 
[164].  The production of antimicrobial peptides such as cathelicidin then creates an association 
between the adaptive and innate immune system, such that direct anti-mycobacterial actions act 
synergistically with the ability to stimulate chemotaxis of cells involved in the adaptive immune 
response [165].  
It has also been shown that  1,25(OH)2D3 results in the release of superoxide from M.tb infected 
cells [166] and it has been suggested that 1,25(OH)2D3 suppresses the growth of M. tuberculosis in 
macrophages through the production of nitric oxide [167] in addition to promoting the anti-
mycobacterial step of phagolysosome fusion [168].  
 




Dendritic cells are vital in antigen presentation to T cells and the capability of dendritic cells to 
activate T lymphocytes affects the host’s pathogenic response.  Studies have shown that the 
maturation and differentiation of dendritic cells can be inhibited by the action of 1,25(OH)2D3 in 
vitro [169], resulting in down regulation of MHC Class II molecules and thereby T cell activity.  
The presence of maturation markers in dendritic cells is reduced after exposure to both 25(OH)D3 
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and 1,25(OH)2D3 and the cytokine profile differs in those cells exposed to 25(OH)D3 compared to 
those not exposed, specifically with a reduction in pro-inflammatory cytokines such as IL12 (vital in 
Th1 responses) in immature dendritic cells [170].   
It has also been shown that 1,25(OH)2 D3  inhibits the  Th1 inducing capacity of myeloid dendritic 
cells (i.e. capability of inducing naïve CD4+ T cells to differentiate) [171], with exposure to 
1,25(OH)2 D3 resulting in regulatory dendritic cells that are poor stimulators of T cells, inducing T 
cell hypo-responsiveness [172]. 
 
T cell activity 
 
The cytokine profile produced during mycobacterial induced toll like receptor (TLR) activation 
determines whether a Th1 (predominantly cell–mediated response) or a Th2 (predominantly 
humoral) response is dominant.   
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Cytokine TH1 TH2 
IL-2 + - 
IFNγ ++ - 
TNF-α ++ - 
GM-CSF  ++ + 
IL3 ++ ++ 
IL4 - ++ 
IL5 - ++ 
IL10 - ++ 
IL13 - ++ 
 
Table 1.7 Cytokine production in TH1 and TH2 immune response. 
Th1 (T helper1) and Th2 (T helper 2) responses produce particular cytokine combinations, resulting in 
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The production of IL12 by macrophages induces the production of IFNγ [173]. Consistent with this, 
the disruption of the IL12 gene in mice results in the inability to produce IFNγ and subsequent 
overwhelming bacterial infection in the mice [174].  
The above evidence would point towards suppression of the TH1 response in TB, which may appear 
unusual, given that IFNγ is a key component in activity against intracellular pathogens, including 
mycobacteria.  However it may be that the unwanted TH1 effects are reduced and whilst enhancing 
chemotactic and phagocytic activity, 1,25(OH)2D3 appears to impair the production of pathogenic T 
cells [175].  Whilst vitamin D suppresses the TH1 response, murine studies on graft survival have 
indicated that this does not overtly compromise the host’s ability to fight infection [176].  
 
T cell subtypes – regulatory T cells (Treg) and  Th17 activity. 
 
Inflammatory cytokines are important in determining induction of T cell subtypes.  TGFβ is required 
for the development of inducible T regs, whilst both TGFβ and IL6 are required for the development 
of a newer T cell subset, Th17 [177].  Both types may be relevant to M.tb infection. 
T regs are involved in immune tolerance and are characterised by the high surface expression of 
CD4, CD25 (IL2 receptor) and low surface expression of CD127 (IL17 receptor).  They also express 
a transcription factor FoxP3 (forkhead box P3) and intracellularly express CTLA4+.  Activated T 
cells are known to express VDR [178] and it has been shown that whilst 1,25(OH)2D3 inhibits 
inflammatory cytokine production such as IFNϒ, IL17 and IL2, the regulatory cytokine IL10 
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increases in the presence of vitamin D [179].  The percentage of Tregs also increases with vitamin D 
supplementation in healthy individuals [180].   The relevance of these findings in relation to 
tuberculosis is that whilst T reg function regulates the pathological consequences of infection, their 
presence may also down regulate the immune response resulting in persistence of infection in the 
latent state.     
Th17 cells are characterised by the expression of  IL17A, IL17F, IL17AF, IL21, IL22 cytokines and 
surface expression of chemokine receptors CCR5 and CCR6 [181].  An important function of T17 
cells is to mediate the recruitment of neutrophils and monocytes to sites of inflammation, through 
the production of IL6, IL8, G-CSF and SCF (stem cell factor).  This is particularly important in 
extracellular infections. 
1,25(OH)2D3 has been shown to directly reduce IL17 production and indirectly by reducing IL17 
polarizing cytokines produced by dendritic cells [182], suppressing inflammatory outcomes whilst 
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CD4+ Subset Cytokines Main Transcription 
Factors 
Function 




















Table 1.8  CD4 T helper cells, their cytokines, main transcription factors and functions. 
Naïve T cells interact with an antigen – MHC complex and depending on the cytokines present in the 
environment, will result in differentiation into differing CD4+ lineages. The combination of cytokine signals 
and activation of specific transcription factors, which initiate and regulate the transcription of genes, result in 
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B cell activity 
 
B cells stimulated in the presence of 1,25(OH)2D3 exhibit up-regulation of VDR , whilst exposure of 
unstimulated B cells to 1,25(OH)2D3 causes inhibition of B cell proliferation, plasma cell 
proliferation and immunoglobulin production [183]. 
A recent study indicates that activating VDR using calcitriol results in impaired NF-kB 
(transcription factor) activation in human naïve B cells, specifically reducing p105/p50 expression 
[184], involved in IgE class switching.  B cells are also able to upregulate IL-10, which promotes B 
cell differentiation, by converting pre-vitamin D3 to calcitriol [185]. 





Monocytes are known to be sensitive to lipopolysaccharide (LPS) and the response to this 
stimulation results in the production of numerous cytokines.   The effects of vitamin D on 
monocytes has been studied and it is known to have a modulatory effect on cytokine production 
including IL-alpha, IL-6 and TNFα [186], a mechanism thought to be actioned via MAPK-1 (a 
mitogen activated protein kinase phosphatase), resulting in suppression of p38 (a mitogen activated 
protein kinase) phosphorylation and cytokine production [187].  The relevance of this effect on M.tb 
infected cells needs further elucidation. 
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1.8 Aims of the MD 
 
 
The aims of the MD are based on the following hypotheses: 
 
1. Genetic polymorphisms in the vitamin D axis determine the response to vitamin 
D supplementation in patients with tuberculosis. 
There is growing evidence that vitamin D deficiency, genetic polymorphisms which associate with 
this and genetic variations that determine response to vitamin D are linked to tuberculosis. It also 
seems likely that supplementation with vitamin D could help in TB treatment. However, a 
systematic study of genes determining vitamin D levels and response to supplementation in patients 
with tuberculosis has not been carried out.  Previous studies have selected only a few SNPs, and 
their role in response to supplementation has not been replicated. This MD will use an open label 
study of vitamin D supplementation in active TB patients to explore the role of genetic 
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2. Baseline vitamin D and other elements of the vitamin D axis may affect clinical 
outcome / antimicrobial response. 
The relationship of TB outcomes to vitamin D level and the interaction above will be sought in 
clinical trial patients.  Clinical improvement will be defined by change in TB score, sputum 
bacteriology and radiology. Relevant cytokines indicating antimicrobial response and response to 
vitamin D will also be measured, as will level of DBP, since this has potential to influence 
interaction between DBP and vitamin D. 
 
3. Vitamin D exerts an immune modulatory effect in vitro and ex vivo, in both 
health and mycobacterial disease. 
In vitro work will determine the effect of vitamin D on  
a) stimulated monocytes in determining inflammatory cytokine response (IL6) and 
antimicrobial (LL37) production in healthy subjects, active and latent TB patients.  The 
response pre and post in vivo supplementation as well as the mechanism of potential benefit 
will be explored. 
b) the effect on T reg and Th17 balance in  relevant subsets of healthy subjects, active and 
latent TB patients exploring the mechanism by which vitamin D may be beneficial, and 
determining if T cell response to vitamin D is impaired in TB.  
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4.  Genetic polymorphisms of the vitamin D axis determine the in vitro / ex vivo 
response to vitamin D supplementation in patients with mycobacterial infection. 
Understanding the functional role of polymorphism within the vitamin D axis may aid our 
understanding of poor response to vitamin D clinically in previous supplementation trials. Data from 


















2.1 Study Design, Outcome and Sample Size 
 
2.1.1  Design 
 
The study was an open label exploratory observational study, in which subjects with a clinical 
diagnosis of active tuberculosis were supplemented with vitamin D.  All subjects received 
supplements, regardless of their baseline vitamin D levels and all other treatment was dictated by the 
clinician.  The main reason not to run the study as a controlled study was based on the fact that this 
would have resulted in patients with severe vitamin D deficiency potentially having no 
supplementation for up to six months during the period of the trial.  This could not be justified and 
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2.1.2 Ethics and Medicines Health Regulatory Authority (MHRA) Approval 
 
Since this was a trial of a food supplement it would not usually require MHRA approval, however 
since in this case some outcome measures were outside the usual licence indications for vitamin D 
we were asked by the MHRA to classify this as a phase III clinical trial of an investigational 
medicinal product (CTIMP). 
The trial was an observational study using Vitamin D (Dekristol 100,000 units) in patients with 
active tuberculosis. As part of my work towards this thesis I completed all necessary steps for 
ethical and MHRA approval and gained permission from the Coventry and Warwickshire Research 
Ethics Committee (REC). The initial trial design is summarised in the flowchart below.  
Amendments to the design were made at 4 time points in order to address problems with recruitment 
rates, and extend the in-vitro elements of the study to latent TB patients. The final trial protocol is 
described in section 2.2 and copies of relevant REC and MHRA documents, including consent 
forms, can be found in the appendices. 
 
2.1.3 Primary outcomes and Sample Size Calculations 
 
The primary outcome was to define the interaction between vitamin D binding protein genotype 
(GC genotype) and pre-supplementation vitamin D level in determining post-supplementation 
vitamin D level at visit 1. This is defined as a departure from additivity of effects when considering 
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genotype and starting vitamin D level as predictors of post supplementation level, and would be 
suggestive of a biological interaction, as predicted from DBP protein structure and function. 
Power calculations can be unreliable in observational studies and the primary outcome was to 
identify if vitamin D baseline levels and DBP genotype determine post supplementation vitamin D 
response. Vitamin D has influences on many antimicrobial factors, which we did not have pilot data 
on, and we could not assume that total vitamin D response is proportional to a sole marker. Other 
outcomes including LL37 levels are measured in a different manner to vitamin D and therefore the 
powering of the study for the variety of outcomes proved difficult.   
However sample size calculations for this study identified in the original study protocol were based 
on the minor allele frequency (risk allele) of the main electrophoretic variants.  
GC genotype would be unknown at the time of enrolment hence we aimed for a total of 160 patients 
enrolled, to allow for inequality of genotype distribution. The minor allele frequencies of rs4588 and 
rs7041 vary between races such that the minor allele of rs4588 is seen in 27% of Caucasians, 32% of 
Gujarati Indians and 5% of black Africans. The minor allele worldwide of rs7041 is seen as the 
major allele in Caucasians, with a frequency of 57%, and as a minor allele in Indians (49%) and 
African races (18%). Initial data from Heartlands and UHB shows that 35% of registered cases in 
2009 occurred in Caucasians, 50% in Indian or Pakistani patients, 12% in black Africans, with the 
remainder in other ethnic groups. Based on these incidence figures and mean allele frequencies for 
rs4588 and rs7041 a risk allele will occur in 24/56 Caucasians, 32/80 Indian/Pakistanis and 2/19 
black Africans of 160 recruited, being more than adequate for comparison to the non-risk allele 
carriers (n=58 v n=102). We aimed to recruit 30 patients of each GC genotype of importance to the 
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study.  These estimates also allow for drop outs of up to 40% in each arm, although current local 
figures suggest this will be closer to 15%, since 86% of patients complete treatment. 
As the study progressed, recruitment was slower than expected and the in vitro work was added in to 
support the clinical study and allow for lower patient numbers than were originally planned for in 
















Diagnosis of TB made and vitamin D level checked 
 
 
Diagnosis of TB made and vitamin D level checked 
 
Enrolment to study. Blood taken for DBP, cathelicidin and LL37 
measurement and DNA extraction. 100000IU vitamin D3 administered orally  
 
Enrolment to study. Blood taken for DBP, cathelicidin and LL37 measurement 
and DNA extraction. 100000IU vitamin D3 administered orally  
Follow up visit. Blood taken for ELISAs as above, vitamin D and calciu  
measurement. 100000IU vitamin D3 given to patient. 
 
 
Follow up visit. Blood taken for ELISAs as above, vitamin D and calcium 
measurement. 100000IU vitamin D3 given to patient. 
 
Follow up visit. Blood taken for ELISAs as above, vitamin D and calcium 
measurement. 100000IU vitamin D3 given to patient. 
 
 
40 cyclesFollow up visit. Blood taken for ELISAs as above, vitamin D and calcium 
measurement. 100000IU vitamin D3 given to patient. 
 
Follow up visit 
Blood taken for DBP, vitamin D and calcium measurement 
 
 
Follow up visit 
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2.2 Clinical Methods 
 
 
2.2.1 Subject Selection 
 
Patients were selected from respiratory / tuberculosis clinics at the Heart of England Foundation 
Trust on a consecutive basis.  Adult patients able to consent to research with a microbiologically or 
histologically confirmed diagnosis of active TB were included. A positive microbiological diagnosis 
was defined by positive microscopy smear or culture of M.tb in the setting of clinical suspicion of 
M.tb infection.  Patients were enrolled at the start of their anti-TB therapy.  
 
Exclusion criteria were: 
1. Patients being managed with regimes outside of the standard NICE guidance [188] 
2. Drug resistant M.tb 
3. HIV positive  
4. Known intolerance of vitamin D 
5. Sarcoidosis 
6. Hyperparathyroidism or nephrolithiasis 
7. Taking vitamin D supplementation in the two months preceding enrolment 
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8. Baseline serum corrected calcium >2.65 mmol/L  
9. Current haemodialysis 
10. Children under 18 years, pregnant or breastfeeding individuals 
11. Concomitant benzothiadiazine derivative, cardiac glycoside, carbamazepine, phenobarbital, 
phenytoin, primidone or long-term immunosuppressant therapy  
Once recruited, patients were clinically assessed using the TB score (see below) and radiology 
findings.  Blood was taken for extraction of serum and plasma and whole blood was frozen for DNA 
quantification.  Each patient was given (directly observed) 100,000 units of Dekristol© 
(cholecalciferol) at week 0, 8 and 16.  Follow up was maintained for 6 months in clinic and if 
treatment lasted longer than 6 months, notes were reviewed. 
 
2.2.2 Demographic Data Collection 
 
Demographic data was recorded including baseline information (age, address, gender, height and 
weight) ethnic origin, year of entry to the UK, HIV status if known (checked as routine clinical 
practice in all TB cases if consent obtained), smoking history, history of illicit drug abuse or alcohol 
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2.2.3 TB Score 
 
At the time of enrolment TB severity was assessed using the TB score, which is a composite of 
symptoms and signs, recognised as a predictor of subsequent mortality, with a maximum score of 13 
and good inter-observer agreement [189].  The TB Score was recorded at each subsequent visit at 8, 





The severity of pulmonary disease was recorded using either chest radiography or CT thorax.  
Scoring systems for radiological investigations in tuberculosis are not widely used.   X- rays were 
graded according to percentage lung involved and whether cavities were present.  This is known to 
determine sputum positivity duration [190].   CT images were available for some patients and these 
could be scored in the same way if necessary.  CT imaging provides a more detailed view of the 
lung tissue and smaller lesions which are present on CT may not be visible on CXR.  Where 
possible, CXR scoring was calculated.  The CXR score used was validated by Ralph et al [191], 
which calculates a score based on consolidation extent noted on CXR and the presence of cavitation. 
CXR Score = % proportion of total lung affected + 40 (if cavitation present) 
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2.2.5 Blood Sampling 
 
Blood was taken for 25(OH)D3 level (nmol/l), calcium level, C reactive protein , full blood count, 
urea and electrolytes and liver function tests at 0, 8, 16 and 24 weeks.  These were measured by the 
Heartlands Hospital Laboratories as part of their NHS assessment.   In addition blood was taken for 
the measurement of DBP and LL37 and extraction of DNA for genotyping which was carried out at 
the University of Birmingham Research Laboratories. Since these tests were specific to the research 
trial they are described within the laboratory methods (section 2.3).   Serum and plasma were stored 
for measurement of other potential biological markers later in the project, which were determined as 
initial results were generated. 
 
2.2.6 Smear Microscopy, Culture and Histology 
 
Samples were sent for microscopy (acid fast stain) and subsequent culture for M.tb on all patients 
able to expectorate. In some the diagnosis was made on bronchoscopy washings to confirm the 
diagnosis. Further sputum samples were sent at each subsequent visit to determine sputum 
conversion rates, if the patient was able to provide one.  Histology sampling was carried out prior to 
the first clinic visit as appropriate. All such tests were part of routine NHS practice. 
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2.2.7 Dosing Regimen of Vitamin D 
 
Clinic visits occurred at 0, 8, 16 and 24 weeks, and at each visit the vitamin D level (25OHD3) 
checked.  All subjects received 100000 units of vitamin D3 orally (Dekristol capsules) at the 
baseline visit, and at 8 and 16 weeks, directly observed by the investigating team. 
Vitamin D replacement at this dose results in a rise in vitamin D levels that would elevate to the 
sufficient range (>50nmol/l) and should also result in stable levels within the normal range over the 
subsequent 8 weeks, as shown elsewhere [192].  This pharmacokinetic study justifies the dose and 
dosing schedule chosen here. 
 
 
2.3 Laboratory Methods 
 
 
2.3.1 Acquisition of serum and plasma from whole blood 
 
One serum and three plasma / EDTA vacuettes of blood (Greiner bio-one, UK) were centrifuged for 
10 minutes at 500 rpm immediately after venepuncture (within 30 minutes) to avoid potential 
cytokine degradation.  With regard to time from acquisition to centrifugation, one study showed no 
significant effect on levels of vitamin D between 2 and 24 hours [193] whilst another study looking 
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at transport of samples by post showed that although there was an alteration in results over time, 
these varied by just a few percent  [194].   
A Pasteur pipette was used to remove the supernatant (plasma / serum); 500µl aliquots were pipetted 
into labelled 1ml eppendorfs and put on ice to transfer to storage at -80
o
C.    The samples for routine 
biochemical evaluation and vitamin D levels were transported in a specimen carrier to the base 
hospital. 
 
2.3.2 DNA Extraction 
 
The following methods describe the general methods used for extraction and quantification of DNA.  
Specific genotyping tests are described in the section 2.3.5. 
Stage 1 - Pelleting 
This method was used for all participants, where blood was collected in a single EDTA vacuette.  
The collection tubes were frozen at -70
o 
C until  sixteen samples were available to process together. 
Blood was mixed and emptied into a 50ml Falcon tube.  It was then mixed with Reagent A (see 
Appendix 2) to lyse the cells, placed on a rotary mixer at speed 170rpm for 4 minutes and then 
centrifuged at 2400rpm for 4 minutes.  The supernatant was discarded safely and 7.5mls of Reagent 
A was added to the pellet remaining.  The sample was centrifuged again at 2400rpm for 4 minutes 
and the supernatant discarded safely without disturbing the pellet.  The pellets were stored at -80
o
C. 
Stage 2 - DNA Precipitation 
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The frozen pellets were defrosted for around 30 minutes.  2mls of Reagent B (Appendix 4) was 
added to the blood pellet and re-suspended using the Vortex to lyse it.  This was then poured into a 
5ml labelled centrifuge tube (Alpha Labs, UK) and 500 µl of Sodium Perchlorate 5M (Fisher 
Scientific, UK) was added and mixed by inversion to denature the protein.   Chloroform at -20°C 
was then added to fill each tube and centrifuged at 3000rpm for 5 minutes.  The supernatant was 
pipetted into a fresh labelled tube without disturbing the underlying protein layer. 
To precipitate the DNA, 100% ethanol at -20
o
C was added to fill the tube to the top of the label and 
mixed by inversion.  If there was no evidence of this (absence of a white swirl in the tube), it was 
incubated for 30 minutes at -80
o
C. This was then centrifuged at 3000rpm for 10 minutes and the 
ethanol was carefully poured off into a small blood beaker, leaving the remaining DNA pellet.  1ml 
of 70% ethanol was added and the tube inverted to wash the pellet.  This was then centrifuged at 
3000rpm for 5 minutes and the ethanol carefully poured away / blotted with tissue, leaving the 
remaining pellet in the tube. This was then air dried flat until the pellet turned transparent (taking 
approximately three hours but could safely be left overnight). 100 µl of T.E buffer (Appendix 4) was 
added and the tube left in the fridge for 2-3 days to re-suspend the DNA. This was then centrifuged 
at 3000 rpm for 5 minutes.  Using a 1000µl ART reach tip (Aerosol Resistant Tips – to prevent 
carryover contamination), the contents of the tube was transferred into a labelled red screw top 
eppendorf, ensuring DNA was transferred to the tube. 
 
2.3.3 DNA Quantitation 
 
This was done using the Picogreen © method for determining DNA concentration.  
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Picogreen is a fluorochrome that selectively binds double stranded DNA (dsDNA).  It is fluorescent 
when bound and has been shown to be a reliable method of DNA quantitation [195].   
A standard curve is required using calf thymus DNA (Sigma, UK) as shown in table 2.1. A single 
vial of 1mg/ml calf thymus DNA was mixed with 1ml of T.E Buffer and left overnight to re-
suspend.  DNA dilutions were also prepared on the first day in preparation. 
The stock DNA was diluted 1:100 by mixing 198µl of T.E buffer with 2µl of stock DNA to each 
eppendorf.  They were then vortexed and left refrigerated overnight to re-suspend. On the second 
day, the plate was set out as shown in table 2.2.  The Picogreen was also taken out of the freezer and 
allowed to thaw. 
The standards and blanks were placed in rows A and B. 5 µl aliquots of the 36 diluted DNA samples 
made on day one were added in duplicate across the plate from row C to H to fill the 72 remaining 
wells.  Picogreen solution A was prepared in a brown 1.5ml eppendorf, adding 1194µl of T.E. 
Buffer to 6µl of thawed Picogreen.  This was then added in 50µl aliquots to the standards in rows A 
and B.  Picogreen solution B was prepared in a foil wrapped 15 ml falcon tube by adding 7580 µl of 
T.E buffer and 20µl of Picogreen.  This was then poured into a sterile trough with foil lid and using 





   81 
 
 Calf thymus DNA TE (µl) Concentration after addition of Picogreen® (ng/ml) 
1 4µl of 1mg/ml stock 1246 1600 
2 600µl of 1 600 800 (Standard 1) 
3 600µl of 2 600 400 (Standard 2) 
4 600µl of 3 600 200 (Standard 3) 
5 600µl of 4 600 100 (Standard 4) 
6 600µl of 5 600 50 (Standard 5) 
7 600µl of 6 600 25 (Standard 6) 
8 600µl of 7 600 12.5 (Standard 7) 
9 600µl of 8 600 6.25 (Standard 8) 
 
Table 2.1  Dilutions of calf thymus DNA for producing the standard curve for DNA quantitation.   
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 1 2 3 4 5 6 7 8 9 10 11 12 
A BLANK 800 400 200 100 50 25 12.5 6.25    
B BLANK 800 400 200 100 50 25 12.5 6.25    
C S1 S1 S2 S2 S3 S3 S4 S4 S5 S5 S6 S6 
D S7 S7 S8 S8 S9 S9 S10 S10 S11 S11 S12 S12 
E S13 S13 S14 S14 S15 S15 S16 S16 S17 S17 S18 S18 
F S19 S19 S20 S20 S21 S21 S22 S22 S23 S23 S24 S24 
G S25 S25 S26 S26 S27 S27 S28 S28 S29 S29 S30 S30 
H S31 S31 S32 S32 S33 S33 S34 S34 S35 S35 S36 S36 
 
Table 2.2  The plate layout for Picogreen method of DNA quantification. 
A1 and B1 contain 50µl of T.E buffer (used as blanks).  The standards prepared as in Table 2.1 above are 
placed in wells A2-9 and B2-9.  The plate was read at the standard fluorescein wavelength (excitation 480nm, 
emission 520nm) in a spectrofluorometer.  The fluorescence value of the blank was subtracted from the each 
of the sample values, and the DNA concentration of each sample was derived from the standard curve. If the 
standard curve duplicates deviated by more than 20% from one another the plate was rejected and repeated 
with new standard curve dilutions.  If individual paired sample readings deviated by more than 20% from one 
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2.3.4 Choice of tag SNPs 
 
Prior to genotyping individuals for specific single nucleotide polymorphisms (SNPs), it was 
necessary to determine which SNP primers were required to identify relevant polymorphisms in 
patient samples.  As shown in section 1.6, key enzymes / proteins in the vitamin D axis were 
identified through a systematic literature search. Since the primary gene thought to influence 
downstream effects of vitamin D was GC, we chose to select tags that would cover the whole of this 
gene. Another relevant gene which were also identified was interleukin 6 (IL6) which is known to 
be produced by LPS stimulated monocytes and which has been shown to be suppressed in a dose 
dependent manner by vitamin D in vitro [196]. 
 
The next step involved the use of the genetics database, HapMap (www.hapmap.org), which 
analyses data from multiple racial groups – in earlier builds of HapMap this was only European, 
African and Asian populations but has now been expanded to much more specific sub-groups which 
include ASW: African ancestry in Southwest USA, CEU: Utah residents with Northern and Western 
European ancestry from the CEPH collection, CHB: Han Chinese in Beijing, China, CHD: Chinese 
in Metropolitan Denver, Colorado, GIH: Gujarati Indians in Houston, Texas, JPT: Japanese in 
Tokyo, Japan, LWK: Luhya in Webuye, Kenya, MEX: Mexican ancestry in Los Angeles, 
California, MKK: Maasai in Kinyawa, Kenya, TSI: Toscans in Italy, YRI: Yoruba in Ibadan, 
Nigeria, although full linkage disequilibrium (LD) data is not available yet for all.  For this study 
SNPs for the listed vitamin D related enzmes / proteins and cytokines in CEU and YRI groups for 
whom full LD data was available were identified.     The aim was to identify links between genetic 
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variants and disease and the individuals response to therapeutic agents.  The possibility of using 
genetic link to disease in this way may provide a route for individualising treatment for patients 
based on known genetic response.   
Genetic variants lying close to each other in the gene tend to be inherited together (see also section 
1.6), due to linkage disequilibrium.   Thus, if a single nucleotide change occurs (SNP), then other 
genetic variations lying close to this SNP will always be inherited with it.  This region or block is 
known as the haplotype and by identifying a single SNP (tagSNP), it is possible to identify the other 
polymorphisms present with a reasonable degree of confidence, if LD is sufficiently high. 
Settings were configured to include minor allele frequencies of >0.05 and r
2
>0.8 (measure of 
strength of LD).  Nine different SNPs were identified using Hapmap for CYP27b1, CYP24a1, GC, 
VDR, CYP2R1, NADSYN1 and IL6. These tagSNPs are shown in table 3.2, alongside the SNPs that 
they capture through LD.  
 
2.3.5 PCR and Genotyping 
 
What is PCR? 
Once a DNA sequence has been identified, enough needs to be produced for research purposes.  
This is done through a series of heating and cooling cycles.  There are three main stages which are 
illustrated in figure 2.1) 
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1)  Denaturation – this is the process whereby heating the DNA enables the double helix to be 
split and form separate strands. 
2) Annealing – Cooling allows primers (specific DNA sequences) to bind to the single strand of 
DNA. 
3) Extension – Further heating allows an enzyme, DNA polmerase to catalyse the production of 














   86 
 
 
Figure 2.1  Polymerase chain reaction (PCR).  
Double stranded DNA is denatured by heating to 95
o
C.  The primer, consisting of a complementary sequence 
of nucleotides to the DNA in question anneals to a single DNA strand at a temperature specific for that 
particular sequence and kit.  The complementary DNA strand then extends out from the primer, guided by 
DNA polymerase on further heating to 72
o
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TaqMan® SNP genotyping 
Taqman (Applied Biosystems® TaqMan®) genotyping technologies were used to detect 
polymorphisms within the genome by fluoresence.  The main components of the kit required for 
PCR through this system include: 
 
 MgCl2- this is a source of magnesium and forms complexes with dNTPs  which then bind to  
 Taq (DNA) polymerase, resulting in the extension of the DNA strand of interest.  Without it 
the extension phase of PCR will not occur. 
 Deoxynucleotide triphosphates (dNTPs) - these are the source of free nucleotides required in 
the formation of new DNA strand during extension. 
 Primer - the primer are synthetic segments of DNA that anneal or bind to a specific 
nucleotide sequence on the template DNA. Each primer has a fluorophore (VIC or FAM), 
and it is the relative expression of each that determines the genotype. The mechanism by 
which this occurs is shown in Figure 2.1. 
 
The PCR reactions were set up on 384 well plates (Greiner Bio-one, UK), using 4 blanks as negative 
controls per plate.  1050µl of genotyping master mix (supplied ready mixed, containing dNTPs, 
MgCl2 and Taq polymerase and optimised for use with TaqMan® genotyping assays by Applied 
Biosystems, UK), 70µl of genotyping assay at a 20x concentration (ABI, UK) and 35µl of MillQ 
water were mixed in an opaque eppendorf (Alpha labs, UK), since the assay is light sensitive. For 
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assays supplied at a 40x concentration the amount of assay was halved and the amount of water 
correspondingly increased, such that the total volume was unchanged.  A volume of 2.25µl of DNA 
at 20ng/µl was pipetted into each well of a 384 well plate, leaving 4 wells free to act as blanks, to 
which the same volume of MillQ water was added in order to standardise the reaction volume.  
2.75µl of master mix was then added to each well.  The plate was sealed with an optically clear seal 
(Alpha Labs, UK), and covered with foil.  The plate was then centrifuged at 1000rpm for 1 minute 
to ensure that all reagents were at the bottom of the plate and once completed the plates were placed 
in a thermal cycler (MJ Research (PTC-225) UK) and PCR performed under the following 
conditions: 
 
  50°C  2 minutes 
  95°C 10 minutes 
  92°C 15 seconds 
  60°C 1 minute 
 
 
After completion of the PCR the plates were again covered with foil to prevent degradation of the 
light sensitive assay and stored at 4°C until they could be read. This step was carried out using an 
ABI-7900HT (ABI, UK), which is able to read the fluorescent signals emitted by the VIC and FAM 
markers within each assay.  For each tag ABI supplied information indicating which allele the VIC 
and FAM markers detect, such that this can be specified prior to reading the plate. The instrument 
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ABI, UK).  The software presents the results as a scatterplot. There are four potential clusters of 
points, which correspond to the two homozygous genotypes, heterozygotes or no amplification. 
Parameters may be set to indicate cut-off values for allocation of genotypes within the software, and 
was set at 95% for the studies contained herein (as recommended by the manufacturers).  Each plot 
was reviewed for the position and relative signal quality of samples where a genotype could not be 
allocated by the software, and a genotype assigned manually if possible. If the signal quality was 
<80% or the position was such that the genotype was unclear samples were reanalysed. 
 
2.3.6 ELISA (Enzyme Linked Immunosorbent Assay) 
 
This is a common method used to quantify cytokines, or other markers in secretions, blood or cell 
supernatants. Two of the main types of assay are: 
1. Antibody detection ‘sandwich’ assay 
2. Antigen detection ‘sandwich type’ assay. 
These are illustrated in Figure 2.2. ELISAs carried out during this project included IL2, IL6, IL10, 
TNFα, IFNγ and LL37.  Commercial ELISA kits may come in a variety of designs, with varying 
amounts of preparation required by the researcher or done at source by the manufacturer. Detailed 
methods for each are discussed below. 
 
 





Figure 2.2  Antibody detection sandwich assay and antigen detection sandwich type assay.  
The antigen or antibody is bound to the solid surface.  The sample is added and incubated and if the antibody 
or antigen in question is present, it binds.  The plate is then washed to remove any unbound antigen / 
antibody.  A second specific antibody conjugated to an enzyme is added and incubated.  A second wash 
removes any unbound antibody.  An enzyme substrate is added and the plate is incubated again.  The reaction 
is stopped by the addition of acid and the reaction is measured by colourimetry, the degree of colour change 












The DBP ELISA (Immunodiagnostik, Germany) is a sandwich assay for Vitamin D binding 
assessment.   Plasma samples from each of the patients in the TB study were used which had been 
stored at -80
o
C in 500µl aliquots.  These were defrosted prior to commencing the assay and diluted 
1:40000 with SAMPLEBUF (dilution buffer, ready to use) in the following way. 
 10µl Sample + 990µl SAMPLEBUF = 1:100 (Dilution I) 
 10µl Dilution I + 990µl SAMPLEBUF = 1:10000 (Dilution II) 
 250µl Dilution II + 750µl SAMPLEBUF = 1:40000 (Dilution III) 
100µl of Dilution III was used at the appropriate time for analysis in each well. 
The standards at 60ng/ml, 20ng/ml, 6.6ng/ml, 2.2ng/ml and 0ng/ml and CTRL (controls) were 
reconstituted with 500µl of deionized water.  These were each allowed to dissolve for 10 minutes 
and mixed gently by inversion.  
The conjugate (rabbit-anti-DBP, Peroxidase-labelled) was diluted 1:100 in wash buffer. 100ml of 
wash buffer concentrate was diluted with 900ml of deionised water (1:10 dilution) and mixed well.  
The remaining could then be refrigerated at 2-8
o
C.  100µl of standards and controls and the pre-
diluted 1:40000 samples were added to the appropriate wells according to the Table 2.3 below.  This 
was then incubated for 1hour on a horizontal mixer at room temperature. The plate contents were 
decanted and washed 5 times with 250µl of diluted wash buffer.  100µl of diluted conjugate was 
added and incubated for 1 hour on a horizontal mixer at room temperature.  The contents were 
decanted again and the wells washed 5 times with 250µl of diluted wash buffer. 100µl of 
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tetramethylbenzidine (TMB) substrate was added to each well and the plate was incubated for 10-20 
minutes at room temperature. 50µl of stop solution (acidic solution) was then added and mixed. The 




























Table 2.3  DBP ELISA plate 
Standard concentrations of DBP were added to the labelled wells with control and TB patient’s plasma 
samples added according to the colour key.  The plate was then treated as per the above protocol and read on 









  1 2 3 4 5 6 7 8 9 10 11 12 
A 0 0 2 2 10 10 18 18       
B 2.2 2.2 3 3 11 11 19 19       
C 6.6 6.6 4 4 12 12         
D 20 20 5 5 13 13         
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further to the 
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 IL-6 ELISA (Duo-kit method) 
 
This method describes the IL-6 ELISA, IL6 being an inflammatory readout for the monocyte work.  
This contains the components required for a sandwich ELISA designed to measure human and 
recombinant IL-6.  The samples containing LPS were diluted to a 1:40 concentration (determined as 
optimal from the dose response work) and the controls, and supernatants containing 25(OH)D3 only 
were not diluted. 
Day 1 
Separate quantities of 1L and 400ml of Phosphate Buffer Solution (PBS) were made up as per 
instructions.  Wash Buffer was made up by mixing 0.5ml Tween with 999.5ml of PBS. The capture 
antibody (360µg/ml of mouse anti-human IL-6) was reconstituted with 1ml of filtered PBS.  This 
was the diluted to a working concentration of 2.0µg/ml in PBS without carrier protein. A 96 well 
microplate was coated with 100µl per well of the diluted capture antibody.  The plate was sealed 
with an adhesive covering and incubated at room temperature overnight to allow the antibody to 
bind to the plate. 
Day 2 
The Reagent Diluent (1% BSA in PBS) was prepared by diluting 5ml of 10X strength reagent 
diluent with 45ml of distilled water. The wells were aspirated and washed three times with Wash 
Buffer.  Excess liquid was removed using by inverting the plates and blotting against clean paper 
towels. The plate was then blocked by adding 300µl of Reagent Diluent to each well and incubated 
for 1 hour.  The aspiration / washes X 3 were then repeated as above.   
   95 
 
Standards were then prepared in 0.5ml eppendorfs as directed in Table 2.4 below. 
 
Tube Volume Reagent Diluent Volume standard Concentration (pg/ml) 
1 491.73µl 8.57µl of reconstituted vial 600 
2 250µl 250µl tube 1 300 
3 250µl 250µl tube 2 150 
4 250µl 250µl tube 3 75 
5 250µl 250µl tube 4 37.5 
6 250µl 250µl tube 5 18.75 
7 250µl 250µl tube 6 9.375 
8 250µl only   
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100µl of the supernatant (diluted as described in paragraph 1 of this section) or standard in Reagent 
Diluent were added to the appropriate wells, covered with an adhesive cover and incubated for 2 
hours.  The plate was then aspirated / washed as above.  100µl of Detection Antibody diluted with 
Reagent Diluent was added to each well. The Detection Antibody (9µg/ml of biotinylated goat anti-
human IL-6) was initially reconstituted with 1.0ml of reagent diluent and then diluted to a working 
concentration of 0.05µg/ml.  This was then covered with an adhesive cover and incubated for 2 
hours.  The plate was then aspirated and washed as above. 
100µl of the working dilution of Streptavidin HRP (1ml of streptavidin conjugated to horseradish 
peroxidase diluted to 1:200) was added to each well and the plate was covered and left to incubate 
for 20 minutes at room temperature, out of direct light. The plate was then aspirated / washed as 
above and 100µl of Substrate Solution (tetramethylbenzidine) was added to each well.  This was left 
to incubate for 20 minutes at room temperature, out of direct light. 50µl of Stop Solution was then 
added to each well (from DBP ELISA kit) and the plate was gently tapped to ensure thorough 
mixing. The plate was read at wavelength 450nm, subtracting readings at 540nm to correct for 
optical imperfections. 
Dilution determination of supernatants for IL6 ELISA 
Initial IL6 assays carried out on monocyte supernatant led to results which lay above and below the 
standard curve.  The results above the upper limit of the standard curve correlated with LPS 
exposure.  Therefore in order to determine the correct dilution for each of the supernatants, an IL-6 
assay was carried out using five of the control supernatants which included those resulting in the 3 
highest and 2 lowest results on initial ELISA.  These samples were control (RPMI only), 25(OH)D3 
50nmol, LPS1µg/ml, LPS 100ng/ml, LPS 1µg/ml + 1,25(OH)2D3. 
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  1 2 3 4 5 6 7 8 9 10 11 12 
A 600   1 in 3   1 in 3   1 in 3   1 in 3   1 in 3   
B 300   1 in 5   1 in 5   1 in 5   1 in 5   1 in 5   
C 150   1 in 10   1 in 10   1 in 10   1 in 10   1 in 10   
D 75   1 in 20   1 in 20   1 in 20   1 in 20   1 in 20   
E 37.5   1 in 40   1 in 40   1 in 40   1 in 40   1 in 40   
F 18.75   1 in 80   1 in 80   1 in 80   1 in 80   1 in 80   
G 9.375   1 in 100   1 in 100   1 in 100   1 in 100   1 in 100   
H RD*   1 in 160   1 in 160   1 in 160   1 in 160   1 in 160   
  Standards & Control 
  Control (RPMI) 
   25D 50nmol 
   LPS 1 µg/ml 
   LPS 100 ng/ml 
  LPS 1 µg/ml + 1-25D 50nmol 
 
Table 2.5  IL-6 duo kit plate layout for various dilutions of monocyte supernatants. 
The values of IL-6 concentrations on the ELISA plate were analysed and dilutions falling within the standard 
curve were chosen for subsequent work.  Consequently any samples containing LPS were diluted 1: 40 and 
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 LL-37 ELISA 
 
This human LL-37 kit (Hycult® biotech) is a ready to use solid phase ELISA and was used in the 
functional work with monocytes as an antimicrobial readout. Each sample was assayed in duplicate 
and mean values taken.  40 ml of wash / dilution buffer A was mixed with 360ml of distilled water.  
20ml of wash/ dilution buffer B was mixed with 380ml of distilled water.  These solutions were 
combined and mixed well.  This was the wash/dilution buffer used for the ELISA. The standard 
solution (vial 3 in the duokit) was made up by reconstituting 0.5ml of distilled water with the 
standard provided.  This was then serially diluted in eppendorfs according to the table below to give 
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Tube Volume wash/ dilution buffer Volume standard Concentration (ng/ml) 
1  150µl vial 3 100 
2 250µl 125µl tube 1 33 
3 250µl 125µl tube 2 11 
4 250µl 125µl tube 3 3.7 
5 250µl 125µl tube 4 1.2 
6 250µl 125µl tube 5 0.4 
7 250µl 125µl tube 6 0.1 
8 250µl  0 
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Supernatant samples were diluted 5X with supplied wash / dilution buffer and 100µl of each sample 
and each standard were added to the wells. The plate was covered with an adhesive sheet and tapped 
to eliminate any air bubbles. The plate was incubated at room temperature for 1 hour.  The contents 
were then removed by inversion and tapped on tissue paper.   Following this it was washed with 
wash/dilution buffer on the plate washer.  200µl of wash buffer was then added to each well and 
after 20 seconds, emptied and washed as described above.  This was done 3 times in total. 100µl of 
diluted tracer (reconstituted with 1ml of distilled water and diluted with 11ml of wash / dilution 
buffer) was added to each well and the tray covered with an adhesive layer and incubated for 1 hour 
at room temperature. The plate was then washed repetitively as above and 100µl of diluted 
streptavidin-peroxidase added to each well.  The streptavidin-peroxidase solution was made up by 
reconstituting the supplied vial with 1ml of distilled water and diluting the reconstituted solution 
with 23ml wash / dilution buffer.  The tray was covered as above and incubated for 1 hour at room 
temperature.  It was then washed as above and 100µl of TMB substrate added to each well.  The 
plate was then covered with a fresh adhesive cover and incubated for 20-30 minutes at room 
temperature, avoiding sunlight (foil cover).  The reaction was stopped by adding 100µl of stop 
solution and covering with an adhesive cover for 20-30 minutes having mixed the solutions by 
swirling gently. The plate was read at 450nm using a plate reader and the mean absorbance for the 
duplicate standards and samples was calculated. Intra-assay coefficient of variation (cv) was <6%, 
inter-assay cv <4%.   
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2.3.7 Flow Cytometry 
 
Fluorescence activated cell sorting (FACS) has been used in T cell analysis for this project; the 
process is summarised in Figure 2.3.  The general principles of FACS are described here and the 
specific panels of markers used in section 2.3.9 and table 2.10, 2.11 and 2.12.  The use of FACS 
enables certain cellular characteristics / properties to be identified through labelling with particular 
fluorophores.  Both external and intracellular markers can be identified in this way, enabling 
identification of CD3+ or CD4+ cells for example.  The labelled cells are passed into a sheath and 
directed in a flow chamber towards a laser beam.  As the cells enter the light source, absorption 
occurs and a state of excitation arises and any fluorescent particles will fluoresce, according to the 
fluorophore labelling, light is excited and emitted at a different wavelengths, and this fluorescence 
in each cell can be measured on an individual basis.  The measurement of each wavelength is 
converted to an electrical signal at the optical detectors. 
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Figure 2.3  The pathway through the flow cytometer.  
Cells are propelled along in a fluid suspension towards a laser beam.  As the cells individually pass the laser 
it results excitation and emission of forward and side scatter light.  The degree of forward scatter and side 
scatter may characterise the cells, however, fluorochromes are also used to detect specific target proteins.  
These fluorochromes emit light when excited by a laser with the corresponding excitation wavelength.  
Fluorescence from any cells that have been stained is detected by sensors and this is then converted to 
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Displaying Data 
Light signals, converted to electronic signals, are produced in a digitalised format by the computer 





 Dot and Density plots. 
 
Dot and density plots are very similar with each dot 
representing a single event / cell.  In density plots the 
colour denotes the event frequency. 
 
   
 
This displays the number of events for a 
particular measurement e.g. APC fluorescence.  
The greater the fluorescence intensity the further 
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 Gating 
In order to analyse multiple parameters (e.g. cells which are identifiable by the presence of more 
than two surface markers), when two parameters are plotted against each other, regions can be 
marked out and this cell population is then put onto a further plot with different surface marker 
parameters in order to complete the analysis.  This is known as gating (see figure 2.4).  For example, 
CD3+ CD4+ cells can be gated against one another and the region of cells which are positive for 

























             
        
 
Figure 2.4  Gating dot and density plots. 
This shows gating of CD3+/CD4+ cells (represented in the polygon outline) onto CD25+/CTLA4+ plot.  The 
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2.3.8 Assessing the functional effect of Vitamin D on monocytes 
 
 Monocyte Isolation 
 
36-42 mls of blood was taken using Li-heparin vacuettes (BD Vacutainer®).  The blood was poured 
in equal volumes into two 50ml Falcon tubes and mixed with equal volumes of 0.9% normal saline. 
12 ml of Lymphoprep 
TM
 (used to create a density gradient to allow the separation of peripheral 
blood mononuclear cells from other white cells and red cells) was placed in several clean 50ml 
Falcon tubes and the 15ml of the blood / saline solution was overlayered (blood saline solution was 
carefully pipetted onto the surface of the lymphoprep using a 25ml automated pipette at slow speed).  
The tubes were centrifuged at 800g to allow separation of the cells, acceleration 1, brake 0 at 20
o
C 
for 30 minutes. Whilst the mixture was being centrifuged, RPMI culture medium was warming to 
room temperature.  Using defrosted foetal calf serum (FCS) which provides a source of growth 
factors, a 10% solution of RPMI/FCS was made up by adding 45 ml of RPMI to 5 ml FCS in a 50ml 
Falcon tube. The Falcon tubes were removed from the centrifuge and the interphase (consisting of 
leucocytes) was aspirated and placed into a 50ml Falcon tube. A cell count/trypan blue exclusion 
test was carried out to determine total cell count.  This was done by mixing 50µl interphase with 
50µl of trypan blue and pipetting the mixture onto a haemocytometer.  The number of cells on each 
grid of the haemocytometer was counted and the average value was multiplied by 20000 to obtain 
the total number of cells / ml 

















Figure 2.5  View of the haemocytometer grid under a light microscope.  
The haemocytometer is used to count blood cells.  The area bound by the lines is known as is the depth 
of the haemocytometer chamber.  Any cells lying within each small square and any lying on the left or 
inferior border of each small square are counted.    In this way, it is possible to count the cells in a 
specific volume and determine the concentration of cells in the fluid overall. 
 
Figure 2.5  View of the haemocytometer grid under a light microscope.  
Any cells lying within each small square and any lying on the left or inferior border of each small square are counted.   
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A differential cell count was then carried out by performing cytospin at 200 rpm for 3 minutes.  The 
slides were then stained using Diff Quik cellular staining kit and viewed at X40 magnification on a 
light microscope. The first 100 cells were counted and identified as monocytes, lymphocytes or 
neutrophils, allowing calculation of % monocytes of the total cell count.  For example, if the 
differential cell count showed 10% monocytes and the total cell count was 20 million then the 
number of monocytes in the sample was 2 million. 
0.9% saline was then added to wash the cells, filling the Falcon tube containing the interphase.  This 
was mixed by inversion and then centrifuged at 500g for 10 minutes with the brake on.  The 
supernatant was then discarded, leaving a pellet at the bottom of the Falcon tube.   
The pellet was then resuspended using RPMI/FCS solution prepared earlier to a concentration of 1 
million monocytes per ml, using the formula below to calculate this   
 
Volume (ml) =    total number of monocytes 
desired concentration (cells /ml) 
 
This was then added to a 24 well plate in 0.5ml aliquots and incubated at 37
o
C, 5% CO2 for 24 
hours.  The time course was based on existing laboratory protocols and for convenience – the 
monocytes require enough time to adhere to the plastic culture wells (2-4 hours) whilst enabling the 
culture conditions to be applied at a convenient time for the operator. 
The method below indicates how the conditions for LPS and vitamin D were made up.  This was 
done following assessment of LPS dose response effect on monocytes to determine the LPS 
   109 
 
concentration used.  The optimum vitamin D and LPS concentrations were determined using the 
methods described in section 4.1.1 below and in Figure 4.1.  
After 24 hours of monocyte incubation LPS 1µg/ml and 100ng/ml were made up. Stock solution, 
strength 1mg/ml was taken and defrosted.  It was then diluted to 1:1000 by mixing 5µl of stock 
solution with 4995µl of warm RPMI / 10%FCS in a bijou. 300µl of the LPS 1µg/ml solution 
(diluted as above) was taken and mixed with 2700µl   RPMI / 10%FCS (1:10 dilution). In addition 




A solution of 1000nmol was initially made by diluting 1µl of stock solution (strength 1mmol) with 
999µl of RPMI / 10%FCS.  In order to dilute it to 50nmol strength in the wells, 25µl of the 
1000nmol solution was added to each required 500µl well which contained either RPMI / 10%FCS 
or LPS.  A 24 well diagram is shown below to give an example of the plate layout. 
1.25(OH)2D3 50nmol 
 
A solution of 1000 nmol was initially made by diluting 10µl of stock solution (100µmol) with 990µl 
of RPMI / 10%FCS in a bijou.  In order to dilute it to 50nmol strength in the wells, 25µl of the 
1000nmol solution was added to each required 500µl well which contained either RPMI / 10%FCS 
or LPS.  A 24 well diagram is shown below to give an example of the plate layout. 





















































Table 2.7  Monocyte conditions in duplicate on a 24 well culture plate following adherence isolation. 
Monocyte cultures were stimulated with two different concentrations of LPS in the presence or absence of 
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LPS Dose Response – optimisation experiments 
 
Two control samples were used in order to determine the suitable LPS concentration used in the 
monocyte culture media as an inflammatory stimulus (i.e. produce adequate stimulation of 
monocytes). The production of IL6 was then measured using an IL6 ELISA Duokit (method 
described in section 2.3.6).  In addition to various LPS conditions, 25(OH)D3 was also added to the 
media in separate wells at varying concentrations, to determine any additive effect on IL6 values at 
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1 2 3 4 5 6 7 8 9 10 11 12 
A 600 Control LPS 1000 Control LPS 1000 
  
B 300 25D LPS 750 25D LPS 750 
  
C 150 25D + LPS 1000 LPS 500 25D + LPS 1000 LPS 500 
  
D 75 25D + LPS 750 LPS 250 25D + LPS 750 LPS 250 
  
E 37.5 25D + LPS 500 LPS 100 25D + LPS 500 LPS 100 
  
F 18.75 25D + LPS 250 LPS 50 25D + LPS 250 LPS 50 
  
G 9.375 25D + LPS 100 
  
25D + LPS 100 
    
H RD 25D + LPS 50 
  
25D + LPS 50 
    
         
    
           Control 1  Control 2 
Standards = pg/ml Samples containing LPS were measured at a 1:40 dilution 
Samples LPS = ng/ml  All other samples i.e. controls, 25(OH)D3 & 1,25(OH)2D3D were measured neat. 
Vitamin D = 50nmol 
Table 2.8 LPS dose response experiment : IL6 ELISA plate. 
Standard solutions are placed in columns 1 and 2, with control sample 1 and 2 in the remaining wells.  All 
conditions were tested in duplicate and any samples containing LPS were diluted 1:40 in order to achieve a 
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Vitamin D dose response 
 
In order to determine if there is any variability in IL6 response according to the concentration of 
25(OH)D3, a dose response IL-6 ELISA was carried out.  This assessed the IL-6 response of 
monocytes when treated with various concentrations (10nmol, 20nmol, 50nmol, 100nmol) of 
25(OH)D3 (i.e. the effect of vitamin D on inflammatory cytokines in vitro).  RPMI 1640 medium 
was used as the control wells. 
The plate was set up using 2 control samples.  The monocytes were isolated on day 1 and on day 2 
each well was treated with 25(OH)D3 at concentrations of 10nmol, 20nmol, 50nmol, 100nmol.  In 
addition further wells were treated with combinations of LPS 100ng/ml in addition to 
25(OH)D3(same concentrations as listed above). The samples were incubated at 37
o
C and 5% CO2 
for 24 hours.  The supernatants were then removed and IL-6 levels determined using IL-6 duokit 
ELISA.  Standard dilutions were prepared as described in Table 2.4.  An example of the plate layout 
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1 2 3 4 5 6 7 8 9 10 11 12 
A 600 Control 
25D 100nmol + 
LPS 100ng/ml 
Control 
25D 100nmol + 
LPS 100ng/ml 
  
B 300 25D 10nmol 
 
25D 10nmol  
  
C 150 25D 20nmol 
 
25D 20nmol  
  
D 75 25D 50nmol 
 
25D 50nmol  
  
E 37.5 25D 100nmol 
 
25D 100nmol  
  
F 18.75 
25D 10nmol + 
LPS 100ng/ml 
 







25D 20nmol + 
LPS 100ng/ml 
  
25D 20nmol + 
LPS 100ng/ml 
    
H RD 
25D 50nmol + 
LPS 100ng/ml 
  
25D 50nmol + 
LPS 100ng/ml 
    
 
Table 2.9  Vitamin D dose response : IL6 ELISA plate. 
Standards in columns 1 and 2 and various concentrations of vitamin D with and without LPS stimulation. 
Standards measured in pg/ml.  Samples containing LPS were measured at a 1:40 dilution.  All other samples 
i.e. controls, 25D & were measured at 1:4 concentration. 
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DBP genotype effect on cytokine response 
 
Experiments to determine the effect of DBP genotype on cytokine response in plasma were carried 
out.  Pooled plasma from each of the GC genotypes GC1S-GC1S, GC1F-GC1F, GC1S-GC2, GC1F-
GC2, GC2-GC2, GC1S-GC1F from the study were obtained.  At least three from each genotype 
group were pooled to minimise heterogeneity. 
Optimisation experiments were initially carried out using control monocyte cultures in order to 
determine the optimal dilution of plasma with LPS in order to obtain measurable IL6 levels (i.e. 






















Figure 2.6  Monocyte culture plate for optimisation of IL6 response with addition of pooled plasma. 
Optimisation experiments: monocyte cultures stimulated with LPS and supplemented with vitamin D were 
subjected to pooled plasma of a single GC genotype in order to determine the optimal dilution of plasma 








































Ratios indicate the 
ratio of pooled 
plasma added to 
each well.  All wells 
were made up to a 




shown + LPS + 25D. 
   117 
 
Monocytes were cultured from control blood of four individuals using the method described in the 
monocyte isolation protocol above.  The supernatant was then removed at 24 hours and culture 
media (RPMI) / LPS mix (volume added to wells varied in order to give a final LPS concentration 
of 100ng/ml once pooled plasma was added in the varying proportions).  Initial experiments 
identified that pooled plasma in a 1:4 proportion was satisfactory / optimal to obtain adequate IL6 
values on ELISA.  The pooled plasma from the various GC genotypes was then added to the LPS/ 
RPMI mix to make up to a volume of 500ul in each well including 50nmol of 25(OH)D.  After a 
further 24 hours, the supernatant was removed and frozen.  Assays were then carried out to 
determine concentrations of IL6, TNFα, IL1β and GCSF using Luminex assay (RnD systems). This 
allowed identification of any relevant pooled plasma genotypes effect on cytokine response to 
vitamin D supplementation.  
 




12-16 ml of blood was taken in Li-heparin vacutainers.  The blood was emptied into a single 50ml 
Falcon tube and diluted in a 1:1 ratio with phosphate buffered solution (PBS).  The blood PBS 
mixture was then overlayered onto 12 ml of Ficoll or lymphoprep and centrifuged for 25 minutes, 
20
o
C, 2200rpm, acceleration 1, brake 0.  This allows separation of whole blood through a density 
gradient. 
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The interphase was aspirated and placed in a new 50ml Falcon tube.  This was then washed with 
PBS to remove any contaminating separation medium and centrifuged at 2200rpm, brake on for 10 
minutes.  If the solution was cloudy, the pellet remaining after aspiration was further washed at a 
lower speed with brake on at 1200 rpm for 5 minutes.   
The PBS was then aspirated, the pellet washed again with PBS and centrifuged at 1500rpm for 5 
minutes.  The PBS was aspirated and the pellet was finally resuspended with 1ml of serum-free cell 
growing medium - SCGM (CellGenixGmbh, Germany) supplemented with 50U/ml penicillin and 
streptomycin (Life Technologies/Invitrogen) and then made up to a volume of 5 ml with the same 
media. 
A cell count was performed using a haemocytometer by pipetting 7µl onto one grid of the 
haemocytometer and using the 4X4 large grid square in the corners, the number of cells in the 4 
squares diagonally in each 4X4 was counted.  The total cell count was calculated by multiplying this 
value by 10
4
 (e.g. total counted = 239X10
4
/ml). 
The cell solution was then diluted to a concentration of 1,250,000 per ml (i.e.125X10
4
/ml) and a 
volume of 9.8ml (this allowed for 22 wells of 400µl on a 48 well plate to be filled and the remaining 
volume was divided up, placing 100µl in 10 clean FACS tubes for use in the next stage of the 







S1 S2                Iso CD4-FitC  CD4- Pe  CD3- PercP  CD4APC  CD4e450   CD127- PeCy7    Blank  
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Cell Culture and Vitamin D Supplementation. 
 
500 µl of cells at 0.5million cells / ml concentration were plated into a 48 well plate (Becton 
Dickinson, USA) and incubated at 37
o
 C, 5%CO2 atmosphere. 
Cells were either left a) unstimulated/ untreated control b) stimulated with SEB (staphylococcal 
enterotoxin B) at a  concentration of 1µg/ml (Sigma, USA) or c) stimulated with PPD (purified 
protein derivative) at a concentration of 1000 unit/ml (Statens serum institute).  More specific M tb 
antigens such as ESAT6 were also attempted during initial optimisation experiments, but were not 
continued for this thesis due to the low numbers of activated cells. 
The stimulated cells were also treated with 10nM 1,25(OH)2D3 or 100nM 25(OH)D3 (Sigma, USA). 






























Figure 2.7  Peripheral blood mononuclear cell culture plate layout (in triplicate) : SEB / PPD stimulation and 
treatment with vitamin D. 
Each plate was laid out to allow culture of PBMCs in the presence / absence of both SEB and PPD.  The 
cultures were also carried out in the presence or absence of vitamin D.  US (unstimulated); UT (untreated); 











  PPD 
 
  PPD 
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Antibodies for Staining Panels 
 
The following monoclonal antibodies (mAbs) were purchased from BD Biosciences: anti-human 
CD4, anti-human CD69, anti-human CD25 conjugated to FITC, anti-human CD3 conjugated to 
PerCP, anti-human CD4 and anti-human CD8 conjugated to allophycocyanin, anti-human CD25 and 
anti-human CTLA-4 conjugated to PE. The following mAbs were purchased from eBioscience: anti-
human IL-17 and anti-human IL-2 conjugated to PE, anti-human IFNγ, anti-human TNFα and anti-
human CD4 conjugated to PB, anti-human CD127 conjugated to PeCy7, and anti-human FoxP3 
conjugated to allophycocyanin. Isotype-matched controls were purchased from eBioscience or BD 
Biosciences as appropriate and used to account for non-specific binding. 2% Goat serum (Sigma, 
USA) was used to block non-specific binding. Stains were obtained from BD bioscience. 
 
 Ex vivo T reg detection by FACS 
 
After plating out the cells as shown above, the remaining cell / media mix was distributed into 
FACS tubes with a volume of 100-200µl per tube. 
Surface staining on live cells was then carried out.   PBS 1ml was added to each FACS tube and 
centrifuged at 1500rpm for 5 minutes.  The supernatant was tipped off and excess blotted onto 
tissue.   
45µl of 2% goat serum / PBS to each tube (980µl PBS +20µl goat serum) was added to each tube 
and antibodies against surface markers CD3, CD4, CD25 and CD127 were then added to stain the 
live cells (table 2.10).  The cells were vortexed gently and left on ice for 30 minutes. 
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The cells were then washed with PBS 1 ml, centrifuged at 1500 rpm for 5 minutes and the 
supernatant tipped off.  This wash step was repeated once more and 500µl of (FoxP3) fix/perm 
buffer prepared by 1:3 mix of concentrate (brown bottle) 1.25ml with diluent (colourless bottle) 
3.75µl was added to each tube.  The tubes were then covered with foil and placed in the refrigerator 
overnight. 
The following day the cells in the FACS tubes were washed with 1ml PBS (added directly to the 
500µl of fix/perm buffer) and centrifuged at 1500rpm for 5 minutes.  They were then washed once 
with 1X permeabilisation buffer (prepared from 10X stock by diluting with PBS, 1ml + 9ml PBS) 
and centrifuged again at 1500rpm.  The supernatant was tipped off and the antibodies and goat 
serum were added as per table 2.10. 
The cells were incubated in the refrigerator, covered with silver foil for 45 minutes.  1ml of 
permeabilization buffer was added to wash and the cells centrifuged at 1500rpm for 5 minutes and 
the supernatant tipped off.  The cells were then washed twice more with 1ml PBS as above and 
resuspended in 200ul of PBS.  The tubes were then covered and stored in the refrigerator until ready 
to FACS. 
The same process was used for T reg analysis post stimulation, adding the antibodies after fixation 
and permeabilisation.  The staining panel used is shown in Table 2.12. 
 
Assessment of cytokine production by FACS 
 
After 24 hours incubation, unstimulated cells were treated with PMA (Phorbol 12-Myristate 13-
Acetate) at a concentration of 50ng/ml stock and ionomycin at 1µM (Sigma Aldrich, USA).  After 
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90 minutes Brefeldin A (cytokine secretion blocking agent) was added at a concentration of 10µg/ml 
and incubated for a further four and a half hours at 37
o
C. 
200µl of cells was then re-suspended and transferred into labelled FACS tubes for fixation and 








Each FACS tube was centrifuged at 1500rpm for 5 minutes and the supernatant tipped off.  The cells 
were then resuspended in 500µl of 3% PFA and incubated at room temperature for 12 minutes.  The 
FACS tubes were then centrifuged at 1500rpm for 5 minutes and the supernatant tipped off.  This 
process was repeated, washing once with PBS 1ml and finally the 200µl of PBS was added to each 
tube.  Cells were then washed with 0.1% saponin and antibody mastermix (as shown in table 2.11).  
After resting at room temperature for 30 minutes the cells were washed once more with 0.1% 




S1    S2      Iso 
 
 
Blank FitC CD3     APC CD8        IL-2PE         CD3 PP     IFNg e450               
 
***B  FitC CD3   APC CD8     IL-2PE          CD3 PP     IFNg e450               
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Treg cells ex-vivo 
Stain 1  Stain 2 Isotype Control 
CD25-PE 4 CTLA-4-PE 3 IgG-PE 4 
FoxP3-APC 2.5 FoxP3-APC 2.5 IgG-APC 2.5 
CD3-PerCP 1.5 CD3-PerCP 1.5 CD3-PerCP 1.5 
CD4-e450 0.6 CD4-e450 0.6 CD4-e450 0.6 
CD127-PeCy7 1.5 CD127-PeCy7 1.5     
2% goat serum-PBS 45 2% goat serum-PBS 45 2% goat serum-PBS 45 
Table 2.10  Staining panel for Treg cells ex-vivo. 
For markers shown in bold in table 2.10, antibodies were added after permeabilization directly to the cell 
pellet. 
 
Cytokine production ex-vivo 
Stain 1 Stain 2 Isotype Control 
CD4-FITC 3 CD4-FITC 3 CD4-FITC 3 
IL-17-PE 0.6 IL-2-PE 0.6 IgG-PE 0.6 
IFNγ-e450 0.8 TNFα-e450 2 IgG-e450 0.8 
CD3-PerCP 1.5 CD3-PerCP 1.5 CD3-PerCP 1.5 
CD8-APC 2.5 CD8-APC 2.5 CD8-APC 2.5 
2% goat saponin 41.6 2% goat saponin 40.4 2% goat saponin 41.6 






   125 
 
 
CD25, CTLA-4 and FoxP3 expression post stimulation 
Stain Isotype Control 
CD25-FITC 2 CD25-FITC 2 
CTLA-4-PE 1 IgG-PE 1 
CD3-PerCP 1.5 CD3-PerCP 1.5 
CD4-e450 0.6 CD4-e450 0.6 
FoxP3-APC 1 IgG-APC 1 
Goat serum 3 Goat serum 3 
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 Cytokine production post stimulation 
 
300µl of supernatant from each condition (stimulation with SEB/ PPD / Vitamin D) was pipetted 
into individual labelled eppendorfs and frozen at -80
o
C for analysis by ELISA of cytokine 
production including IL-2, TNFα, IFNγ (all from Ebioscience, USA) and IL-17 (R&D system, 
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 IL17 IL2 IFNγ TNFα 
Un-stimulated non-diluted non-diluted 
SEB/untreated 1:100 1:200 1:100 
SEB/1,25D3 1:50 1:50 1:100 
SEB/25D3 1:50 1:50 1:100 
PPD/untreated 1:10 1:10 1:10 
PPD/1,25D3 1:10 1:10 1:10 
 
Table 2.13  Dilution factors for cytokine ELISAs 
Dilution factors for the cytokine ELISAs indicated in the table were determined in optimisation experiments 
(carried out as part of a BMed Sci project).  IL17 ELISAs were measured undiluted whereas IL2, IFNγ and 





















All statistics were carried out in SPSS version 18.0. Data normality was assessed using the 
Kolmogorov-Smirnov test, and for normally distributed data mean and standard error (SEM) 
calculated. For non-normal data median and inter-quartile range (IQR) was calculated. Mann 
Whitney test was used for independent groups which were not normally distributed and Wilcoxon 
signed ranks test was used to compare data in the same group when conditions were applied (e.g. 
administration of vitamin D between 0 and 8 week).  Kruskal Wallis Test was used to determine if 
there were statistically significant differences between two or more groups of an independent 












The Role of Genetic Polymorphism, baseline vitamin D and other 




3.1  Results 
 
3.1.1  Recruitment, Exclusions and Demographic Data 
 
Forty nine patients with positive smear for acid fast bacilli, positive culture for Mycobacterium 
tuberculosis or granulomatous changes on histopathology of a biopsy sample were recruited. 
Six patients were then excluded from the study due to various reasons including absence at follow 
up appointment due to deportation from the country and emigration, adverse drug reaction to TB 
medications with decision to discontinue trial by patient, multidrug resistant TB on culture and a 
subsequent malignancy diagnosis.  Forty three patients’ vitamin D levels were therefore analysed at 
Week 8. 
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At week 16 thirty five patients remained in the study.  Further exclusion of six patients was due to 
non-attendance (n=6), growth of Mycobacterium kansasii (n=1), patient decision to leave the trial 
(n=1).  Two patient’s vitamin D levels failed to produce a result in the laboratory, resulting in the 
analysis of thirty three patients’ vitamin D levels at Week 16. 
At week 24 thirty patients remained in the study.  Exclusions were due to non- attendance (n=5) and 
a further two patients vitamin D levels were not obtained from the laboratory sample sent, resulting 
in vitamin D analysis of twenty eight patients. 
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Figure 3.1 Recruitment, exclusion and dropout during the study. 
This figure shows the number of patients analysed at each time interval during the study.  The numbers fell from 
49 initially recruited to 30, of whom only 28 patients vitamin D levels could be analysed.  The main reason for this 
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Study Population and baseline characteristics 
 
Gender  
              Male  








30 (15.16, 21) 
 
Ethnicity  
          Caucasian 
          Indian subcontinent 
          Black African  
          Middle Eastern 
          SE Asian 










Site of Disease 
          Pulmonary 






        





Vit D Level nmol/l 
          
 
12.05 (20.86, 14.6) 
 
Table 3.1  Demographics of the study population. 
Data is presented as mean (standard error of the mean) or median (standard deviation, interquartile range) 
dependent on its distribution.  The majority of patients were male and had pulmonary tuberculosis.  The 
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The majority of patients were male 33/49 (67%) with a mean age of 35 years.  61.2% of the group 
were from the Indian Subcontinent (India / Pakistan) with just one person each from the Yemen and 
Thailand.   
71.4% of the group had pulmonary (pulmonary or pleural) tuberculosis (n=35) with the remainder 
falling into the extrapulmonary category (n=14), which included bony tuberculosis (n=2), lymph 
node tuberculosis (n=9), soft tissue abscesses (n=1), nasal tuberculosis (n=1) and gastrointestinal 
tuberculosis (n=1). 
The median vitamin D level was 12.1nmol/l which is severely deficient. 









Figure 3.2 Microbiology results of the study population. 
The figure shows the number of patients with pulmonary TB (PTB) and extrapulmonary TB (EPTB) and the 
smear and culture results for each group.  The majority (31/35) of PTB patients eventually cultured positive 








Smear +ve 21 
Culture +ve  
16 





1 MDR TB 
1 M kansasii 
Smear -ve 14 
Culture +ve 13 
Culture -ve 1 
EPTB 14 
Smear +ve 4 
Culture +ve 1 
Culture -ve 1 
Culture 
unknown 2 
Smear -ve 10 
Culture +ve 5 
Culture -ve 5 
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Figure 3.2 shows the microbiology results of the pulmonary and extrapulmonary tuberculosis 
groups.  After the maximal culture time of ten weeks the pulmonary TB group positively cultured in 
31 of the 35 patients with two of the positive cultures being due to one multi-drug resistant TB 
patient and one Mycobacterium kansasii infection (a non-tuberculous mycobacterial infection).  
These two individuals were excluded at this point from the trial. 
In the extrapulmonary TB group (n=14), eight of whom had lymph node TB, six were culture 
positive for M.TB and six culture negative with two unknown results.  This is not unusual given that 
extrapulmonary tuberculosis such as lymph node TB tends to culture less easily than cavitatory 
pulmonary tuberculosis.  Patients with smear or culture negative biopsies still remained eligible for 
the study however as all those who had negative microbiology were required to fulfil the inclusion 
criteria with histological confirmation of necrotising granulomatous changes as stated in the 
methods section. 
As a group, there was no significant effect of baseline vitamin D levels or the severity of vitamin D 
deficiency on sputum conversion i.e. those with severe deficiency did not have significantly 
different sputum conversion rates.  However the numbers were very small and therefore analysis of 
genotype effect was not carried out further.  Neither was there any relationship between baseline 
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Site of Infection and Vitamin D levels 
 
The pulmonary and extrapulmonary groups were analysed using Mann Whitney-U test to determine 
if there was any difference in the baseline and subsequent vitamin D levels according to the site of 
disease.  There was no statistically significant difference in the vitamin D levels in the pulmonary 













   137 
 




Figure 3.3  Mean baseline vitamin D levels for patients according to season of recruitment. 
Although mean vitamin D levels appear to vary with month of blood draw in the above figure, using Kruskal 
Wallis test there is no significant difference in the vitamin D levels at baseline of the study participants 
(p=0.273) according to month of recruitment, i.e. season did not affect baseline vitamin D levels when 






































Figure 3.4  Mean and median baseline vitamin D levels according to yearly quarter of recruitment. 
Quarter 1Jan-March, quarter 2 April-June, quarter 3 July-September, quarter 4 October –December. 
 
 
Although baseline vitamin D levels in this study did not appear to vary with month / season of blood 
draw, there have been examples of studies which have shown a seasonal tendency of TB which 
suggest that the number of TB cases is related to hours of sunshine [197].  This would fit with peaks 

























Year Quarter 1-4 
Mean
Median
   139 
 






Figure 3.5 Mean baseline vitamin D levels and ethnicity. 
 (n=48, Standard Error of mean is shown).  The largest ethnic group in the cohort included patients from the 
Indian Subcontinent.   It was noted in post hoc analysis that there was a significant difference in vitamin D 
































Caucasian n=7             ISC n=30                 African n=6                   Middle Eastern n=1     SE Asian n=1        Black Caribbean n=3 
 
Caucasian n=7             ISC n=30                 African n=6                   Middle Eastern n=1     SE Asian n=1        Black Caribbean n=3 
Ethnicity 
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At baseline there was a significant difference in vitamin D levels between ethnic groups (Kruskal 
Wallis test p=0.009). Post–hoc analysis of the groups using Mann Whitney-U test showed that 
baseline 25(OH)D levels were significantly higher (p<0.05) in the  Caucasian group compared to the 
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3.1.2  Genetic Polymorphisms and baseline vitamin D in determining response to Vitamin 
D supplementation 
 




Figure 3.6  25(OH)D levels (nmol/l) at Week 0, 8, 16 and 24.  
This figure illustrates vitamin D levels (and median lines) at each time interval.  There is a statistically 
significant rise in vitamin D levels with supplementation during the study. ***p<0.0001, ** p<0.05.  Most 
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Figure 3.6 shows the vitamin D levels of individuals at Week 0, 8, 16 and 24.  Wilcoxon ranks test 
shows that there is a significant rise in the 25(OH)D levels between weeks 0 and 8 and thereafter 
there is a steady rise which is also significant from baseline. 
Sufficiency was determined as 25(OH)D levels ≥50nmol/l.  At 8 weeks 17/43 (39.5%) achieved 
sufficiency.  At 16 weeks 17/33 (51.5%) achieved sufficiency and at 24 weeks 19/28 (68%) 
achieved sufficiency.  Note that the numbers in the groups decline due to exclusions at the 
respective time periods. 
There was no significant difference in baseline CRP, DBP or LL37 levels in those who had 



























Figure 3.7  Change in 25(OH)D levels with baseline vitamin D status. 
Patients with vitamin D deficiency (<20nmol/l) had a greater rise in vitamin D levels with supplementation at 
week 8.  i.e. those with lower levels had greater response. 
 
There was a significantly greater rise in vitamin D levels between weeks 0 and 8 in those patients 
who had 25(OH)D levels ≤20nmol/l at baseline than those whose levels were >20nmol/l,   (** p = 
0.009).  This indicates that those who are severely deficient respond more vigorously to 
supplementation than those who are deficient. 
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Effects of Single Nucleotide Polymorphisms (SNPs) in the Vitamin D Axis. 
  
The following SNPs were analysed :  
GC: rs7041, rs4588, rs2070741, rs2298849, rs3755967, rs1352844, rs222035, rs2282679. 





VDR rs2228570, rs1544410 
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Gene SNP Allele carriage/ haplotype carriage 
GC rs7041, rs4588, rs2070741, rs2298849, 
rs3755967, rs1352844, rs222035, 
rs2282679 
T allele carriage, TT homozygous 
rs7041, 
CC homozygote rs4588, 
GC1S carriage,  
GC2 carriage,  
GC2-2 carriage,  
GC1S-1S carriage,  
C allele rs2298849,  
C allele rs2282679,  
 
CYP27B1 rs10877012, rs4646536 CC homozygotes  rs4646536,  
TT homozygotes rs 4646536  
 
CYP2r1 rs10741657 A allele rs10741657,  
GG homozygote rs10741657 
DHCR7 rs12785878 Tallele carriage rs 12785878,  
GG homozygote rs 12785878  
 
IL6 rs1800796 GG homozygote rs1800796 
 
VDR rs2228570, rs1544410 CC homozygote rs 2228570, Tallele 
rs2228570,  
G allele rs1544410,  
AA homozygote rs1544410 
Table 3.2  Genes, single nucleotide polymorphisms (SNPS) and allele / haplotype used for statistical analysis. 
Key enzymes were identified through extensive literature searches and vitamin D / TB related SNPs were 
chosen to optimise the possibility of identifying relevant polymorphisms. 
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Figure 3.8  Allelic Discrimination Plots.   
The above figure exemplifies the use of the allelic discrimination plots at SNPs rs7041 and rs4588.   These 
figures are produced through TaqMan®SNP genotyping as described in section 2.3.5.  PCR results in the 
relative expression of each fluorophore, the results of which are represented in a scatterplot.  The four 
potential clusters of points correspond to the two homozygote genotypes or the heterozygote genotype (or no 
amplification).  The combination of the above 2 SNPs enabled the GC genotype to be determined and the 
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GC haplotype  TB patients (n=43) 25(OH)D level nmol/l 
 
Ethnic origin 
GC1F-1F 2 10.7 (1.05, -) Caribbean 
GC1S-1S 14 17.5 (25.2, 37) Caucasian, ISC, African Middle 
Eastern. 
GC2-1S 13 10.5 (13.4, 11.2) Caucasian, ISC, African 
GC2-1F 7 27.2 (11.7) Caucasian, ISC, African, Caribbean. 
GC2-2 4 12.88 (4.8) Caucasian, ISC, African 
GC1F-1S 3 12.1 (5.4) ISC, African 
 
Table 3.3 GC haplotype of TB patients with mean and median vitamin D levels. 
This table shows the GC haplotype groups which were identified in the TB population.  43 of the 48 
individuals were included in the study.  Five of the patients were not analysed due to insufficient genetic 
material or failure of the assay in discriminating the allele.  Data is presented as mean (standard error of the 
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Analysis of DBP genotype using Mann Whitney showed that there was a significantly greater rise in 
DBP levels between weeks 0 and 8 in rs7041 TT homozygotes (p0.048).  There were no other 
correlations found for any of the other SNPs or genotypes analysed. 
Further analysis of the DBP and CRP levels showed no correlation between these measures at week 
0 or 8 and there was no significant correlation between change in DBP or CRP between week 0 and 
week 8, indicating that resulting changes in levels are not reflective of an interaction between the 
two e.g. change in inflammatory protein production with change in inflammatory response. 
Haplotype analysis of DBP levels and mean levels for the groups with adequate numbers for 
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Figure 3.9  Vitamin D binding protein level variation with haplotype at Week 0.    
p=0.02 analysed with one way Anova.  Haplotype of DBP appears to affect the DBP levels. This may reflect 
that genotypes with the greatest affinity for vitamin D require lower amounts of the protein to produce the 
same effect in terms of vitamin D transportation, compared to those genotypes with lower vitamin D affinity.  
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For GC (rs7041, rs4588, rs2070741, rs2298849, rs3755967, rs1352844, rs222035, rs2282679), 
Mann Whitney U tests were used to determine if there is any association of the above SNPs with 
baseline vitamin D levels. There was no significant difference in baseline vitamin D levels and 
carriage of GC1s-GC1s, GC2 or GC1s.   
Response to vitamin D appears to vary with genotype.  Carriage of CC allele of GC rs 4588 
(p=0.048) was also found to have a significant association with change / increase in levels between 0 
and 16 weeks but this was not maintained at week 24, possibly due to a reduction in numbers 
analysed at this time point. 
Further analysis of GC genotype and vitamin D levels during the study are summarised in the table 
below.  This analysed the carriage of 3 or more major alleles combinations  (named WT+)  from 
rs7041/rs4588 combination and whether this had any significant influence on vitamin D levels at 
each time interval when compared to those who carried <3 major alleles (WT-) in their genetic 
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17 12.1 (25.8) 15 44 (44.4) 10 53.4 (54.2) 10 53.4 
(57.7) 
Heterozygote 17 12.1 (23.9) 16 41.8 
(48.4) 
13 42 (49.6) 12 60.9 
(62.4) 
Minor homozygote (TT) 12 11.8 (21.2) 9 42.5 
(45.7) 











Heterozygote 19 11.0 (20.0) 17 41.0 
(41.1) 




4 14.5 (12.9) 3 35.5 
(37.0) 
2 34.8 (35.0) 1 63.1 
(63.1) 
WT+ 19 13.0 (17.9) 17 39.1 
(40.8) 
12 53.0 (53.0) 11 49.5 
(59.7) 
WT- 24 12.6(14.8) 21 39.0 
(42.2) 
17 47.1 (45.9) 13 63.1 
(62.5) 
 
Table 3.4 Median and (mean) values for 25(OH)D according to GC genotype rs7041 and rs4588 at various 
time intervals.   
Wild type + (carriage of ≥3major alleles in the rs4588 and rs5041 allelic combination ) or wild type - 
(carriage of <3 major alleles) is shown with the corresponding median (mean) vitamin D levels.  
WT wild type. 
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VDR (rs2228570, rs1544410). 
 
Carriage of rs2228570 T allele (VDR Fok1) was associated with a significantly higher level of 
vitamin D at baseline (week 0) (mean rank 25.83vs 17.57, p0.029) i,e, baseline vitamin D levels 
appears to vary with genotype. 
Response to vitamin D appears to vary with VDR genotype.  VDR rs22228570 CC homozygotes 
had greater change in vitamin D levels between 0 and 8 weeks (p=0.026 Mann Whitney).   
 
Other SNPS (CYP27B1 rs4646536, CYP2R1 rs10741657, DHCR7 rs12785878 and IL6 rs1800796). 
 
No other allele carriage in the various SNPs listed was associated with baseline vitamin D levels.  
However, response to vitamin D appears to vary with genotype.  With regard to the effect of 
genotype on change in vitamin D with supplementation, DHCR7 rs12785878 GG homozygote had 
greater change in vitamin D levels between 0 and 8 weeks (p=0.029 Mann Whitney).   
A negative correlation (i.e. non carriage of the following genotypes was associated with greater 
interval vitamin D change) was noted at 8 and 16 weeks with carriage of cyp27b1 rs4646536 CC 
homozygote and at 8 weeks with carriage of rs2228570 T allele as did DHCR7 rs12785878 T allele 
carriage at 8 weeks (p=0.029). 
However there does not appear to be a relationship between genotype and achieving vitamin D 
sufficiency (>50nmol/l) when measured at 8 and 16 weeks. 
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Due to small numbers of patients reaching the final 24 week time point, analysis of genotype and 
vitamin D levels have not been done in this group.   For the same reason, further analysis of severe 
vitamin D deficiency was not further analysed against genotype. The results are likely to be affected 
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3.1.3  Effect of Baseline Vitamin D and Other Elements of the Vitamin D Axis on Clinical  
Outcome / Antimicrobial Response. 
 






Figure 3.10  Vitamin D binding protein levels (mg/dl) at Week 0, 8, 16 and 24.  
Vitamin D binding protein levels increase at each time interval during the study, although no direct 
correlation was noted with vitamin D levels during the study i.e. the availability of vitamin D does not 
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The levels of vitamin D binding protein rose between weeks 0 and 24.  Using Wilcoxon Ranks test it 
can be seen that there is a significant difference in levels of DBP at each time interval. This does not 
reach significance between weeks 16 and 24, but does so between weeks 0 and 24 and it is clear that 
there is a steady increase nevertheless.   
 
Using both Kruskal Wallis and Mann Whitney tests, given that the DBP data had a non-normal 
distribution, it was determined that neither age, gender or ethnicity affect DBP levels and therefore 
























Figure 3.11 LL37 levels at Weeks 0 (n=49), 8 (n=38), 16 (n=34) and 24 (n=26) in TB patients.  
Levels of LL37 fell significantly by week 8, with a return to baseline levels thereafter.  There is no 
correlation with vitamin D levels in the study.  Total systemic LL37 levels however, may not reflect localised 
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There was a statistically significant fall in the LL37 levels between week 0 and 8 but this did not 
persist at weeks 16 and 24 and the levels returned to a levels comparable with the baseline. The 
Wilcoxon Ranks test takes into account the dropouts during the study. 
 It may be expected to see a fall in the LL37 levels in the initial treatment period as the 
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L L 3 7   a n d  V ita m in  D  le v e ls  a t  B a s e lin e
















Figure 3.12 Baseline vitamin D and LL37 levels.   
There is no correlation between baseline LL37 and vitamin D levels.  Further analysis showed that 
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Analysis of baseline LL37 and vitamin D levels show that there is no correlation between these 
parameters.  This concurs with previous findings by Yamschchikov [64]. 
Neither was a relationship identified between LL37 levels and severity of vitamin D deficiency i.e. 
in those patients with levels of 25 (OH)D3 <20nmol/l, the LL37 levels were not statistically different 
from those with 25(OH)D3 levels ≥20nmol/l (Mann Whitney test). 
Further analysis of LL37 levels and other variables showed that there was no relationship between 
smear positivity, gender, TB score (Mann Whitney) or ethnicity (Kruskal Wallis test) at baseline and 
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L L 3 7  a n d  C R P  le v e ls  a t  b a s e lin e






Figure 3.13 Baseline LL37 and CRP levels 
There is a positive correlation (p=0.06) between LL37 and CRP level at baseline.  Rising CRP is reflected by 
greater LL37 levels, which may be a result of disease activity at baseline, prior to TB treatment.  However the 
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Baseline LL37 levels appeared to have a positive correlation with baseline CRP levels (p0.06) and 
this this relationship appears to continue at weeks 8 (p=0.024) and at week 16 (p=0.006) but is lost 
at week 24.  There was also a correlation with total white cell count (WCC) at week 0, (Figure 3.14), 
however this relationship was again lost at weeks 8-24.  This may indicate that the greatest levels of 
inflammation prior to TB therapy results in a rise in all inflammatory markers which would be 
expected.  However, it would also be expected that as inflammation reduces with treatment, all 
markers would do so, this does not appear to be the case however, with LL37 declining by week 8 
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L L 3 7  le v e ls  a n d  to ta l W C C a t  b a s e lin e









Figure 3.14 Baseline LL37 level and total white cell count.   
There is a significant correlation between the LL37 levels and total white cell count at baseline. (Spearman 
test p=0.004).   White cells are a source of LL37 and may reflect the conditions of inflammation.   Consistent 
findings are shown below in Figure 3.15 which show further correlations of LL37 with lymphocyte / 
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The positive correlation between LL37 levels and total WCC persists at week 8 (p=0.007) but is lost 
at weeks 16 and 24.  The correlation does not follow for total lymphocyte count but there is a 
statistically significant negative correlation between the lymphocyte / monocyte ratio and LL37 
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L y m p h o c y te  / M o n o c y te  ra t io  a n d  L L 3 7  le v e ls  a t  b a s e lin e .










Figure 3.15 LL37 levels and lymphocyte / monocyte ratio at baseline.  
(p=0.006 Spearman Correlation test at baseline).  There is a weakly negative correlation between LL37 levels 
and lymphocyte / monocyte ratio at baseline with rs= -0.398.  Rising lymphocyte monocyte ratio levels during 
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Figure 3.16 The TB score (maximum 13) at Week 0 to 24.  
*** p<0.0001  There is a significant reduction in TB score (TB score 4 at week 0, TB score 0.5 at weeks 8).  
Further breakdown of the cohort showed that those with extra-pulmonary disease had lower TB score than 
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There is a significant reduction in the TB score between Week 0 and 8 (median 4.0 at week 0, 
median 0.5 at week 8) and remains at a similar level thereafter.  The median TB score at baseline 
appears to be associated with a greater inflammatory process and patients with TB Score ≥4 have a 
significantly higher CRP value (Mann Whitney U test p<0.005).  The TB score is significantly lower 
in patients with extrapulmonary TB (median 2.00) than those with pulmonary TB (median 5.00) 
(p=0.00). 
The relationship between vitamin D levels and TB score was analysed.  No significant correlation 
was found between baseline vitamin D levels and TB score <4 (i.e. those with less severe disease do 
not appear to have significantly different vitamin D levels to others).    Those with severe deficiency 
i.e.<20nmol/l did not have statistically significant different change in TB scores between baseline 
and each of the interval measurements at weeks 8,16 and 24 (p>0.05). 
In calculating the TB score, the MUAC (Mean Upper Arm Circumference) and BMI was calculated. 
Using Mann Whitney Tests, it was calculated that the MUAC had no relationship to vitamin D 
levels at baseline.  The numbers of patients with MUAC <220 was only 8/48 with results and so 
with a small cohort the results may be unreliable.  Previous studies have identified a relationship 
between BMI and vitamin D levels. In the same way BMI was calculated and grouped into those 
with a BMI <16 or <18.  However no relationship with baseline vitamin D results was identified.  
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Radiology Score  
 
No significant difference was found in CXR score in severe vs non severe vitamin D deficiency i.e. 
those with levels <20nmol/l vs those with levels >20nmol/l p=0.066.  No statistically sig difference 
between high and low TB score <4 or ≥4) on CXR score (p=0.34), even when the group was split in 
pulmonary and extrapulmonary disease. 
No sig correlation was identified between CXR score and baseline vitamin D, LL37 or CRP using 
Spearman’s rho test for the non-parametric data.  Neither was baseline TB score noted to have a 
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Other Markers in the Circulating Blood 
 
 
Figure 3.17 CRP levels with median values between week 0 and 24 
As treatment and vitamin D supplementation progressed throughout the study, the CRP levels declined, 
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CRP levels show a significant reduction between week 0 and 8 (see figure 3.17) with a steady 
reduction towards zero thereafter (*** p<0.0001).   
The stimulus for CRP is likely to be IL6 (secreted by T cells and macrophages), IL1 (produced by 
macrophages, monocytes, fibroblasts and dendritic cells, resulting in increased expression of 
adhesion factors to help with tissue transmigration) and TNFα (produced by activated 
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Figure 3.18  Lymphocyte / monocyte ratio with treatment.  
**p<0.05.  Lymphopenia  and a monocytosis is commonly found with M.tb infection and as treatment 
progresses, the lymphopenia recovers and monocyte numbers decline to normal levels.  This correlates with 
previous work showing monocyte / lymphocyte ratios are greatest in those infected with tuberculosis 
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During the trial the lymphocyte / monocyte ratio rise at each interval (see figure 3.18).   
There was no association between lymphocyte / monocyte ratio (L/M) and vitamin D levels or TB 
score.  However L/M ratio <3 is associated with significantly higher levels of LL37.  The reason for 
this is unclear, perhaps LL37 drives tissue transmigration of lymphocytes, thereby reducing 
numbers. 
 
A statistically significant rise in lymphocyte count is noted between week 0 and 8 (see figure 3.19) 
**p<0.05 (0.043) but this is not incrementally statistically significant at other time intervals. 
Twelve (25%) of the patients were lymphopenic (<1.1x 10
9
/L) at baseline.   
 
The converse is true for monocyte count with a gradual reduction in levels (significant between 











Figure 3.19 Lymphocyte levels with median values during treatment.  
Lymphopenia in tuberculosis is commonly seen and levels tend towards normality with treatment. There is a 
significant increase in levels between weeks 0 and 8 which remains as such throughout the study with no 
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Figure 3.20 Monocyte levels with median values during treatment. 
Monocyte levels are essentially a reflection of the lymphocyte response to treatment as illustrated in figure 
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3.2 Discussion  
 
 
3.2.1 Recruitment, Exclusions and Demographic Data 
 
The study finally recruited forty nine patients for the main clinical trial and this was fewer than the 
one hundred patients I had initially aimed for.  Several factors contributed to this figure, including 
delays in obtaining final MHRA approval, pharmacy administration and availability of suitable 
patients during the remaining recruiting period.  Maintaining study participants in the study proved 
to be a challenge and this reflected the reality of the TB population served, in that they are 
frequently mobile, some leading chaotic lifestyles.  Although some of the patients did not attend for 
the trial follow up, every effort was made to ensure that despite this, they maintained their 
antituberculous therapy using a team of dedicated nurses who provide home or work visits to ensure 
that this is the case. The loss to follow up rates for patients with drug sensitive TB in 2013 for the 
West Midlands was 4% [18].  This compares to the study populations failure to complete the trial 
protocol at 43% (28/49 patients).  This figure would not be reflective of the final completion rates in 
the TB patients on active treatment and indeed, the figure for the West Midlands is 85.9% 
completion in 2013 for drug sensitive disease which meets national standards and may reflect either 
loss to follow up or difficulties with the clinical management / treatment of the patient.   
The reason for the higher loss to follow up rates in this study was partly because study sampling and 
recruitment was only carried out at the designated clinics.  Although some leeway was given for 
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collection of samples either side of the allocated time intervals, we did not collect from patients’ 
residence / outside clinic times and this may be something which, if taken into account may allow 
for additional recruitment in further studies. 
Despite these challenges the results of the main clinical trial and the results from the functional work 
which was carried out concurrently have given some interesting findings on which to build future 
work.  
The ethnicity of the population studied is reflective of the diversity of ethnicities in Birmingham.  
61.2% of the group were from the Indian Subcontinent (India / Pakistan) and this is similar to 























Table 3.5  Most frequent countries of birth for non-UK born tuberculosis cases and time since entry to the 














Median time since 
entry UK (IQR)**
India 1,858 30.7 4 (2 - 13)
Pakistan 1,091 18.0 7 (2 - 21)
Somalia 380 6.3 8 (3 - 12)
Bangladesh 276 4.6 7 (2 - 23)
Nepal 216 3.6 2 (1 - 5)
Nigeria 184 3.0 5 (1 - 10)
Philippines 136 2.3 5 (2 - 9)
Zimbabwe 132 2.2 9 (7 - 11)
Kenya 98 1.6 13 (6 - 40)
Sri Lanka 98 1.6 7 (2 - 15)
Eritrea 87 1.4 4 (2 - 5)
Romania 78 1.3 2 (0 - 4)
Afghanistan 75 1.2 5 (2 - 10)
Poland 71 1.2 5 (2 - 7)
Others (each <1%) 1,265 21.1 5 (1 - 13)
Total* 6,045 100 6 (2 -13)
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The age and gender of the population described was characteristic of the types of patients which 
attend the tuberculosis clinics in Birmingham, frequently a younger population, with the majority of 
older patients having reactivation of tuberculosis which may have been contracted many years 
earlier.    
Culture results for TB patients are essential, in order to identify the organism and treat appropriately 
according to drug sensitivity results.  The West Midlands rates for culture confirmation of 
pulmonary tuberculosis in 2013 were 64.9% (figure 3.21) below shows the rates of culture 
confirmation for the west midlands).  This compares to the local rate within the study of 31/35 
(89%) for a positive culture of any mycobacteria and 29/35 (83%) positive culture of drug sensitive 
M.tb.  However these rates will inevitably be higher given that patients were only recruited if there 
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Figure 3.21 Rates of culture confirmation in pulmonary TB in the West Midlands.   
The legend shows in black circles the rates for England, and superimposed the rates for the West Midlands 
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3.2.2 Genetic Polymorphisms and baseline vitamin D in determining response to Vitamin 
D supplementation. 
 
Aim 1 of this MD was to ascertain the role of polymorphism in the vitamin D axis genes in 
determining response to vitamin D in tuberculosis patients.  In doing so I studied the effect of the 
baseline vitamin D level and effect on the response to supplementation, and whether polymorphisms 
in the vitamin D axis has any relationship to the baseline and response vitamin D levels in vivo.   
Additionally on this theme, the response of monocytes to vitamin D supplementation has been 
ascertained, including the genetic polymorphism effect on this in vitro response.  
Supplementation with vitamin D clearly results in a significant rise in vitamin D compared to 
baseline.  However, the degree of response in achieving sufficiency was unsatisfactory with only 
68% of those remaining in the study achieving levels ≥50nmol.  Previous studies such as those by 
Martineau and Wejse have had similar problems with failure to achieve sufficiency or a significant 
rise with oral supplementation [75] [5].   
The degree of response appears to be affected by the baseline vitamin D level and this concurs with 
previous findings by Didrickson et al where those with the lowest baseline serum 25(OH)D (without 
regard to genotype) had the highest increase after supplementation.  Other studies also identified 
similar findings [199-201].   
The relevance of this may be that in individuals from regions with high sun exposure or with 
ethnicities which are prone to vitamin D deficiency, to a greater or lesser degree, the 
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supplementation regime may be adjusted accordingly.  However, it is likely that both those who are 
severely deficient or insufficient will need adequate doses to obtain sufficiency regardless of their 
initial response to supplementation.  It has been difficult in previous studies to attain sufficiency 
with some of the study dosing regimens and this may be due to concerns regarding over 
supplementation and its theoretical risks. 
There appears to be a relationship between both baseline vitamin D levels, change / response to 
supplementation and genotype.  Baseline vitamin D values appear to be affected by rs2228570 T 
allele carriage (Fok1), which showed that carriage of the T allele resulted in higher vitamin D levels.  
Further work is required to determine whether this is maintained in a larger trial. However a 
systematic review from 2010 [202] noted that two of three studies examining  rs10735810 (now 
merged to rs2228570) found a significant relationship with 25OHD concentrations.   Two studies 
reported significant associations [203, 204]  with the minor allele (T allele) associated with higher 
concentrations of 25OHD.  Other studies do not corroborate this [205, 206] and clearly larger 
studies are required.  Other studies have varied results with regard to VDR polymorphisms and 
findings include correlation of vitamin D levels with Bsm1 SNPs [207] and Taq1 SNPS [206]. 
Change in vitamin D levels / response to supplementation appears to have a genetic relationship and 
the findings that the change in vitamin D at 0-8 weeks in DHCR7 rs12785878 GG homozygote and 
VDR rs2228570 CC homozygotes carriers and 0-16 weeks in CC allele of GC rs 4588 carriers 
would suggest this.  The finding regarding DHCR7 rs12785878 concurs with the finding in a recent 
GWAS that genotypic variation in the DHCR7 gene accounts for 1-4% variation in 25(OH)D level 
concentrations [208].  However the other findings regarding GCrs4588 and VDR rs 2228570 have 
not been corroborated in GWAS. 
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In order to determine if specific independent variables affected prediction of baseline vitamin D 
levels, analysis of ethnicity, age and season of blood draw was analysed. This is discussed in section 
3.1.1 of the results. 
Ethnicity was found to be related to the vitamin D status with baseline 25(OH)D levels that were 
significantly higher in the  Caucasian group compared to the Indian Subcontinent (ISC), African and 
Black Caribbean groups.   
Previous studies have confirmed the above finding, Mitchell et al noting higher vitamin D levels in 
Caucasians [209] and Ekeroma et al noting lower levels in ethnicities with darker skin compared to 
those of European descent [210]. 
 
3.2.3 Effect of Baseline Vitamin D and Other Elements of the Vitamin D Axis on Clinical 
Outcome / Antimicrobial Response. 
 
The second aim of this study was to identify any relationship of TB outcomes to vitamin D level.  In 
determining whether disease activity is affected by vitamin D levels at baseline and with 
supplementation, several parameters were looked at including TB score, sputum smear positivity, 
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Relationship between baseline vitamin D levels and TB score 
  
A previous study by Wejse showed no significant effect of vitamin D supplementation on TB score 
compared to the placebo group [68, 211]. 
This study showed that there was a significant reduction in TB score over time.  Whether this was 
due to vitamin D supplementation or solely related to treatment with anti-tuberculous therapy is 
difficult to say without a placebo controlled trial.  However, it was possible to look at the 
relationship between vitamin D baseline and TB score and the effect of change of vitamin D levels 
with supplementation on the TB score. By analysing the baseline vitamin D score, including those 
with severe deficiency it was possible to conclude that in this study there does not appear to be any 
correlation between the baseline or change in vitamin D level and the TB score / change in TB score 
at week 8. This correlates with findings by Wejse et al and Salahuddin et al that a reduction in TB 
score did not differ between patients in the vitamin D treatment or placebo arms [211, 212].  
However, more recently Junaid et al noted that those with profound vitamin D deficiency was 
associated with delayed sputum conversion and bilateral vs unilateral disease [213]. 
Unsurprisingly those patients with extrapulmonary tuberculosis had lower TB scores at baseline (2.0 
vs 5.0) which may reflect the variation in immune responses between the two subsets, with a greater 
cytopathogenic response in pulmonary disease, resulting in an increase in systemic signs and 
symptoms.  Recent work by doubling in serum concentration of 25(OH)D confers a significantly 
reduced risk of extrapulmonary disease which is interesting and suggests that greater vitamin D 
levels in fact reduce the likelihood of dissemination outside the lungs which  
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The results from analysis of the TB score and vitamin D deficiency at baseline suggest that there is 
no correlation between the severity of vitamin D deficiency at baseline and the change in TB score 
with time, i.e. being severely deficient (<20nmol/l) did not appear to affect their overall response to 
treatment.  This may be because they were all supplemented and this therefore counteracted the 
effect of deficiency.  However it appears that even accounting for change in vitamin D over time 
with supplementation, no relationship with TB score could be identified. 
 
In identifying whether MUAC or BMI was related to baseline vitamin D levels, there was no 
statistically significant relationship identified in this observational study.  However the numbers are 
small and a larger cohort may yield further findings.  A previous study by Baradaran et al shows that 
BMI is not associated with vitamin D levels (age adjusted) [214], however a systematic review and 
meta-analysis in 2013 showed that there was an overall significant inverse, but weak, association 
between serum 25(OH)D levels and BMI with a significant heterogeneity between the studies [215]    
 
Sputum conversion.   
 
It was not possible to accurately analyse whether sputum smear conversion was related to baseline 
vitamin D due to the small numbers (single figures) of pulmonary TB patients who were able to 
provide sputum samples subsequent to baseline analysis and the fact that many of the pulmonary TB 
patients were smear negative but culture positive at onset, so smear positivity could not be 
monitored.  A larger cohort would have been needed to accurately assess this, although studies 
looking at this have been conflicting, with Salahuddin et al noted no significant relationship between 
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vitamin D supplementation and smear conversion whilst Nursyam et al and Martineau et al noted 
that sputum smear conversion is speeded up by vitamin D supplementation [74, 77] and Junaid et al 
noted profound vitamin D deficiency was associated with delayed sputum conversion [213]. 
 
Radiology Score.   
 
The radiology / CXR score was calculated using an equation, validated by Ralph [190] et al.  
Various markers were analysed against CXR score, with no significant differences or correlations 
with baseline inflammatory markers, vitamin D severity or clinical severity markers such as TB 
score. 
Ralph et al noted that CXR score was significantly associated with sputum smear grade at diagnosis 
and therefore representative of the severity of pulmonary disease.  This was shown to be more 
accurate at determining 2 month smear status by using both % consolidation as well as a weighting 
for cavitation than % consolidation alone.  However numbers in this study may well have 
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DBP levels rose incrementally throughout the study at each time interval.  Although both vitamin D 
and DBP levels rise during the trial, there does not appear to be a direct correlation between the two, 
i.e. the availability of vitamin D does not significantly affect the circulating DBP. It may be 
expected that as vitamin D levels rise, DBP levels will fall, however the turnover of DBP is high and 
the snapshot of DBP levels may not be reflective of its activity.  A study by Winters et al showed 
that DBP was not an important determinant of circulating vitamin D levels [216].   Additionally, the 
free vitamin D may not reflect that which is bound to DBP and therefore remains unmeasured, with 
GC genotype affecting the degree of affinity for vitamin D.  For example TT allele is likely to 
produce GC1F variant which has been shown to have greater affinity for vitamin D, and as such 
may existing DBP may reach saturation more quickly, resulting in a subsequent increase in 
production via a positive feedback loop. 
Another possible explanation for the rise in DBP may be that conversion to macrophage activating 
factor (MAF) which occurs in the acute inflammatory response, declines as treatment effect occurs 
nd inflammation regresses with improving clinical condition. 
The finding that DBP haplotype appears to have a direct effect on DBP levels is an interesting one 
and has previously been discussed in work by Coussens et al [217] which found GC1S1S 
individuals had greater DBP total levels compared to GC1F1F.  One explanation for this may be that 
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the haplotypes with greatest affinity for vitamin D are required in lesser amounts to provide the 




LL37 levels dropped significantly between week 0 and 8.   
Interestingly analysis of baseline levels of LL37, the antimicrobial protein related to vitamin D 
metabolites, shows that there is no correlation with baseline vitamin D levels.  This concurs with 
previous findings by Yamschchikov [64],  however conflicts with other findings by Jeng et al which 
found a correlation between serum vitamin D levels and systemic levels of LL37 [218].  One reason 
for the finding in this study may be that localised autocrine levels (also shown to have a relation to 
vitamin D) may be a more important measurement and may not be reflected in the total systemic 
values of LL37as detailed by Adams et al with hCAP (the precursor to LL37) [219].  Further related 
cell work is discussed later in this thesis. 
The study highlighted that LL37 had a positive correlation with both total white cell count and 
monocyte / lymphocyte ratio.  The findings may reflect the fact that white cells are a source of LL37 
[220], with rising counts  in a condition of inflammation, resulting in elevated LL37 levels. The 
reason that monocyte / lymphocyte ratio was considered was because work by Naranbhai and Wang 
that hazards of tuberculosis correlates to particularly low or high M/L ratios [221] and median 
monocyte to lymphocyte ration was greater in TB infection compared with controls, and recovered 
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post treatment to normal levels [222]. This suggests that LL37 levels seem to be related to immune 
activation, although no correlation could be identified with disease severity in the form of TB score. 
The initial decline in LL37 levels may include the fact that treatment of the mycobacterial infection 
with antimicrobial therapy results in a reduction in some mononuclear cells such as neutrophils and 
monocytes (although lymphopenia usually corrects), thus possibly leading to an overall reduction in 
LL37.  However, with no healthy controls to compare, it is difficult to determine if this response is 
purely due to treatment or due to the effect of vitamin D.   Interestingly Coussens et al found that 
vitamin D accelerated treatment induced decreases in LL37 (rather than just decreasing the total 
LL37 levels) [223].   Previous studies noted that vitamin D induced the production of antimicrobial 
proteins, but the findings by Coussens that antituberculous therapy suppressed LL37 levels but that 
the levels were further suppressed by vitamin D are similar to the findings at Week 0-8 in this study.   
Indeed LL37 may not be the ideal substance to measure and previous work by Martineau may 
suggest that measurement of hCAP18 gene may be a better indicator of antimicrobial activity [224].     
Vitamin D has also been found to suppress hCAP18 as well as M.tb and these would be reasonable 
explanations for the pattern of LL37 expression between weeks 0 and 8. 
Despite the initial drop in LL37 levels, they return to baseline levels during the remainder of the 
study period and this raises the question:  which effect has the greatest impact – the antituberculous 
therapy or the vitamin D treatment on LL37?  An explanation for the latter rise in levels may be that 
once the initial suppression of LL37 producing cells occurs with antituberculous therapy, vitamin D 
upregulates the response in other immune regulating cells such as lymphocytes, which tend to 
recover with M.tb treatment, thereby resulting in total LL37 similar to pre-treatment levels.   
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Further work in this area would be to measure hCAP gene protein as part of the analysis in order to 
see if this correlates with the LL37 picture.  Analysis of the LL37 levels at weeks 2,4 and 6 may 
have been useful in order to determine whether the levels at week 8 are purely spurious results or 
whether there is indeed a gradual decline in the initial stages of treatment. 
 
Lymphocyte / Monocyte ratio 
 
Monocyte and lymphocyte analysis was reviewed as part of the inflammatory response analysis.  
Previous studies have looked at total monocyte and lymphocyte counts and lymphocyte / monocyte 
ratios in association with risk and susceptibility of disease.   
The lymphocyte / monocyte ratio rises at each time interval during the study and this is reflected 
with statistically significant rises in total lymphocyte count along with a decline in total monocyte 
counts.  These findings correlate with work by Coussens et al which notes that with antituberculous 
therapy monocytosis declines and lymphopenia improves, whilst vitamin D accelerates both. 
Previous studies in this field have shown that hazards of tuberculosis correlates to particularly low 




 centile) in HIV infected patients even with adjustment for CD4+ T 
cell counts [221].  A recent study by Wang et al showed that median monocyte to lymphocyte ration 
was greater in TB infection compared with controls, and recovered post treatment to normal levels 
[222], whilst an earlier study by Sabin et al in rabbits showed that high M/L index resulted in low 
resistance to disease experimentally [225].  Again, these findings correlate with the increasing L/M 
ratio found in this study. 
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No association was found between lymphocyte / monocyte ratio and vitamin D levels or TB score.  
However, an L/M ratio <3 was associated with significantly higher levels of LL37.  This is probably 
reflective of the disease process occurring with a relative monocytosis in early active disease, and 
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Chapter 4 
The Role of Vitamin D and genetic polymorphisms on immune 
modulation and response to vitamin D in vitro / ex vivo in health 
and mycobacterial disease. 
 
 
The aim of this chapter is to determine if vitamin D exerts an immune modulatory effect in vitro and 
ex vivo, in both health and mycobacterial  disease.  The results included were obtained from cell 
work on both monocytes and T cells which was carried out as part of this study.  Initially a greater 
degree of clinical work was envisaged.  However due to patient recruitment and retention the 
decision was made to add further functional work to the study, in order to maximise data pertaining 
to the aims, endeavouring to ensure that despite lower than expected recruitment rates, the patient 
population studied would still enable additional cell work to be completed. 
The most important components of anti-mycobacterial activity are macrophages (innate immunity) 
and lymphocyte subsets (adaptive immunity), with vitamin D exerting both inhibitory and 
stimulatory effects on these systems. 
As discussed in Section 1.7, vitamin D is known to have numerous functions on both the innate and 
adaptive immune response, including upregulation of antimicrobial products, upregulation of the 
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TH2 response and regulatory T cell function and down regulation of the TH1 response.  This is 
illustrated in Figure 1.6. 
 
4.1  Results 
 
4.1.1  The Immune Modulatory Effect of Vitamin D in Vitro and ex Vivo, in health and 
Mycobacterial Disease  
 




In order to determine the optimal LPS concentration to use in the monocyte culture media as an 
inflammatory stimulus (i.e. produce adequate stimulation of monocytes) optimisation experiments 
were carried out with various concentrations of LPS. The production of IL6 was then measured 
using an IL6 ELISA Duokit as described in the methods section.  Additionally, the optimal 
25(OH)D3 was also added to the media in separate wells at varying concentrations, to determine IL6 
suppressive effect.   
 



















Figure 4.1 Optimisation of (a) LPS concentration and (b) 25(OH)D3 concentration.   
 
(a) Dose response curve (n=2 repeats) showing IL6 production with increasing LPS concentration by 
monocytes.   This experiment used concentrations of LPS (0,50,100, 250, 500, 1000 ng/ml) in the 
monocyte culture media as an inflammatory stimulus to determine adequate stimulation of 
monocytes. The production of IL6 was then measured using an IL6 ELISA Duokit at different LPS 
concentrations.  The optimal concentration of LPS which produced maximal stimulation was 
100ng/ml LPS, after which the levels of IL6 did not significantly increase. 
(b) In addition to the various LPS conditions, 25(OH)D3 was also added to the media in separate wells at 
concentrations (10, 20, 50 and 100nmol) to determine any additive effect on IL6 values ( n=2 













































Figure 4.2 Mean (with standard error) IL6 production in the presence of LPS when monocytes were cultured 
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Comparison of controls and TB patients’ monocyte function 
 
Monocytes of TB, latent TB patients and a control group were cultured for 48 hours as described in 
the methods section and stimulated with LPS and subsequently cultured with 25(OH)D3.  The IL6 
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Figure 4.3 Monocyte mean IL6 production in (A) active, latent and control populations with LPS stimulation 
in the presence and absence of vitamin D.  (B) Active and latent populations divided according to response to 
vitamin D (Response is a drop of >10% in the monocyte supernatant IL6 value with the addition of vitamin 
D);   (C) Control population divided according to response to vitamin D. 
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Using Wilcoxon Ranks test, analysing each group individually (control, latent and active disease), 
and comparing the IL6 production with LPS stimulation alone or with LPS in combination with 
vitamin D, there is no significant difference in the IL6 production with or without vitamin D in 
either form (p>0.05).  This is shown graphically in (A). 
 
The IL6 production in the three groups however, varied significantly, regardless of subsequent 
vitamin D response, on initial stimulation with LPS (A). Using Wilcoxon-Mann Whitney tests there 
is a significant difference between the active and latent IL6 production (p<0.007).  This significant 
difference is also seen between the controls and latent group (p≤0.001).  However, the significance 
is lost between the active and control groups (p=0.824-1.0).  Despite the appearance of a difference 
in the mean on the graph, statistically this was not borne out when the groups were analysed. 
 
Graph (B) shows that when the TB infected (latent and active) patient were analysed together, and 
then sub-categorised into responders (>10% reduction in IL6 with supplementation of vitamin D) or 
non-responders, it was noted that neither the responders nor non responders had a significant 
difference in IL6 production when stimulated with LPS.  When the monocytes were cultured along 
with 25(OH)D3 the mean IL6 production was lower in the responders compared to the non-
responders, however it did not reach statistical significance.  This was also the case for the response 
to 1,25(OH)2D3.  This does however show that individuals have large variations in their IL6 
production in response to vitamin D.  This may be multifactorial but the possibility of an underlying 
genetic predisposition is raised.  The standard deviations for the subsets were large and therefore the 
mean is not wholly representative of the statistical data. 
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Graph C shows the IL6 response in the control group which when analysed using Mann Whitney U, 
shows no significant difference in IL6 production with LPS stimulation between responders and 
non-responders, although the graph appears to show a trend.  When 25(OH)D3  is added with the 
LPS, there is a difference which almost reaches significance (p=0.052) between responders and non-
responders in this control group.  When 1,25(OH)2D3 is added there is no statistically significant 
difference between IL6 response in responders vs non responders. 
Further analysis of the genetic relationship of a variety of SNPs are analysed further in this thesis to 
determine if there are any significant associations between genotype and response to vitamin D in 
monocyte culture.  In addition to this the section below (comparison of monocyte response to 
vitamin D in the presence of pooled plasma of varying DBP genotypes) looks at the exposure of 
monocytes to a variety of DBP genotypes through pooled plasma to see if there is any further 
supporting evidence for the possibility of variation in immune response to vitamin D being 
associated with genetic predisposition.  
 
Comparison of monocyte response to vitamin D in the presence of pooled plasma of varying DBP 
genotypes. 
 
In light of the variability seen in initial monocyte vitamin D work, which I hypothesised might be 
due to genetic variation, further experiments were undertaken using DBP genetic variants. 
Pooled plasma was taken from tuberculosis patients, pre- treatment and added to monocyte cultures 
taken from control volunteers.  All wells contained LPS 100ng/ml and 25(OH)D3 50nmol.  The 
plasma for each genotype was pooled from at least three patients per genotype to try and reduce 
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heterogeneity.  The monocytes were cultured with each and the cytokine response (GCSF, IL1-β, 
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Figure 4.4 Effect of pooled plasma with differing DBP genotypes on cytokine response.   
This figure shows the effect of the addition of pooled plasma on monocyte cytokine response.  There is a 
reduction in cytokine response in all cases with the addition of plasma with statistical significance in all 
except TNFα.  Varying vitamin D binding protein genotypes also appear to affect the degree of cytokine 
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Analysis of the data was carried out using Kruskal Wallis tests. 
The addition of pooled plasma resulted in a reduction in cytokine production which was significant 
in GCSF and IL6.  There was a significant drop in IL6 cytokine production on addition of pooled 
plasma when compared to control (LPS +25(OH)D3) in GC1s1s, GC1sGC2 and GC1f1f.  There was 
no significant difference in response between GC2 and non GC2 carriers.  
For GCSF there was no significant change in cytokine production with addition of vitamin D to 
culture (p=0.225) but there was a significant difference in GCSF production with lower levels 
(p<0.05) in all but GC1sGC1f genotype (although this nearly reached significance p= 0.068 and 
may have been affected by the loss of a single result in the group for analysis).  There was no 
difference in response between GC2 carriage and non GC2 carriage. 
For ILlβ there was no significant change in cytokine production with addition of vitamin D to 
culture.  There was a significant difference in cytokine production between the genotypes shown in 
figure 4.4.  There was no significant difference in response between GC2 carriage and non GC2 
carriage. 
The cytokine response variation with DBP genotype could be due to the amount of 25(OH)D3 
available to the monocytes and therefore its action on suppression of cytokine levels as 
demonstrated in previous experiments.  The small numbers and the possible variation in vitamin D 
levels in the pooled plasma may have had an effect on the reliability of this experiment and a larger 
study on this subject may be useful. In addition, the use of a control group with added heat 
inactivated protein would be useful to determine if there was any non-specific effect of the addition 
of more protein to the cultures.   Further discussion around this can be found in chapter 4.3.2, 
monocyte genetics. 
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 T cell analysis in controls and latent TB. 
 
Optimisation of T reg analysis ex vivo 
 
The selection of T reg markers, antigen concentration optimisation and optimal time points for T reg 
analysis was carried out as part of a BMedSci Project by Jin Jin Zhang.  This was done prior to 
commencing analysis of blood from latent TB patients and the following section on optimisation 
includes her findings and figures.    
 
Optimisation of Treg cell detection by Flow cytometry 
 
Flow cytometry was used to detect Treg cells and using differing combinations of fluorophore 
stains, the T reg cell markers were identified (see figure 4.5).  Strength of signal was weakest in  
CD25-FITC and therefore this was not selected.  CD25-PE and CD25-PeCy7 both gave strong 
signals, but CD127-PeCy7 was the clearest stain for this marker, thus it was decided to use CD25-
PE and CD127-PeCy7 in combination. FoxP3 was brighter on APC than e450, thus FoxP3-APC was 
chosen. CTLA-4 detection in the APC channel was poor relative to PE, thus CTLA-4-PE was 
chosen. The final combination of CD3-PerCP, CD4-e450, CD25-PE, CD127-PeCy7, FoxP3-APC 
and CTLA-PE were selected for staining Treg markers.  
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Figure 4.5  Selection of Treg markers by flow cytometry. 
PBMCs stained with combinations of antibodies against Treg markers (CD3+, CD4+, CD25+, FoxP3+, 
CTLA-4+ and CD127 low). 
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Optimisation of cytokine detection by Flow cytometry  
 
Frequencies of IL-17, IFNγ, IL-2 and TNFα producing CD4
+
 cells directly ex-vivo and following 
culture with vitamin D were determined by flow cytometry.  Combinations of fluorophore conjugate 
antibodies to stain cytokines were tested to identify the ideal stain for clearest resolution with the 
minimum quantity of antibody stain.  Cells stimulated with SEB were selected in preference to PMA 
and ionomycin stimulated cells due to greater cytokine production with SEB stimulation.  
Fluorophores conjugate antibodies used for cytokine detection included IL-17-PE, IFNγ-e450, 





 cells. PeCy7 may break down to give signals of PE and APC, thus TNFα-
PeCy7 was not selected due to the inaccurate estimation of cytokine production it may cause. 
Consequently, PE and e450 conjugated to cytokine antibodies were chosen. After titrations, the best 
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  IL-17-PE IL-2-PE IFNγ-e450 TNFα-e450 
Volume (µl) 0.6 0.6 0.8 2 
 
Table 4.1 Volume of antibodies used for cytokine production staining. 
Each fluorophore was assessed in titration experiments in order to determine the minimum volume required 
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 cells, the frequency of cytokine producing cells was low in 




 cells would 
increase the frequencies was considered. CD69 is one of the early activation markers, thus CD69 











 cells, as shown in figure 4.6. 





























PBMCs were stained with anti-CD3, anti-CD4, anti-CD69, anti- TNFα and anti- IFNγ and analysed by Flow 
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Antigen concentration optimisation 
 
In addition to SEB, PPD and ESAT6 were also included as antigens that play stimulatory roles, and 
are more specific to tuberculosis. Concentration of PPD and ESAT6 to use was initially optimised 






 cells in response to various concentration 
of antigen. The final concentration for PPD is 1000 unit/ml was used as this maximised the amount 
of activated cells (figure 4.7).  Co-stimulatory antibodies αCD28 and αCD49d were used in 
combination with ESAT6, according to published methods [226, 227] and because both cross-link of 
T cell receptors (TcR) and co-stimulatory signals (from other molecules) are important in T cell 
activation and proliferation. Cytokine positive frequencies were enhanced by inclusion of co-
stimulatory antibodies, although because of the low numbers of CD69
+
 cells, the estimations are 
subject to error.  Due to the minimal number of responsive cells to ESAT6 and therefore the number 
of cells and amount of ESAT6 required to attain accurate estimations of cytokine frequencies by 
flow cytometry (figure 4.8), it was decided to continue without inclusion of ESAT6 stimulation.  




Figure 4.7  IL-17 and IFNγ production two days post stimulation by PPD. 
PBMCs were stimulated with PPD at various concentrations. FACs plots from a representative experiment 




 cells, then 
activated CD69
+
 and finally showing cells in 3 groups according to IL-17 and IFNγ status. In the next row 
only the activated and specific cell plots are shown at the following concentrations (units/ml): (a)1000  
(b)100  (c)10  (d)1   (e)0.1    (f)PPD negative control. 
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Figure 4.8 IL-17 and IFNγ production at time point of two days with various concentrations of ESAT6 
stimulations.  
PBMCs were stimulated with various volumes of ESAT6 in the presence of co-stimulatory antibodies αCD28 
and αCD49d, IL-17 and IFNγ production two days post stimulation was measured. The top row shows 10µg 





double positive cells. 10µg ESAT6+5ng antibodies and 5µg ESAT6+5ng antibodies resulted in 11% and 








JZLTB002 ESAT6 condition 1  CD69F IL-17Pe IFNy e450 CD3PP CD4APC 2day s.f cs































































































































JZLTB002 ESAT6 condition 2 CD69F IL-17Pe IFNy e450 CD3PP CD4APC 2day s.f cs































































































































JZLTB002 ESAT6 condition 3 CD69F IL-17Pe IFNy e450 CD3PP CD4APC 2day s.f cs
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Determine the optimal time point to measure the effect of SEB stimulation 
 
The best time for detecting responses to SEB stimulation was tested by Flow cytometry. 
Representative FACS plots are shown in figure 4.9. The frequency of cells expressing cytokine and 
their level of production was greater at two days compared to one day. The effect of vitamin D on 
cytokine production at two days point can be distinguished as well. Thus it had been determined that 















 T cells following SEB stimulation with SEB in the 
presence or absence of vitamin D. 
The expression of IFNγ and IL17 in response to SEB in the presence or absence of vitamin D was compared 





 cell population were 2.2% and 1.58% in the absence (UT) and presence of 
vitamin D respectively. Whereas the frequencies for the same cell population were 12.1% and 2.88% 
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Determine optimal time point to read vitamin D response 
  
Cytokine responses to active vitamin D and T cell surface molecules, including CD25, CTLA-4 and 
transcription factor FoxP3 were studied to choose the best time point to detect changes response to 
SEB and PPD stimulation in the presence or absence of vitamin D. The results showed vitamin D 
effect on CTLA-4 expression can be detected at 2 days, 3 days and 4 days separately (Figure 4.10).  




 expressing cells and CTLA-4 median fluorescence intensity 
(MFI) for CD25
+
 cells increased in the presence of vitamin D with maximal effect at day 4. Due to 
collection and processing time restrictions by the investigator, a shorter incubation time was needed 









Figure 4.10  Time course analysis of CD25, CTLA-4 and FoxP3 expression by untreated (vitamin D) and 
1,25(OH)2D3-treated PBMCs in response to SEB.  
PBMCs were stained with anti-CD3, anti-CD4 and anti-CD25 followed by intracellular staining of CTLA-4 
and FoxP3 two days (plots on the left), three days (plots in the middle), and four days (plots on the right) post 
stimulation. The values of CTLA-4 median fluorescence intensity for CD25
+



































   215 
 
T regs in latent TB and health 
 
Characterisation of the T reg cell used antibodies against surface markers CD3, CD4, CD25 and 
CD127 to stain the live cells and FoxP3 along with CTLA4 once the cells were fixed.  The 
frequencies of FoxP3+ CD127 low CD25+ cells and FoxP3+ CD127 low CTLA4+ cells ex vivo 
were analysed using flow cytometry to create FACS plots. Cells expressing CD3/CD4 markers were 
identified, marked and gated onto further plots to identify Fox P3/CD127low cells and these were 
further gated to identify which were CD25+ and CTLA4+ cells.  The frequencies were calculated as 
follows:   The FoxP3+CD127 low population within the CD3+/CD4+ cells were identified and 
measured.  Using Stain 1 (as per table 2.10 Staining panel for Treg cells ex vivo), the population 
within this group which were CD25+ were identified and measured as a % of the FoxP3+CD127 
population.  Using stain 2 (as per table 2.10) the population within the group which were CTLA4+ 
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Figure 4.11 Use of FACS dot-density plots to identify characteristic markers in the identification of T reg 
cells (CD3/CD4, FoxP3 positivity, CD25 positivity and CD127 low expression). 
This figure shows that in order to determine the frequency of regulatory T cells, it is necessary to identify the 
presence / absence of regulatory T cell markers.  The cells are stained with anti-CD3, anti-CD4, anti-CD25, 





















Figure 4.12 Frequency of  FoxP3+ CD127 low cells, expressing (A) CD25+  (B) CTLA4+ and (C) CTLA4 
MFI  in both healthy (HC) and latent TB (LTB) populations. 
This shows the frequency of the T reg populations (including median values), identified using the method 
described above for  both health and latent TB.  There is no significant difference in the expression of these T 
reg markers or T reg numbers respectively in health or latent TB.  Statistical analysis using Mann Whitney U 
test p > 0.05 for (A),(B) and (C). 
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Cytokine production ex vivo 
 
Figure 4.13  Examples of FACS plots identifying CD3+/CD4+ and CD8+ Tcells. 
Cell stimulation using PMA / ionomycin gave a non-specific response by direct intracellular activation of 
protein kinase C.  The cytokine response (IL17, IFNϒ, IL2 and TNFα) was assessed by measuring the 
frequency of cytokine using flow cytometry.  The positive response to antibody markers were measured on 
the FACS plots by gating onto CD3+/CD4+/CD8- cells. 
 




Figures 4.14  Frequency of cytokine producing T cells for  IL17, IFNϒ, IL2 and TNFα Day 1 ex vivo in 
healthy controls and latent TB cases subsequent to PMA / ionomycin stimulation ex vivo. 
This figure shows the baseline cytokine frequency, as determined using FACS.  This shows no significant 
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There was no significant difference in Day 1 cytokine production from CD4+ cells ex vivo of any of 
the above four cytokines p>0.05 using Mann Whitney U test. This suggested that the T cell response 
to stimulation does not differ between those in health and those with latent disease. 
Even the removal of a single significant outlier did not change statistical significance. 
 
Vitamin D - effect on T cells following antigenic stimulation  
 
CTLA-4 and FoxP3 expression post stimulation analysis 
 
The effect of vitamin D on the expression of T regulatory cells (identified by  CTLA-4 / FoxP3 
markers)  was measured using flow cytometry.  The effect of vitamin D on the production of 
cytokines including IL17, IFNϒ, IL2 and TNFα was measured using ELISA.  The cells were 
stimulated using either SEB or PPD and the effect of either 1,25(OH)2D3, 25(OH)D3 or both on the 
above parameters was recorded, with an incubation period of 48 hours before cytokines were 
measured. 
Below is a comparison of the effect of vitamin D upon the expression of CTLA-4 and FoxP3 by 
SEB stimulated T cells from healthy control and latent TB infected patients. 
   221 
 
 
Figure 4.15 FACS plots showing SEB stimulated, untreated (A) and 25(OH)D treated (B) T reg cell marker 
frequencies in latent TB samples. 
This gating strategy (as previously discussed in the methods section) allows evaluation of T regulatory cell 
marker frequencies in stimulated cells.  Using gating methods for determining cell frequencies, the CD25+, 

















Figure 4.16 Comparison of T reg markers in SEB stimulated cells, incubated with vitamin D in health and 
latent TB.  
Regulatory T cell marker expression rises with vitamin D supplementation in both health and latent disease, 
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There is a definite albeit insignificant trend to a rise in T reg markers with vitamin D 
supplementation in SEB stimulated cultures in both health and latent TB. There is no significant 
difference in the cell response in health and latent TB.    
Of note the T reg markers frequency % appears to be higher in the unstimulated population 
compared to the stimulated but as yet untreated cells.  Perhaps the total number of T cells activated 
by the SEB is greater and the corresponding frequency % of CD25+ CTLA4+ FoxP3+ declines due 
to this, although absolute values may well be close within each group.  It would be expected 
however that with inflammatory stimulation, the T reg population frequency might change, although 
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Figure 4.17  The effect of vitamin D supplementation on the CTLA4 MFI in SEB stimulated cultures, 
measured using flow cytometry.   
There is a statistically significant rise in CTLA4+ median fluorescence intensity (MFI) in both health and 
latent disease with vitamin D supplementations.  This is suggestive of a positive effect on regulatory T cells 


















   225 
 
Figure 4.17 shows a statistically significant rise in the CTLA4 MFI in SEB stimulated cells with 
both 1,25(OH)2D3 and 25(OH)D3 supplementation (*p=0.001). The significant rise in CTLA4 
expression with vitamin D supplementation persists in the latent group (**p=0.003), however the 
effect seems to be blunted in latent TB with significantly different values between health and disease 
in all but the vitamin D untreated (UT) group.  This may indicate that vitamin D has positive effect 
on the differentiation of T reg cells which express CTLA4 potently.  This concurs with the finding 
that 1,25(OH)2D3 was readily produced by DCs upon maturation at a level sufficient to promote an 
anti-inflammatory T cell phenotype, exemplified by high CTLA4 and decreased expression of IL17 








Figure 4.18 The effect of vitamin D on the frequency of Treg markers in PPD stimulated cells, measured 
using flow cytometry.  
CD25+ CTLA4+ FoxP3+ frequency rises with vitamin D supplementation, although this was not statistically 
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There is no statistically significant effect of supplementation with vitamin D on the T reg cell 
markers in health or latent TB when cells are stimulated by PPD.  There is no significant difference 
between the health and latent disease results of stimulation.  Although there appears to be a trend 
towards a rise in the markers indicative of T reg cells with supplementation in the healthy controls 











Figure 4.19  The effect of vitamin D on PPD stimulated cells in health and latent TB on CTLA4 
expression on T regs. 
CTLA4 median fluorescence intensity (MFI) rises with vitamin D supplementation in both health 
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Comparing the values of CTLA4 MFI in figure 4.17 which illustrates the effect of vitamin D on 
SEB stimulated cells, the overall effect is significantly blunted in PPD stimulated cells.  This may be 
due to a problem with the concentration of the PPD in producing adequate stimulation, as it appears 
to be the case in both the healthy control and latent groups. 
The proportion of CD4+ /CD3+ / CD25+ Foxp3+ cells co expressing CTLA4 tended to be higher in 
the vitamin D treated cells in both healthy and latent patients but did not reach statistical 
significance. 
 
The CTLA4 MFI  rose in both health and latent TB with vitamin D supplementation in cells which 
were both SEB  and PPD stimulated, which suggests there is evidence that vitamin D may effect 
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Figure 4.20  Graphs to show the effect of vitamin D on cytokine 
production in SEB and PPD stimulated cells in both healthy 
controls and latent TB population. 
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Figure 4.20 shows that there is a significant reduction in IL2 with both 1,25(OH)2D3 and 25(OH)D3 
in health and this is reflected in the  latent TB response to 1,25(OH)2D3.   The IL2 levels of PPD is 
much lower in the stimulated cells than in SEB stimulated cells which may indicate failure of PPD 
to stimulate sufficiently to result in IL2 production. 
There is a reduction in interferon gamma in the SEB stimulated cells of healthy controls and latent 
TB patients with vitamin D and a similar trend in the PPD stimulated cells but again, the  degree of 
cytokine production in the PPD stimulated cells is reduced. 
TNFα levels in SEB stimulated cells are significantly reduced in response to both 1,25(OH)2D3 and 
25(OH)D3 in health and a similar non-significant trend is seen in latent disease.  This trend is 
reflected in the PPD group, with a significant fall in TNFα levels in response to 1,25(OH)2D3 in the 
healthy group. 
IL17 levels show overall reduction in levels in both the SEB and PPD groups with a significant 
effect seen in the SEB stimulated latent group in response to 25(OH)D3.  Again the overall cytokine 
levels in the PPD group is lower and this is reflected throughout the remaining cytokine values as 
shown in the plots, with the exception of TNFα which shows a similar cytokine response when 
stimulated by both SEB and PPD.   
 
The levels of cytokines were comparable between the healthy and latent populations. 
There does not appear to be a significant difference in the response to vitamin D between health and 
latent TB indicating that T cells of TB infected cells are unlikely to be defective in their immune 
response. 
   233 
 
4.1.2 The effect of genetic polymorphisms of the vitamin D axis in determining the in vitro / ex 
vivo response to vitamin D supplementation in patients with mycobacterial infection  
 
This section relates to hypothesis 4 which aims to evaluate if genetic polymorphisms of the vitamin 
D axis determine the in vitro / ex vivo response to vitamin D supplementation in patients with 
mycobacterial infection. 
 
Monocyte Genetics  
  
Studying the same SNPs mentioned above statistical analysis using Using Mann Whitney U  and 
Wilcoxon tests showed that there was no significant association between any of the above SNPs and 
vitamin D response (measured by IL6 suppression) in monocyte supernatants.   
Regarding the addition of pooled plasma of varying DBP genotypes, this resulted in a reduction in 
cytokine production which was significant in GCSF and IL6.  There was a significant drop in IL6 
cytokine production on addition of pooled plasma when compared to control (LPS +25D) in 
GC1s1s, GC1sGC2 and GC1f1f.  There was no significant difference in response between GC2 and 
non GC2 carriers.  
For GCSF there was no significant change in cytokine production with addition of vitamin D to 
culture (p=0.225) but there was a significant difference in GCSF production with lower levels 
(p<0.05) in all but GC1sGC1f genotype (although this nearly reached significance p= 0.068 and 
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may have been affected by the loss of a single result in the group for analysis).  There was no 
difference in response between GC 2 carriage and non GC2 carriage. 
For IL1B there was no significant change in cytokine production with addition of vitamin D to 
culture.  There was a significant difference in cytokine production between the genotypes shown in 
figure 4.4.  There was no significant difference in response between GC2 carriage and non GC2 
carriage. 
Further discussion around this is found in the discussion section. 
Unfortunately due to low numbers, genetic analysis of T cell function / response to vitamin D was 
not carried out and this would be useful to consider in future work. 
  
4.2  Discussion 
 
4.2.1 The Immune Modulatory Effect of Vitamin D in Vitro and ex Vivo, in health and 
Mycobacterial Disease  
 
Functional Effect of Vitamin D / DBP on Stimulated Monocytes in Health and Disease 
 
Part of the third aim of the study was to explore the effect of vitamin D and TB on monocyte 
function, concentrating on the effect of vitamin D on stimulated monocytes and its effect on 
inflammatory cytokine (IL6) and antimicrobial (LL37) production in healthy subjects, active and 
   235 
 
latent TB patients in order to ascertain the mechanism by which vitamin D may be beneficial, and 
determine if monocyte response to vitamin D is impaired in TB.  
During the initial response to infection macrophages produce pro-inflammatory cytokines.  To 
compare the effect of vitamin D on stimulated cells, mimicking the effect of an infectious stimulus, 
monocytes of TB, latent TB patients and a control group were cultured for 48 hours as described in 
the methods section and stimulated with LPS and subsequently cultured with 25(OH)D3.  The IL6 
production was measured in the supernatant of the cultures by ELISA and comparisons in the 
response analysed. 
LPS was chosen as it is commonly used as a stimulant in monocyte culture, however an alternative 
such as TNFα would be interesting to pursue in further experiments in cultures from TB patients and 
those without the disease, as this is also a potent inducer of IL6, but levels in TB patients may be 
variable when compared to healthy controls, thereby potentially affecting the therapeutic dose of 
vitamin D that an infected individual may require when compared to health.  Previous study by Kent 
et al has illustrated this dose dependent response of IL6 to TNFα [229]. 
The optimisation experiments were carried out in order to determine the optimal concentrations of 
LPS and vitamin D to use in the monocyte culture.   Both the LPS concentrations and vitamin D 
(25(OH)D3) gave a dose dependent response in IL6 levels.  LPS, used to stimulate an inflammatory 
response in the monocytes has been shown to upregulate IL6 levels previously in human lymphatic 
endothelium, most likely through activation of NF-kβ [230].  However, the mechanism for this may 
vary according to the cell type analysed.  Although the measurement of IL6 by ELISA is a useful 
tool, further experiments using IL6 mRNA levels would be of interest as previous studies have also 
identified a dose dependent relationship with vitamin D and the suppression of mRNA levels [231] . 
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The optimisation experiments (Figure 4.1) showed that maximal IL6 expression was found with 
LPS concentrations 100 ng/ml, IL-6 levels leveling off at higher concentrations. 
25(OH)D3 levels of 50nmol gave maximal IL6 suppression and this correlates with prior work 
showing that vitamin D inhibits LPS-induced p38 phosphorylation in human monocytes [231] and 
although the cells in the study were pre-treated with vitamin D prior to LPS stimulation there still 
appeared to be a dose dependent response. 
Vitamin D concentrations in vitro don’t necessarily correlate to the circulating levels available in 
vivo which are considerably lower.  The concept of the experiment however was to look at the effect 
of vitamin D on circulating cytokine levels and this could then be extrapolated into therapeutic 
considerations e.g. direct administration into the airways etc. 
Measurement of VDR mRNA along with mRNA in other genes may be worth consideration in 
future experiments in order to determine the effect of vitamin D and LPS on this. Earlier 
experiments suggest that LPS and 1,25(OH)2D3 synergistically induces the VDR mRNA in THP-1 
cells [232]. 
In this study pre-treatment with LPS was not shown to affect the IL6 response to vitamin D and 
therefore experiments were subsequently all carried out without pre-treatment.  Previous studies 
have shown pre-treatment with LPS to enhance or potentiate the IL6 response even using sub-
stimulatory levels of LPS prior to complete activation [233].  Others however suggest the possibility 
of chronic stimulation where infection can exist in a ‘latent’ state which, although there are no overt 
clinical signs, there is still activity / turnover of the bacteria at undetectable levels.  This concept is 
further considered when the cytokine response in latent and active disease and health is observed. 
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IL6 is known to be a pro-inflammatory cytokine, but murine experiments have identified an anti-
inflammatory role in moderating other inflammatory response such as TNFα production [234].  
Hence if certain conditions were to modify the ability to produce IL6, then perhaps other cytokine 
responses would continue unchecked, resulting in greater pathology. Whether supplemental vitamin 
D would modify the IL6 response to the detriment of the individual depends on the effect of vitamin 
D on other pro-inflammatory cytokines in addition to IL6.  This raises the consideration whether 
supplementing patients who are severely vitamin D deficient with TB is the correct decision, 
although the risks vs benefits of other detrimental effects of vitamin D deficiency also needs to be 
considered, or whether altering the timing of vitamin D administration until after the initial phase of 
TB therapy may be wise. 
 The monocyte experiments carried out in controls, latent and active TB patients show the variation 
in mean IL6 response at 48 hours between the groups with controls reaching levels of almost 
4500pg/ml IL6, whilst the TB patients and latent patients reached 2700pg/ml and 1200pg/ml 
respectively.  Consideration needs to be taken when looking at the range of results.   Previous 
experiments have indeed shown that as time proceeds, the LPS stimulated IL6 response would be 
expected to decline from initial measures, but there is clearly a significant variation at identical time 
points between those with no disease and those with disease. 
In addition, it has been previously noted that CD4+ lymphopenia and a reduction in CD4+/CD8+ 
ratio is reduced in tuberculosis infection [235], likely resulting in an imbalance in the cytokine 
response to chronic infection with M.tb.  This may in part account for the lower baseline IL6 levels 
following LPS stimulation in latent and active TB compared with the control population in this 
study. 
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Within the groups of control, latent and TB patients, there were also clearly subgroups who showed 
significant variation in their response to vitamin D in its attenuation of the IL6 response. This has 
been categorised as responders and non- responders for the purpose of this study and the reasons for 
this are discussed further in section 4.1.1. 
Graphs (A) to (C) figure 4.3 indicate the difference between the IL6 production in disease and 
controls with and without vitamin D.  Explanation of this data is given in the results section. 
It may have been interesting to ascertain the IL6 response in those patients who had been treated and 
received vitamin D supplementation and if their subsequent results correlated at all with the original 
healthy population.  This was not however possible due to the small numbers recruited for the 
monocyte response aspect due to drop out rates / failure to attend of those who were recruited. 
 
 The effect of Vitamin D on Stimulated T Cells in Health and Disease. 
 
Part of the third aim of the study was to explore the effect of vitamin D and TB on Treg and Th17 
balance by in vitro work to look at the effect of vitamin D on stimulated T cells and its effect on 
relevant subsets in healthy subjects, active and latent TB patients in order to ascertain the 
mechanism by which vitamin D may be beneficial, and determine if T cell response to vitamin D is 
impaired in TB.  
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T reg analysis ex vivo 
 
FoxP3+ T cells are a subgroup of CD4+ T cells.  Using flow cytometry, T regs in healthy control 
and latent TB population were identified using the methods described in section 2.3.9.  This study 
shows that there is no significant difference in the expression of these T reg markers or T reg 
numbers respectively in health or latent TB and is illustrated in figure 4.12. 
The presence and activity of T regulatory cells in tuberculosis has only recently been considered in 
detail.  It is known that T reg cells tend to accumulate in areas of infection with M.tb [236].  
However latent TB differs from active TB in that there is no clear site of disease activity visible and 
hence the activity and location of T reg cells in this population may vastly differ.  The effect of T 
reg cells in acute infection has been discussed in the introduction of this thesis, highlighting the 
theory that whilst controlling the pathogenic effects of disease, they may be responsible for 
persistence of infection as a secondary effect.   
However previous studies have shown both and increase in peripheral T reg numbers in early 
infection [237] and decrease in T regulatory FoxP3 + cells in active tuberculosis.  There is little 
definite information regarding latent disease and the fact that only a small proportion of those who 
are infected with M.tb progress to develop active disease suggests that further research is needed to 
determine which elements of the T regulatory cell response are key to determining progression to 
disease.   The presence of pathogen specific Treg [238] cells is possible with the effect on the 
individual being secondary to a balance between cytoprotective or cytopathogenic effects of the T 
cells. 
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Murine studies by Scott-Browne et al identify increased T reg numbers in areas of disease activity / 
granuloma formation [239] only. Findings by Semple et al also noted higher T reg levels in active 
disease compared to latent disease in washings from bronchoalveolar lavage (BAL) [236].    
Therefore in peripheral blood samples, one may not expect a significant difference in T reg numbers 
between latent and healthy populations as shown in the above experiment. This is unsurprising given 
the above reasons of disease inactivity / slow mycobacterial turnover in latent disease.   It would be 
interesting to perform the same experiment with an active TB population to determine values in 
relation to these groups also.  Unfortunately due to limited numbers recruited for this part of the 
study and time limitations this was not possible.  It may also be worthwhile considering lymph node 
analysis of T reg cells in latent and healthy populations, to determine the degree of disease control 
which T reg cells may be responsible for in the latent population. 
A small study by Singh et al comparing TB patients with healthy controls noted an expansion in the 
T reg population which was greater in those with higher bacillary load in their sputum (i.e. greater 
infectivity). The T reg population declined towards normal with treatment but stayed elevated in 
those with treatment / drug resistant disease, with higher levels of IL10 production as a result of 
disease activity thereby suppressing host protective T cell response [240]. 
Clearly there is an imbalance in certain situations, resulting in disease persistence which is likely to 
be multifactorial, however the possibility of vitamin D affecting this process is an interesting 
consideration and one which is discussed later in this section.  The effect of vitamin D during an 
infective process such as TB could be considered potentially harmful if the effect of expanding the T 
reg population were to impact on the protective immune response in a negative way.   
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The measurement of CTLA4 MFI was also incorporated into the T cell analysis as shown in Figure 
4.12.  This is because cytotoxic T lymphocyte antigen (CTLA4) is involved in T cell tolerance as it 
acts as an inhibitory T cell receptor. It is always present on CD4+ FoxP3+ cells (T reg cells) and in 
the absence of either CTLA4 or FoxP3 devastating autoimmune disease is present.  The expression 
of CTLA4 rises with T cell receptor activation and therefore measurement of CTLA4 is a way of 
determining activity of T reg cell in disease and health once activated by a stimulus and whether this 
varies according to severity of disease and exposure to possible immune modulators such as vitamin 
D.  This is further discussed in the section below titled ‘CTLA4 and FoxP3 expression post 
stimulation analysis’. 
A murine study by Jain et al showed that CTLA4 expression in activated T cells limited pathology 
and tissue destruction [241].  It may therefore be hypothesised that CTLA4 MFI would be higher in 
patients with TB, particularly in those with tissue damage secondary to infection.  
This study showed no significant difference in the CTLA4 MFI in healthy controls compared to 
latent disease which would correlate with the findings above of no significant difference in CD4+ T 
reg population numbers in these two populations along with the fact that latent TB does not produce 
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Cytokine Production ex vivo 
 
The cytokine response (IL17, IFNϒ, IL2 and TNFα) was assessed by measuring the frequency of 
cytokine using flow cytometry. This study found that there was no significant difference in cytokine 
production between health and latent disease from CD4+ T cells Figure 4.14. 
The importance of individual cytokines in pathology of disease is highlighted in previous studies 
which have shown that TNFα inhibits the suppressive function of T reg cells [242], thereby 
potentially resulting in increased disease activity, with the use of anti-TNFα antibody having the 
effect of enhancing the number of FoxP3+ T reg cells [243], highlighting the importance of T reg 
balance  in disturbed immunity resulting in disease. 
FoxP3, by interacting with NFkβ will suppress the production of certain cytokines including and 
IFNγ, IL2, IL4.  This suppression of cytokines such as IL4 allows the suppression of disease activity 
/ progression in this way.   
The findings in this study are that there is no significant difference in the day 1 ex vivo production 
of  IL17, IFNγ, IL2 and TNFα between health and latent disease,  suggesting that there is no 
significant difference in T cell activity between these two groups one day post stimulation.  The use 
of disease specific stimulation using ESAT-6 or CFP-10 would be of interest to determine if the 
cytokine response differs with a more disease specific mycobacterial stimulus.  However Marin et al 
reported that the number of IFNγ producing cells was not significantly different between latent 
disease and health (when stimulated with either CFP10 or PPD) [244].   Future work may be 
worthwhile to assess further longer term cultures to evaluate the memory cell activation effect on the 
cytokine response, as the 1 day cytokines may only reflect a single snapshot and not that of the 
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disease process.  Culture time periods may also be affecting the cytokine responses.  Marin et al also 
identified variability in the cytokine response between active and latent disease depending on the 
duration of culture, with CD4+ IFNγ levels being notably higher in the early stage of culture in 
active TB, and CD8+ IFNγ release being higher in the latent group [244].   
In addition, the functionality of CD8+ specific T cells in the same situation may also be a useful 
comparator. 
Studies looking cytokine response in health vs. active TB are limited in number. Few are related 
directly to latent disease, the majority concentrating on IFNγ assays and titres.  This is likely due to 
the fact that currently the key diagnostic test for latent TB is to assay TB antigen specific IFNγ titres 
(T-spot / QFN Gold Assays).  
The nature of the immune response to mycobacterial antigens is not just related to a single cytokine 
and measuring thus may underestimate the entirety of the immune response.  Due to the 
polyfunctional nature of the T cell response the presence of a ‘functional signature’ has been 
considered and the detection of polyfunctional T cells (producing multiple cytokines IL2, 
IFNγ,TNFα) have been found to be lower in active disease [244] with lower IFNγ+/IL2+ dual 
secreting CD8 cells in active than in latent disease, possibly conferring a protective function in 
latent [245].  In other situations, bifunctional IFNγ(+) TNFα(+) CD4(+) T-cells have been 
significantly increased in active vs latent disease.  Therefore the situation is unclear as to where the 
balance lies, and whether there may be differing responses according to the pathology caused, i.e. 
response in the lungs differing to the peripheral values. 
IL2, which is produced by activated cells, is known to be associated with T cell tolerance through 
expansion of the T reg population.  Relating this to the clinical population, the current cytokine 
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related diagnostic tests for TB involve measurement of IFNγ titres or production following antigenic 
stimulation of the individuals T cells, but this unfortunately does not differentiate between active 
and latent disease. A previous study by Millington et al looked at IL2 response in active and treated 
TB [246] , showing co-dominance of IFN-gamma-only secreting and IFN-γ/IL-2 dual secreting 
CD4+ T cells in active disease that shifted to dominance of IFN-gamma/IL-2-secreting CD4+ T 
cells and newly detectable IL-2-only secreting CD4+ T cells during and after treatment.  Whether 
IL2 assay can help to determine the disease state was the subject of a recent systematic review [247] 
which suggests that IL2 assay may be a useful tool in differentiating between active and latent TB .  
The conclusion of the review was that when there is no definite gold standard for the diagnosis of 
LTBI, the IL-2 release assay in addition to IGRA can improve the ability of IGRA to identify 
individuals with recently acquired latent TB infection.  The fact that this study did not show this 
may be due to the fact that the IL2 assays were based on cytometric analysis of cell cultures, rather 
than extraction and ELISA analysis from whole blood directly.  It would be useful to compare the 
cytometric analyses in latent and active disease compared to whole blood ELISA analysis in future 
work. 
Finally the IL17 cytometry results are similar to the other cytokine responses in latent and health 
with no significant difference between the two groups.  This is expected given that IL17 is increased 
during a pro-inflammatory response to mycobacterial infection, resulting in tissue damage.  
However in latent and active disease, the cytopathogenic picture is not seen as it is in active disease.   
Further analysis of the same key cytokines in active disease would be useful for comparison. 
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CTLA-4 and FoxP3 expression post stimulation analysis 
 
This section of the study looks at the effect of stimulation on the T reg proportions and markers in 
response to stimulation with SEB or PPD and thereafter the response to supplemental vitamin D 
within the culture. In turn the CTLA4 (immune regulatory receptor) MFI is assessed under the 
above conditions, comparing health and latent populations response. 
T reg frequency appears to rise with vitamin D treatment in both SEB and PPD stimulated T cells, 
although this does not reach statistical significance as shown in figure 4.16 and 4.18.  Both 
1,25(OH)2D3 and 25(OH)D3 have this resultant effect and is likely to be explained by the fact that 
that T cells constitutively secrete α-1hydroxylase resulting in conversion to 1,25(OH)D3 
intracellularly. 
This finding concurs with previous study by Urry et al  which found that in vitro frequency of 
FoxP3+ cells increased with 1,25(OH)2D3 supplementation, allowing selective expansion of this 
group of cells [248] and the findings of Correale et al [249] which show that culture of PBMC in the 
presence of vitamin D significantly increases the proportion of regulatory T cells.  In contrast a 
study by Khoo et al [250] shows that naturally occurring T reg cell proliferation (i.e. those produced 
by the thymus which are not induced by antigen presenting cells) is inhibited by vitamin D, 
highlighting the importance of considering the effect of vitamin D in health and disease and the 
possible differing effects on immune suppression depending on the disease state.  The finding in this 
study suggests that the immune response is similar in health and latent disease. 
Further work of interest would be to confirm differences in active disease states in the proliferation 
of T regulatory cells and the effect of vitamin D on this activity in disease states.  Studies such as 
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that by He et al [251] suggest that M. tuberculosis infection induces circulating 
CD4+CD25+FoxP3+.  Whether vitamin D in this context is beneficial may be debatable and the 
possibility of inducing a chronic immune modulated disease state by further induction of regulatory 
immune response should be considered. 
Acting as an inhibitory T cell receptor, CTLA4 is responsible for regulation of immune response. 
Analysis of the effect of vitamin D on the CTLA4 MFI showed that there is a statistically significant 
rise in the CTLA4 MFI in SEB stimulated cells is noted with both 1,25(OH)2D3 and 25(OH)D3 
supplementation This regulatory effect of vitamin D correlates with previous findings by Jeffery et 
al [252] and the findings concur with a previous study which determined that 1,25(OH)2D3 was 
readily produced by DCs upon maturation at a level sufficient to promote an anti-inflammatory T 
cell phenotype, exemplified by high CTLA4 and decreased expression of IL17, IFNγ [228]. 
The CTLA4 MFI values are blunted in PPD stimulated cells overall, both in health and latent TB.  
The reason for this is unclear but may be multifactorial.  This may be due to a problem with the 
concentration of the PPD in producing adequate stimulation, as the blunted response is common in 
both the healthy control and latent groups.  There may have been a more non-specific T cell 
response to PPD and this may not have therefore been identified in this experiment looking 
specifically at activated regulatory T cells.  Alternatively, the culture may not have been of adequate 
duration and this may have resulted in a suboptimal response being identified. 
The latent group also show a reduced CTLA4 MFI response and the reason is again unclear, but 
disease specific T reg identification should be considered, particularly at disease sites, rather than 
relying solely on peripheral measurement.  Peripheral blood measures may not be reflective of the 
immune state at sites of disease for example in the lymph nodes or lavage washings from the lungs. 
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Overall the finding support the role of vitamin D enhancing the expression of both T reg markers 
and CTLA4 immune regulatory receptor, confirms findings of previous work and is further 
suggestive of the immune regulatory role of vitamin D.   
 
Vitamin D - effect of supplementation on cytokine activity 
 
SEB and PPD stimulated T cells were cultured in the presence of both 1,25(OH)2D3 and 25(OH)D3.  
The findings clearly show a  significant reduction in IL2 IFNγ TNFα, and under certain conditions 
IL17 production with the supplementation of vitamin D (either 25(OH)D3 and / or 1,25(OH)2D3. 
Figure 4.20 summarises the effect of vitamin D on cytokine production in T cell cultures.  
The findings show that vitamin D results in a reduction in cytokine levels in health and this is 
reflected in the latent TB response.  The response to PPD is blunted in all groups and this may 
indicate failure of PPD to stimulate the sufficiently.   
The resultant cytokine response to vitamin D may be multifactorial, including a reduction in the 
ability of the T cells to stimulate antigen presenting cells, as they require stimulation in order to 
produce the resultant cytokine response.  Another reason may be direct inhibition on T cell 
expression.  VDR binding sites within cytokine promoter / effector genes have been identified, 
supporting the likelihood of such a mechanism of action of vitamin D.  Chang et al identified a post 
transcriptional mechanism of suppression of T17 cell function (IL17) [253] by VDR as a result of 
1,25(OH)2D3 treatment as did Selvaraj et al on IFNγ production [254].  
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The levels of cytokines were comparable between the healthy and latent populations and there does 
not appear to be a significant difference in the response to vitamin D between health and latent TB 
indicating that T cells of TB infected cells are unlikely to be defective in their immune response. 
 
4.2.2 The effect of genetic polymorphisms of the vitamin D axis in determining the in vitro 
/ ex vivo response to vitamin D supplementation in patients with mycobacterial infection  
 
Studying the same SNPs mentioned above statistical analysis using Mann Whitney U  and Wilcoxon 
tests showed that there was no significant association between any of the above SNPs and vitamin D 
response (measured by IL6 suppression) in monocyte supernatants.  However, the experiments with 
pooled plasma containing a range of DBP genotypes from patient plasma sources on cytokine 
production from monocyte cultures yielded some interesting results.  Monocytes are incompletely 
differentiated but stimulation results in effects which are essentially antimicrobial and make them 
ideal cells to use in vitro for analysis of the effect of various stimulants / suppressors of immune 
function. 
Chun et al [255] identified the ability of monocytes to take up DBP at low level, without megalin 
mediated mechanisms in order to direct vitamin D to CYP27a1 for hydroxylation intracellularly.  By 
adding pooled plasma to monocytes of differing genotypes the study by Chun et al was able to 
determine if cathelicidin production could be affected in this way and that it is likely that genotype 
will affect the response to vitamin D according to variations in affinity of DBP. 
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Jefferey et al [256] noted that the cytokine response of T cells could be affected by the availability 
of vitamin D to dendritic cells.  By converting vitamin D to its active metabolite, this could increase 
the bioavailability to T cells which inherently, due to lack of Cyp27b1 expression are unable to use 
25(OH)D3 to establish a normal cytokine response.  The presence of DBP appeared to play a role in 
the availability of 25(OH)D3 for immune regulation. 
In a similar way, this study aimed to determine if cytokine response could be affected by the 
presence of varying DBP genotype plasma in the monocyte culture, thereby resulting in varying 
availability of vitamin D to the cells.  Possible problems with this method would include the use of 
high levels of vitamin D in the culture which may saturate the DBP and thereby lose the effect of its 
differential affinity for vitamin D.  Also the baseline vitamin D levels after storage of the samples, 
which were then pooled are not known.  By pooling, the heterogeneity of the effect is reduced and 
the likelihood is that the levels were low as the plasma was retrieved from TB patients used in the 
earlier experiments and thus it was known that the levels of vitamin D in these patients were 
significantly lower than in the general population.  Therefore the additive effect of the vitamin D 
supplementation to the culture would likely outweigh any variation in the pooled plasma levels 
between genotypes. 
By affecting the bioavailability of vitamin D to monocytes, this may in turn affect the cytokine 
response. 
The four cytokines analysed were GCSF, IL6, TNFα, and IL1β.   These were measured in relation to 
exposure to pooled plasma from various DBP genotypes.  The DBP effects transport of vitamin D 
intracellularly and thereby modifies the release of inflammatory cytokines as a result.  The 
hypothesis that variation in the DBP genotype may affect susceptibility to tuberculosis with 
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particularly low vitamin D levels has already been studied [257].  However this in vitro work looks 
more closely at four of the cytokines listed above and the effect of genotype on inflammatory 
response, in the presence of vitamin D sufficiency. 
GCSF was chosen to be measured due to the fact that previous studies have identified that GCSF 
modifies pro-inflammatory cytokine release from monocytes such as TNFα, IL1β and IFNγ [258].   
GCSF which is secreted endogenously by monocytes, used in the described experiments has been 
traditionally used to increase neutrophil counts in patients who had neutropenic sepsis secondary to 
chemotherapy.  It can be released from a variety of sources if it is stimulated by an appropriate 
cytokine e.g. TNFα/ LPS etc. and  it increases phagocytic function and antibody  mediated killing by 
its effect on neutrophils and a reduction in neutrophil apoptosis [259].  Therefore it is an interesting 
cytokine to study in relation to TB and whether its activity is modulated by vitamin D or genotypes 
of plasma which may in turn effect differing responses to infection and degree of phagocytic killing. 
Previous studies have noted that GM-CSF concentrations were significantly higher in vitamin D 
severely deficient individuals as compared to vitamin D sufficient individuals [260]. Murine studies 
have also shown that VDR-/VDR- mice are unable to respond to GCSF in mobilisation of 
hematopoietic stem/progenitor cells which indicates the pluripotent effect of the vitamin D axis on 
the immune response [261]. 
The results in this study show that GCSF levels decline with the addition of pooled plasma in the 
Luminex assays carried out on monocyte cultures. They did not however significantly decrease with 
the addition of vitamin D (small number of samples with wide variation in GCSF levels on 
analysis).  A possible reason for the significant decline on adding plasma within the culture medium 
was that the levels of GCSF in plasma are normally low, rising with infection [262] and declining 
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with recovery.  Although the elevated production of GCSF with LPS stimulation was evident this 
may have been counterbalanced in some way by the plasma.  This may suggest binding, inactivation 
or dilution of the GCSF by an element in the plasma, though clearly it is still detectable by the 
Luminex assay as shown in the figures even after the addition of plasma.  
Interestingly as shown in Figure 4.4, the expected suppression of LPS with 25D in this group did not 
occur in the GCSF group.  This effect may not have been apparent due to small numbers or the wide 
variation in GCSF titres obtained.  Further analysis of larger study cohort would be helpful. 
 
IL6 expression in the presence and absence of vitamin D in vitro has been discussed in the previous 
results section, noting significant reductions in IL6 production in responders to vitamin D 
supplementation.  Indeed figure 4.4 shows a reduction in IL6 with vitamin D supplementation in the 
presence of LPS stimulation of monocytes.  Although the graph indicates no significant difference in 
IL6 production between LPS and LPS+25(OH)D3, it can be seen that one of the six results is an 
outlier, and once this is removed from the calculation, there is a statistically significant reduction in 
IL6 with vitamin D supplementation (p=0.043) which correlates with the findings in the previous 
monocyte experiments. 
The presence of DBP containing plasma results in a significant reduction in IL6 despite the 
continued presence of LPS in the culture media.  This theme is reproduced in all but the IL1β graphs 
and suggests perhaps that the addition of plasma at the concentration / dilution chosen may have an 
effect on suppressing cytokine expression.  However it is notable that the inflammatory response 
varies with genotype. 
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IL1β is an inflammatory cytokine responsible for the activation of blood monocytes.  The trend for 
IL1B remains the same with the addition of plasma but the initial IL1β response to LPS induction is 
blunted compared to the other cytokines and this is the case for all of the healthy control monocytes 
with no outliers in the group.   
IL1β is produced by a mechanism of TLR activation (known to be a key part of the inflammatory 
response in tuberculosis) and involves intracellular production of pro-IL1β and this in turn, cleaved 
by precursors, producing a mature form which is found extracellularly.  The fact that only when it is 
extracellular, we may obtain a measurement of it in the cell culture medium may not be reflective of 
the entire effect of vitamin D on the pathway.  Further studies may include a larger cohort with a 
view to assessing some of the precursors of the mature IL1β which may reflect its activity more 
accurately. 
 
TNFα followed a similar pattern to GCSF and IL6 response with both the addition of LPS and 
pooled plasma with some genotypes exerting a more potent effect on reduction in cytokine response 
than others.  This is discussed further in the section monocyte genetics. 
In all the cytokine responses there is a reduction in levels when pooled plasma is added to the LPS 
stimulated cultures.  This suggests possible formation of LPS-plasma complex [263] [264] which 
may then affect cytokine response.  Another possibility is the presence of something in the plasma 
of TB patients that may be affecting the cytokine response to LPS, rather than purely the DBP or 
other globulin.  To further analyse this, it would be necessary to perform experiments with both TB 
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plasma of varying DBP genotypes as well as healthy control plasma of varying genotypes to 
determine any difference between the groups. 
 
Further work which may add additional information to this area may be to fluorescently tag the DBP 
and using flow cytometry, determine the degree of cellular internalisation of DBP according to the 

















5.1 Limitations of the Study and Future Work 
 
The study has been useful in confirming some findings from previous work in the field and 
stimulating consideration for future studies and experiments in mycobacterial infection.   
The size of the study was a limitation due to the difficulty in obtaining enough participants to 
adequately power the study.  This meant that firm conclusions regarding clinical effects of vitamin 
D supplementation e.g. sputum conversion / radiological changes etc. was not possible.  However, 
further in vitro work was added to the original trial protocol through substantial amendments, with 
the aim that both in vivo and in vitro work would provide further data on which to base additional 
conclusions.   
In the main study, treatment with vitamin D resulted in failure to achieve sufficiency in a percentage 
of the patients and this has been a problem in previous studies to date.  Supplementation with higher 
initial doses or IM dosing may help to achieve sufficiency in greater numbers of participants would 
be useful in ensuring sufficient dosing in all individuals thereby reducing variability in the study. 
The study, as an observational trial, only allowed analysis of those who were treated with vitamin D 
and given the general health benefits of vitamin D it would need to be debated whether withholding 
treatment once deficiency has been identified, would be in the patient’s best interest.  
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The likely interaction of the vitamin D axis on TB outcomes / response to supplementation has been 
highlighted in this study, however it is likely that larger randomised controlled trials would be useful 
in identifying whether the immune response in individuals are only due to vitamin D 
supplementation or genotype response, rather than the sole or additional effect of standard 
antimycobacterial therapy.  Studies have reached varying conclusions as discussed in the 
introduction regarding whether the genotype is influences diseases susceptibility, although a recent 
study by Junaid et al notes that although vitamin D correlates with susceptibility to TB, 
polymorphisms in DBP, VDR and CYP2R1 do not [265].  Larger analyses are required. 
The in vitro work had planned to include active TB patients particularly for the study of T cell 
activity and response.  However due to time limitations this was not possible and this would be a 
further research opportunity in future work both to expand the original population numbers of 
control and latent patients and add to this with active samples. 
The flow cytometry was subjective to a degree when carrying out the gating and frequency analysis.  
To minimise this the initial samples, collected as part of an associated BMedSci project were 
reanalysed to ensure that both the results were similar and to ensure that all samples were calculated 
for final analysis in the same manner to reduce heterogeneity of results. 
Despite this some interesting findings have been noted for potential further study. 
It is clear that there is a sizeable group of patients who suffer with vitamin D deficiency, particularly 
those with tuberculosis and that treatment of these patients may be of benefit.  Not all individuals 
will necessarily benefit from identical treatment regimens and the possibility of individualised 
regimens is highlighted.  This may be of further interest in aiming to personalise treatment 
depending on genotype and severity of vitamin D deficiency in order to achieve optimal therapeutic 
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effect.  Considerations would have to be taken regarding whether this is a practical approach or 
whether broad dosing regimens are more suitable with the by-product of potentially over-treating 
some individuals whilst achieving sufficiency in all. 
Additionally, consideration for future work should be considered using different dosing regimens.  
The benefits and disadvantages of high dose intermittent vitamin D supplementation versus daily 
dosing is debated and there have been suggestions that doses in the region of 100,000 units of 
cholecalciferol will only improve short term levels and fail to suppress PTH, whereas higher dosing 
must be used with caution due to side effects [266].  
There is also the potential for future work to consider the possibility that vitamin D assays may be 
affected by the possibility of C3 epimer in the assay, which exists in an identical structure with the 
exception of a stereochemical difference at one site.    Higher levels of this epimer have been found 
at greater 25(OH)D doses [267], such that dosing regimens which avoid large rises and falls of the 
levels may be beneficial in avoiding the presence of substances which may interfere with the 
accuracy of the current assays. 
Increasing numbers of new entrants to the UK means that the pool of population suitable for latent 
TB treatment is expanding and in this population it would be interesting to investigate any benefit 
that  high dose vitamin D supplementation may have in the likelihood of progression to active 
disease.  This could include a supplementation arm of those who are treated and those who remain 
untreated for latent disease. 
On this theme, the cytokine responses in latent TB would be interesting to investigate, identifying 
those who are likely to have been recently infected and determining if there is any difference in their 
in vivo cytokine production prior to and during treatment.  This may enable the identification of one 
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or more biomarkers which may help to help identify this population and the likelihood of 
progression to active disease. 
Genetic associations appear to be an important dimension in the consideration of which individuals 
may respond to or benefit most from vitamin D treatment and the study highlights the complexity of 
the vitamin D axis in mycobacterial infection. 
Further work of interest would be to confirm differences in active disease states in the proliferation 
of T regulatory cells and the effect of vitamin D on this activity in disease states.  Studies such as 
that by He et al [251] suggest that M. tuberculosis infection induces circulating 
CD4+CD25+FoxP3+.  Whether vitamin D in this context is beneficial may be debatable and the 
possibility of inducing a chronic immune modulated disease state by further induction of regulatory 
immune response should be considered.  
Study of the anti-mycobacterial response in the form of LL37 has yielded results which stimulate 
further consideration regarding the mechanisms and importance of this substances production in TB.   
Further work in this area would be to measure hCAP gene protein as part of the analysis in order to 
see if this correlates with the LL37 picture.  Analysis of the LL37 levels at weeks 2, 4 and 6 may 
have been useful in order to determine whether the levels at week 8 are purely spurious results or 
whether there is indeed a gradual decline in the initial stages of treatment. 
The finding that the vitamin D has an inhibitory effect on pro-inflammatory cytokine production, 
whilst promoting the expression of CTLA4, may be of interest specifically in the mycobacterial field 
where modulation of T cells could provide the potential for managing difficult or severe disease (for 
example cerebral tuberculomas with mass effect) or in the field of the paradoxical immune response 
which sometimes occurs on commencing TB therapy and may result in a significant worsening of 
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the inflammatory component of the disease.  Further work should include similar T cell studies in 
both active and latent disease to compare and contrast the effects between these populations. 
Collaboration to consider the effects of vitamin D in an immunomodulatory role in other diseases 
would be helpful and work has already shown that in asthma, vitamin D supplementation appears to 
reduce the severity of exacerbation requiring corticosteroids and number of hospital admissions 
[268], suggesting  an immune modulatory role, although the mechanism is unclear and only mild to 
moderate severity patients were included..  Additionally a recent study by Chambers et al has shown 
that in severe, steroid resistant asthma phenotypes, a  subgroup with increased  IL17A production in  
sputum and BAL, has a steroid independent response to calcitriol in reducing this inflammatory 
cytokine [269].    Work has also recently been carried out in a multicentre trial on the effects of 
120,000 units of vitamin D supplementation in COPD.  The findings have shown that there was no 
effect of supplementation on infection or exacerbation rates, although subgroup analysis did suggest 
that vitamin D supplementation in those with lower baseline 25(OH)D levels (<50nmol/l) conferred 











This study has enabled both in vivo and in vitro analysis of the immune regulatory effects of vitamin 
D in mycobacterial infection.  It has confirmed previous findings regarding vitamin D deficiency in 
tuberculosis and the relevance of this in latent and active disease. 
Optimisation experiments carried out prior to and during the study have enabled in vitro 
measurements of immune cells, along with examination of the cytokine response to differing 
stimulation. 
In addition the in vitro work shows and confirms previous work that there is a significant immune 
modulatory effect of vitamin D, particularly around the effect on the CTLA4 antigen expression. 
It is possible that vitamin D may be useful in particular subsets of patients, for example, those with 
profound vitamin D deficiency or those with particular genotypes of DBP or VDR which may 
confer an improved response to treatment when combined with vitamin D.  It is likely that not all 
individuals will benefit from ‘standard’ vitamin D supplementation and the dosing may need to be 
adjusted according to requirements / genotype. 
Consideration around the safety of ‘blanket’ supplementation with vitamin D should be considered 
particularly with regard to the possible immune regulatory role which has been confirmed in this 
study, which may theoretically enhance persistence or dissemination of disease following 
pulmonary infection.   
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Currently however, it would seem reasonable to check patients’ vitamin D levels and supplement 
deficiency, in order to provide patients with the multifactorial benefits (particularly musculoskeletal) 
which are already proven. 
The work enhances the already large array of information available and prompts consideration of 
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ARDS Adult respiratory distress syndrome 
ATP Adenosine triphosphate 
BCG Bacille-Calmette Guerin vaccine 
BMI Body mass index 
 BSA Bovine serum albumin 
CCL3L1 Chemokine (C-C motif) ligand 3-like 1 
CCR5 C-C chemokine receptor type 5 
CD Cluster of differentiation  
CFP-10 10 kDa culture filtrate antigen  
CHRNA5 Cholinergic receptor nicotinic alpha 5 subunit 
CISH Cytokine-inducible SH2-containing protein 
CNV Copy number variation 
COPD Chronic obstructive pulmonary disease 
CRP C reactive protein 
 CTLA4 Cytotoxic T-lymphocyte associated protein 4 
CXR Chest X-ray 
 CYP27b1 Cytochrome P450 family 27 subfamily B member 1 
CYP2R1 Cytochrome P450 2R1 / vitamin D 25-hydroxylase 
DBP  Vitamin D binding protein 
dbSNP Single nucleotide polymorphism database 
DC  Dendritic cell 
 
DC-SIGN 
Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-
integrin 
DEF4B Defensin B4 
 DHCR7  7-Dehydrocholesterol Reductase 
DNA Deoxyribonucleic acid 
dNTP Deoxynucleotide triphosphates 
EDTA Ethylenediaminetetraacetic acid  
ELISA Enzyme-linked immunosorbent assay 
EPTB Extrapulmonary tuberculosis 
ESAT-6 Early secretory antigenic target  
FACS Fluorescence activated cell sorting 
FCS Fetal Calf Serum 
 FoxP3 Forkhead box P3 
 GATA3 GATA transcription factor 3 
GC Group-specific component 
G-CSF Granulocyte colony stimulating factor  
 
GM-CSF Granulocyte-macrophage colony-stimulating factor 
GWAS Genome wide association study 
HapMap Haplotype map 
 HBC High burden country 
 HC Healthy control 
 h-CAP Human cathelicidin antimicrobial protein 
HIV Human immunodeficiency virus 
HLA Human leukocyte antigen 
HRP Horseradish Peroxidase 
Ig  Immunoglobulin 
 IGRA Interferon gamma release assay 
IL  Interleukin 23 Receptor 
IL1B Interleukin 1 beta 
 IL23R Interleukin 23 Receptor 
IQR  Interquartile range 
 ISC  Indian subcontinent 
 LD  Linkage disequilibrium 
LL-37 Cathelicidin derived antimicrobial peptide 
LPS  Lipopolysaccharide 
 LTB Latent TB 
  M.tb Mycobacterium tuberculosis 
MAF Macrophage activating factor 
MAP-c  Mycolic acid arabinogalactan peptidoglycan complex 
MBL Mannose binding lectin 
MDG  Millennium development goals 
MDR-TB Multidrug resistant tuberculosis 
MFI Median fluorescence intensity 
MHRA Medicines and healthcare products regulatory agency 
MRI Magnetic resonance imaging 
mRNA Microsomal RNA 
 MUAC Mid upper arm circumference 
NAAT Nucleic acid amplification test 
NADSYN1 Nicotinamide adenine dinucleotide synthetase 1 
NF-kB Nuclear factor kappa B 
NICE National institute for health and care excellence 
NOS2A Nitric oxide synthase 
 NRAMP1 Natural resistance-associated macrophage protein 1 
OMIM Online Mendelian Iinheritance in Man 
PAMP  Pathogen associated molecular pattern 
PBMC  Peripheral blood mononuclear cells 
PCR Polymerase chain reaction 
PMA  Phorbol 12-myristate 13-acetate 
PMA  Phorbol 12-myristate 13-acetate 
 
PPD Purified protein derivative 
PTB  Pulmonary tuberculosis 
RORgt RAR-related orphan receptor gamma  
RXR Retinoid X receptor 
 SAC South African Coloured population 
SEB Staphylococcal enterotoxin B  
SEM Standard error of the mean 
SNP Single nucleotide polymorphism 
SP110 SP110 nuclear body protein 
T reg Regulatory T cells 
 Tbet T-box expressed in T cells  
TGF Transforming growth factor 
TH1/2 T helper 1/2 lymphocytes 
THP-1 Human leukaemia monocytic cell line 
TIRAP Toll-interleukin 1 receptor (TIR) domain-containing adapter protein  
TMB  Tetramethylbenzidine 
TNFalpha Tumour necrosis factor alpha 
US Unstimulated 
 UT  Untreated 
  UVB Ultraviolet B 
 VDDR1A Vitamin D dependent rickets type 1A 
VDR  Vitamin D receptor 
 VDREs Vitamin D response elements 
WCC White cell count 
 WHO  World health organisation 
WT Wild Type  
 WT1 Wilm's tumour 1 












APPENDIX 1 Patient Information Leaflets 
 
Patient information leaflet and Consent for Main Study Version 1. 
Study code: 2010-023189-27 
Title: The pharmacogenetics of vitamin D response in tuberculosis 
 
 
You have been asked to participate in a clinical study for research purposes. Before you 
decide to take part it is important that you understand why the study is being performed, what 
it involves, and the possible risks and benefits for you. Take your time reading the following 
information and discuss it with others if you wish. 
 
Introduction to the research & invitation to take part 
This study is being carried out at the University of Birmingham and participants are being 
recruited from the Heart of England NHS Trust and University Hospital Birmingham. You 
have been chosen because your hospital doctor has identified you as possibly having 
tuberculosis and believes that you are suitable to take part in the study. 
 
What is the research about? 
The main purpose of the study is to look for Vitamin D deficiency amongst patients with 
tuberculosis.  We will treat the Vitamin D deficiency if identified and also look at whether the 
protein that binds vitamin D varies from person to person.  We may then be able to establish if 
some patients respond better than others to treatment.  We also hope to determine if Vitamin 
D supplements have a positive effect in those with tuberculosis.  We will do this by looking at 
changes in X-rays, blood tests and symptoms.   
 
 
What will I have to do? 
 
Please read this section carefully as it details the procedures that are specific to research and 
not part of usual clinical care 
 
If you agree to take part you will be seen by a member of the research team at the time of your 
usual out-patient clinic appointment. They will explain more about the study and what it 
would mean for you. The study will take place over 24 weeks (6 months) which is the 
minimum amount of time you should expect to be followed up if treated for tuberculosis.  It 
will involve seeing a member of the research team after one of your out-patient appointments 
after 2 months, 4 months and 6 months. There will be no extra visits to the hospital other than 




A blood sample will be collected from you. This can be done at the same time as any other 
blood tests your hospital doctor has asked for. We will collect blood at each of your outpatient 
appointments.    
 
We will process the blood and sputum samples so that they can be stored safely in secure 
freezers at the University of Birmingham. For this study they will be used to examine markers 
relevant to vitamin D and tuberculosis. They will not be used for other studies without prior 
ethical approval.  
 
We will also extract your DNA from your blood, which will be stored in the same way. Your 
DNA will be used to look for genes that may influence the response of individuals to vitamin 
D supplements.  Your DNA will not be used for other studies. 
 
As well as collecting these samples we will also collect information about you by talking to 
you and by looking at your medical notes. We will also ask some questions about symptoms 
that people with tuberculosis often experience, and ask you to fill in a questionnaire about the 
way your illness affects you. We will also look in your medical notes to see what medicines 
 
you take, and scans you have had (not all patients will have needed scans). All of this 
information will be recorded in written form only. 
 
All of the above procedures should take no more than half an hour on the first occasion, and 
be a little shorter on later visits. This will be in addition to seeing your usual hospital doctor. 
 
What are the benefits? 
You will benefit by being identified and treated if you have vitamin D deficiency.   Your 
participation and donation of samples may benefit patients with lung disease in the future by 
helping us to understand the role of vitamin D in the treatment of infectious lung diseases 
better. 
 
What are the risks? 
We do not expect any harm to come to you as a result of providing samples or talking to the 
researchers. Sometimes blood tests can be uncomfortable, or leave bruising, but this will be 
temporary.  There is a theoretical risk of elevated calcium levels in the blood with vitamin D 
supplementation but this will be monitored. 
 
What if I do not want to take part? 
The study is entirely voluntary and if you do not wish to participate it will not affect your 
future care. 
 
What happens to the information? 
If you decide to take part you will need to allow access to your medical records. They may be 
looked at by the doctors carrying out the research, by the hospital research and development 
department and by regulatory authorities who check that the study is being carried out 
properly. By signing this form you are giving permission for this to be done. 
 
The information collected will be stored on a secure computer, but your name will not. This is 
known as linked anonymised data, meaning that only the lead researching doctor will have 
 
access to your details. They will have sole access to a written record of your information, 
stored in a secure facility at University Hospitals Birmingham. All the data collected, samples 
you provide, and their results, including any information about your genes, will be coded with 
a number. The results of tests on your samples and about your genes will not be available to 
anyone outside of the research team and our collaborators. The link to your name will be 
destroyed after 15 years. Once the data is collected it will be the property of the research 
department. 
 
The results of the study may be published in a medical journal, but your identity will not be 
revealed. The results may be used in statistical tests, research and development of new 
treatments, diagnostic tests and medical aids. 
 
Who else is taking part? 
About 200 other patients with tuberculosis will be asked to take part. 
 
What if something goes wrong? 
Since the study involves only simple tests and treatments that could form part of your routine 
care, we do not expect any harm to come to you. Whatever part of the study you choose or 
decide not to take part in will not affect your future care. If you are harmed by taking part in 
this research project there are no special compensation arrangements.  
 
What happens at the end of the study? 
Throughout the study, and when it ends, your hospital doctor and general practitioner will 
continue to monitor you. 
 
What happens if I have more questions? 
If you do not understand something in this leaflet, or have further questions you may ask the 
researcher now, or your hospital doctor. 
 
What happens now if I decide to take part? 
 
If you decide to take part you will be asked to read, sign and date the Written Consent Form 
attached to this sheet. By signing it you acknowledge that you have understood the aims of the 
research, and what you are being asked to do.  
 
   
In summary 
The research aims to find a relationship between the response to vitamin D supplementation 
and the genetic type of that individuals protein that binds the vitamin.  It will also look at 
whether there is an improved response to tuberculosis treatment with vitamin D 
supplementation. 
If you take part you will be asked to provide blood and sputum samples, and answer questions 
about yourself and your symptoms at four out-patient appointments. 
All information will be stored in such a way that you cannot be identified by anyone without 
the lead researcher’s permission 
 
Will my General Practitioner (GP) be informed? 
If you give your permission, your GP will be told about your participation in the study.  
 
What happens if I change my mind during the study? 
You are free to withdraw your participation at any time, and it will not affect your future care. 
If you withdraw your consent after your samples have been analysed it will be the 
responsibility of your hospital doctor to ensure that the samples are destroyed if you so wish. 
 
Who can I contact about the study? 
In the first instance any concerns or questions should be addressed to either your GP or 
hospital doctor. If you have further concerns you can contact 
 Dr Alice Wood  
 Dr Gemma Hawthorne 
 





Study code: 2010-023189-27 
Title: The pharmacogenetics of vitamin D response in tuberculosis 
 
 
I………………………………………………………………… (Name in BLOCK 
CAPITALS) 
 
Have read the attached information concerning my participation in this study and have had 
the opportunity to discuss it and ask questions. All my questions have been answered in a 
satisfactory way. 
 
I voluntarily consent to take part in this study. 
 
I know that at any time, and without giving a reason, withdraw my participation in the study 
 and that my future care and management will not be affected. 
 
I understand that I will have a copy of this Patient Information Leaflet and Written Consent 
to keep. 
 
I understand that relevant sections of my medical notes and data collected during the study  
may be looked at by individuals from regulatory authorities or from the NHS Trust, where it 
is relevant to my taking part in this research.  I give permission for these individuals to have  
access to my records. 
 
I understand that samples taken as part of this study will not be used in other studies  
without prior ethical approval. 
 





participation in this research study. 
 
………………………………………………………………………………………..      
…………………… 
Patient’s signature                                                                                     Date 
 
……………………………………………………………………………………….. 
Name in BLOCK CAPITALS 
 
Responsible investigator 
I have explained the nature and purpose of this study for the person named above 
 
…………………………………………………………………………………………      
……………………. 
Responsible investigator/representative signature                             Date 
 
………………………………………………………………………………………… 
Name in BLOCK CAPITALS 
 










ADDITIONAL INFORMATION AND CONSENT FORM FOR LATENT 
TUBERCULOSIS PATIENTS  VERSION 1A 
Introduction to the research & invitation to take part 
This study is being carried out at the University of Birmingham and participants are being 
recruited from the Heart of England NHS Trust and University Hospital Birmingham. You 
have been chosen because your hospital doctor has identified you as possibly having latent 
tuberculosis and believes that you are suitable to take part in the study. 
 
What is the research about? 
The purpose of this study is to look at the numbers and types of immune cells in the blood 
amongst patients with active and latent tuberculosis. We may also evaluate the response of 
these cells to vitamin D in the laboratory.   We are also carrying out a larger clinical trial 
researching vitamin D deficiency but this will not affect you. 
 
What will I have to do? 
Please read this section carefully as it details the procedures that are specific to research and 
not part of usual clinical care 
 
If you agree to take part you will be seen by a member of the research team at the time of 
your usual out-patient clinic appointment. They will explain more about the study and what it 
would mean for you. The study will involve seeing a member of the research team at your 
initial outpatient.  There will be no extra visits to the hospital other than those for your usual 
out-patient appointments.  
 
A blood sample will be collected from you. This can be done at the same time as any other 
blood tests your hospital doctor has asked for.  
 
We will process the blood samples for analysis and some may be stored safely in secure 
freezers at the University of Birmingham.  They will not be used for other studies without 
prior ethical approval.  
 
All of the above procedures should take no more than fifteen minutes. This will be in addition 
to seeing your usual hospital doctor. 
 
 
What are the benefits? 
Your participation and donation of samples may benefit patients with tuberculosis in the 
future by helping us to understand the role of immune cells in the activity of tuberculosis. 
 
What are the risks? 
We do not expect any harm to come to you as a result of providing samples or talking to the 
researchers. Sometimes blood tests can be uncomfortable, or leave bruising, but this will be 
temporary.   
 
What if I do not want to take part? 
The study is entirely voluntary and if you do not wish to participate it will not affect your 
future care. 
 
What happens to the information? 
If you decide to take part you will need to allow access to your medical records. They may be 
looked at by the doctors carrying out the research, by the hospital research and development 
department and by regulatory authorities who check that the study is being carried out 
properly. By signing this form you are giving permission for this to be done. 
 
The information collected will be stored on a secure computer, but your name will not. This 
is known as linked anonymised data, meaning that only the lead researching doctor will have 
access to your details. They will have sole access to a written record of your information, 
stored in a secure facility at University Hospitals Birmingham. All the data collected, samples 
you provide, and their results, will be coded with a number. The results of tests on your 
samples and about your genes will not be available to anyone outside of the research team 
and our collaborators. The link to your name will be destroyed after 15 years. Once the data 
is collected it will be the property of the research department. 
 
The results of the study may be published in a medical journal, but your identity will not be 
revealed. The results may be used in statistical tests, research and development of new 
treatments, diagnostic tests and medical aids. 
 
 
Who else is taking part? 
About 30 other patients with active and latent tuberculosis will be asked to take part. 
What if something goes wrong? 
Since the study involves only simple tests that could form part of your routine care, we do not 
expect any harm to come to you. Whatever part of the study you choose or decide not to take 
part in will not affect your future care. If you are harmed by taking part in this research 
project there are no special compensation arrangements.  
 
What happens at the end of the study? 
Throughout the study, and when it ends, your hospital doctor and general practitioner will 
continue to monitor you. 
 
What happens if I have more questions? 
If you do not understand something in this leaflet, or have further questions you may ask the 
researcher now, or your hospital doctor. 
 
What happens now if I decide to take part? 
If you decide to take part you will be asked to read, sign and date the Written Consent Form 
attached to this sheet. By signing it you acknowledge that you have understood the aims of 
the research, and what you are being asked to do.  
 
Will my General Practitioner (GP) be informed? 
If you give your permission, your GP will be told about your participation in the study.  
 
What happens if I change my mind during the study? 
You are free to withdraw your participation at any time, and it will not affect your future 
care. If you withdraw your consent after your samples have been analysed it will be the 
responsibility of your hospital doctor to ensure that the samples are destroyed if you so wish. 
 
Who can I contact about the study? 
 
In the first instance any concerns or questions should be addressed to either your GP or 
hospital doctor. If you have further concerns you can contact 
Dr Alice Wood  
Dr Gemma Hawthorne  
Study code: EUDRACT No: 2010-023189-27 Enrolment No: 
Title: The pharmacogenetics of vitamin D response in tuberculosis.  
Sub- study looking at T cell proportions in latent tuberculosis 
Sub- study looking at response of immune cells in latent tuberculosis 
 
I………………………………………………………………… (Name in BLOCK 
CAPITALS) 
 
Have read the attached information concerning my participation in this study and have had 
the opportunity to discuss it and ask questions. All my questions have been answered in a 
satisfactory way. 
 
I voluntarily consent to take part in this study. 
 
I know that at any time, and without giving a reason, withdraw my participation in the study 
 and that my future care and management will not be affected. 
 
I understand that I will have a copy of this Patient Information Leaflet and Written Consent 
to keep. 
 
I understand that relevant sections of my medical notes and data collected during the study  
may be looked at by individuals from regulatory authorities or from the NHS Trust, where it 
is relevant to my taking part in this research.  I give permission for these individuals to have  






I understand that samples taken as part of this study will not be used in other studies  
without prior ethical approval. 
 
I hereby give permission for my GP and hospital consultant to be informed about my  
participation in this research study. 
 
………………………………………………………………………………………..      
…………………… 
Patient’s signature                                                                                     Date 
 
……………………………………………………………………………………….. 
Name in BLOCK CAPITALS 
 
Responsible investigator 
I have explained the nature and purpose of this study for the person named above 
 
…………………………………………………………………………………………      
……………………. 
Responsible investigator/representative signature                             Date 
 
………………………………………………………………………………………… 
Name in BLOCK CAPITALS 
 




APPENDIX 2  Data Collection Proforma 
 







HOSPITAL NUMBER  
 
GENDER (m/f)  
 
DATE OF BIRTH 
(dd/mm/yyyy) 
 











MICROBIOLOGICAL CONFIRMATION OF TUBERCULOSIS 
Smear positive (circle one) 
  + 
  ++ 




Results of subsequent sputum smear 
 
HIV Status (circle one) 
  Positive  
  Negative 
  Unknown 
CULTURE 
 Positive  Sputum 
 
    BAL 
  
    Lymph node 
 





VITAMIN D LEVELS 
  
 Baseline 8 weeks 16 weeks 24 weeks 
1,25 (OH)2D3     
25 (OH) D3     
VDBP GENOTYPE (circle one) 
   GC1S 
   GC1F  
 
   GC2 
 
CALCIUM LEVEL   





Full Blood Count 
Hb  













LFTS (if checked) 
Protein  
Albumin  






 Lobar  Multilobar Unilateral  Bilateral 
Baseline     
8 weeks     
16 weeks     
24 weeks     
 
If no chest X-ray changes please tick box  
TB SCORE 
Score 1 point for each positive response.  Positive responses to all questions will give maximum 
score of 13. 
  Score (1 point for each 
positive response) 
Symptoms Cough  
 Dyspnoea (shortness of breath)  
 Night Sweats  
 Haemoptysis  
 Chest pain  
   
Signs Anaemia (pale conjunctivae)  
 Tachycardia  
 Positive auscultatory findings 
(rhonchi, absence of breath 
sounds, crackles) 
 




 BMI  <18  
 BMI <16  
 Mid upper arm circumference 
(MUAC) <220 
 
 Mid upper arm circumference 
(MUAC) <200 
 






History of alcohol or drug misuse. 
(If yes – explain) 
 
 











Smoker   
 





Exclusion Criteria Checklist (please tick appropriate column). 
If any of the answers are ‘yes’, the patient is excluded from the study. 
 Yes No 
Managed with drug regime 
other than standard 6 months 
  
Known HIV positive   
Known drug resistant TB   
Known intolerance of Vitamin 
D 
  
Sarcoidosis   
                                      
Vitamin D supplementation in 
last 8 weeks 
  
Baseline serum corrected 
Calcium >2.65 
  
Current haemodialysis   
Pregnant or breastfeeding   















Confirmation of Administration of Dekristol 100000 IU (initial)  
Initial box to confirm administration 
 0 weeks 8 weeks 16 weeks 





















APPENDIX 3  Standard Operating Procedures for Trial 
 
SOP for the Pharmacogenetics of Vitamin D response in Tuberculosis 
 
SOP for acquisition of serum from whole blood 
Materials 
Blood collection apparatus (vacutainer set and butterfly needle) 
1 red top tube. 
Centrifuge 
Pasteur pipette 
500 microlitre pipette and tips 
Sterile eppendorfs  
Ice blocks and cool box for transfer or -20 freezer if prolonged wait prior to transfer back to 
lab. 
Labelling 
All tubes should be labelled with the patient number e.g.  Patient number 1, Visit 1 will be 
labelled 1.1; patient number 2 visit 3 will be labelled 2.3.  In addition labelling should include 
the date. 
All eppendorfs will also be labelled with this patient / visit number. 
In addition the eppendorfs should be labelled with the date and serum or plasma marker (S or 
P). 
Processing 
Place the red top tube in the centrifuge at 500 rcf for 10 minutes. 
Using a Pasteur pipette transfer the supernatant into a sterile tube. 
Pipette off 500 microlitre aliquots from this into each sterile eppendorf. 





SOP for acquisition of plasma from whole blood 
Materials  
Blood collection apparatus (vacutainer set and butterfly needle) 
1 EDTA tube. 
Centrifuge (NOTE: always make sure the rotor is balanced) 
Pasteur pipette 
500 microlitre pipette and tips 
Sterile eppendorfs  
Ice blocks and cool box for transfer or -20 freezer if prolonged wait prior to transfer back to 
lab. 
Labelling 
All tubes should be labelled with the patient number e.g.  Patient number 1, Visit 1 will be 
labelled 1.1; patient number 2 visit 3 will be labelled 2.3.  In addition labelling should include 
the date. 
All eppendorfs will also be labelled with this patient / visit number. 




Place the EDTA tube in the centrifuge at 500 rcf for 10 minutes. 
Using a Pasteur pipette transfer the supernatant into a sterile tube. 
Pipette off 500 microlitre aliquots from this into each sterile eppendorf. 







SOP for obtaining whole blood for DNA extraction. 
Materials  
Blood collection apparatus (vacutainer set and butterfly needle) 
2 EDTA tubes. 
Labelling 
All tubes should be labelled with the patient number e.g.  Patient number 1, Visit 1 will be 



























REAGENT A 10ml Triton X 
   110g sucrose 
   1ml Tris HCl pH 7.4 
   1.02ml 4.9M MgCl2 
   Make up to 1l with distilled water 
 
REAGENT B  400ml 1M Tris HCl 
   120ml 0.5M EDTA 
   30ml 5M NaCl 
   40ml 25% SDS 


















Clinical Trial Prescription 
The Pharmacogenetics of Vitamin D Response in Tuberculosis 
 
EUDRACT No: 2010-023189-27 
Protocol: RG-10-179   
 
 
Patient Initials  
Patient ID  
Date of Birth  
  




1x5 Vitamin D 20,000 IU capsules (Dekristol) 
Open label, for clinical trial use only 
 
 
Date   
Prescribing Signature  
Printed Name  




Pharmacy Use Only   
Date Issued:   Sign  Print  




Collected by Sign  Print  
 Date  Time  
 
Request Form 
The Pharmacogenetics of Vitamin D Response in Tuberculosis 




Principal Investigator: Dr Gemma Hawthorne 




Please Supply :  ........ of bottles of Vitamin D 20000 IU capsules (Dekristol) Supplied in 







Investigator: ……………………………..………          Date:……………………. 
   Print Name /Signature 
                           






Pharmacy Use Only 
 
Supplied by: __________________________________ Date:________________ 
     
Checked by: __________________________________ 
 
Collected by: __________________________________ Date: ________________ 
 
Pharmacy Use Only 
 
Supplied by: __________________________________ Date:________________ 
     
Checked by: __________________________________ 
 
Collected by: __________________________________ Date: ________________ 
